

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 21st (Sun)	17:20	17:25	P-0001	HCV Basic (1)	10539	Jinchao	Han	Artificial Peptides Derived Hepatitis C Virus Core Protein Interfere Virus Replication in Vitro
February 21st (Sun)	17:25	17:30	P-0002	HCV Basic (1)	10988	Ryuichi	Sugiyama	Amino Acid Substitutions in ISDR of HCV-NS5A Affect Infectious Virus Production and ISG Induction.
February 21st (Sun)	17:30	17:35	P-0003	HCV Basic (1)	10125	Chia-Yen	Dai	Association between microRNA Let-7g and Hepatitis C
February 21st (Sun)	17:35	17:40	P-0004	HCV Basic (1)	10364	Da-Xian	Wu	Combined HRM with Bayes Discriminant Method: A Novel HCV Genotyping Method
February 21st (Sun)	17:40	17:45	P-0005	HCV Basic (1)	10951	Asako	Murayama	Host Factors for HCV Replication and Infectious Virus Production in Vero Cells
February 21st (Sun)	17:45	17:50	P-0006	HCV Basic (2)	10013	Ragaa A.	Ramadan	Hypermethylation of Placental Bikunin Gene in Chronic Hepatitis C Virus Infection
February 21st (Sun)	17:50	17:55	P-0007	HCV Basic (2)	10986	Tao	Shen	Non-Neutralizing Epitopes Induce Robust ADCC Mediated by CD56 ⁺ CD57 ⁺ NK Cells in Chronic HCV Infection
February 21st (Sun)	17:55	18:00	P-0008	HCV Basic (2)	11154	Po-Sung	Chu	NKG2D, the Mediator of Host T Cell Response, Correlates to Naturally Occurring HCV NS5A Variants
February 21st (Sun)	18:00	18:05	P-0009	HCV Basic (2)	10575	Febi	Andriani	Primary Hepatocyte of Tupaia Javanica as A Model for Hepatitis C Virus Infection
February 21st (Sun)	18:05	18:10	P-0010	HCV Basic (2)	10825	Takuya	Kuwashiro	Extracellular Matrices Impair the IFN- α Signaling Via the Beta 1 Integrin-Mediated Signaling
February 21st (Sun)	18:10	18:15	P-0011	HCV Basic (2)	10772	Cheng	Peng	Inhibitory Effect of miR-125b on HCV Core Protein- Induced TLR2/MyD88 Signaling in THP-1 Cells
February 21st (Sun)	17:20	17:25	P-0012	Epidemiology and HCV Genotypes (1)	10997	Vinoth	Kumar	A Study on Distribution of HCV Genotypes in South India
February 21st (Sun)	17:25	17:30	P-0013	Epidemiology and HCV Genotypes (1)	10596	Wang	Guo-Jian	Epidemiologic Features in Chinese Descent in Burmese with CHC in Hospital of Dehong District, China
February 21st (Sun)	17:30	17:35	P-0014	Epidemiology and HCV Genotypes (1)	10654	Rujipat	Wasitthankasem	Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade; An Evidence-Based Study.
February 21st (Sun)	17:35	17:40	P-0015	Epidemiology and HCV Genotypes (1)	11316	Mrudul V.	Dharod	Determining Modes of Transmission of Hepatitis C Virus (HCV)
February 21st (Sun)	17:40	17:45	P-0016	Epidemiology and HCV Genotypes (1)	10377	Ozlem	Kandemir	Distribution of Hepatitis C Virus Genotypes in Injection Drug Users with Chronic Hepatitis C
February 21st (Sun)	17:45	17:50	P-0017	Epidemiology and HCV Genotypes (1)	11296	Rui	Hua	HCV Genotype-Specific Epitope Peptides Screen and B-Cell Epitope Prediction
February 21st (Sun)	17:50	17:55	P-0018	Epidemiology and HCV Genotypes (1)	10177	Mohamed	Elateek	Interfamilial Transmission of Hepatitis C Genotype 4 in Egypt
February 21st (Sun)	17:55	18:00	P-0019	Epidemiology and HCV Genotypes (2)	10829	Tomomi	Okubo	Elderly and Low Serum 25(OH)D3 Level Contributes to Drug Resistance of NS5A Region
February 21st (Sun)	18:00	18:05	P-0020	Epidemiology and HCV Genotypes (2)	10616	Do Young	Kim	Elimination of Hepatitis C Virus (HCV) in South Korea
February 21st (Sun)	18:05	18:10	P-0021	Epidemiology and HCV Genotypes (2)	10361	Irakli	Rtskhiladze	Emergence of Hepatitis C Virus Genotype Recombinant Forms 2k/1b in Georgia
February 21st (Sun)	18:10	18:15	P-0022	Epidemiology and HCV Genotypes (2)	10550	John H.	Rim	Frequency and Distribution of Discrepant Anti-HCV Screening Results in Korea during Recent 4 Years
February 21st (Sun)	18:15	18:20	P-0023	Epidemiology and HCV Genotypes (2)	10116	Peng	Huang	Genetic Variants in Interferon-Lambda 4 Influences HCV Clearance in Chinese Han Population
February 21st (Sun)	18:20	18:25	P-0024	Epidemiology and HCV Genotypes (2)	11057	Pauline	Nguyen	Rising Inpatient Hospital Charges(IHC) in Ethnically Diverse U.S. Chronic Hepatitis C(CHC) Patients
February 21st (Sun)	18:25	18:30	P-0025	Epidemiology and HCV Genotypes (2)	11354	Shiqi	Tao	Investigation into the High Prevalence of HCV Infection in A Rural Village in Southwest China
February 21st (Sun)	17:20	17:25	P-0026	Epidemiology and HCV Genotypes (3)	11012	Lei	Shi	HIV and HCV Cooperatively Promote Hepatic Fibrogenesis through Epimorphin Mediated Via FAK-ERK
February 21st (Sun)	17:25	17:30	P-0027	Epidemiology and HCV Genotypes (3)	10569	Febi	Andriani	Identification of Inter-Genotype Recombinant in Indonesian Chronic HCV Patient
February 21st (Sun)	17:30	17:35	P-0028	Epidemiology and HCV Genotypes (3)	10157	Tomohisa	Nagano	Impact of Chronic HCV G1b Infection on TG Concentration in Serum Lipoprotein Fractions
February 21st (Sun)	17:35	17:40	P-0029	Epidemiology and HCV Genotypes (3)	10902	Zobair M.	Younossi	Increased Cancer Rates in CHC Patients: An Analysis of the Cancer Registry in A Large U.S. HMO
February 21st (Sun)	17:40	17:45	P-0030	Epidemiology and HCV Genotypes (3)	11321	Seyed Reza	Mohebbi	Parvovirus 4 Infection in Iranian HCV Infected Patients and Healthy Individuals
February 21st (Sun)	17:45	17:50	P-0031	Epidemiology and HCV Genotypes (3)	10163	Chih-Lang	Lin	Intrahepatic HCV RNA and Genotype 1 Independently Associate with Hepatic Reticulon 3 Expression
February 21st (Sun)	17:50	17:55	P-0032	Epidemiology and HCV Genotypes (3)	10025	Metin	Basaranoglu	There An Increase in the Prevalence of Hepatitis C Virus Subtype 3a in Turkey
February 21st (Sun)	17:55	18:00	P-0033	Epidemiology and HCV Genotypes (4)	10175	Emre	Guven	Investigation of the Effect of PON1 and IL28B Gene Polymorphism on HCV Infection Progress
February 21st (Sun)	18:00	18:05	P-0034	Epidemiology and HCV Genotypes (4)	11015	Satoshi	Hiramine	Length of TA Repeat Near IL28B was Associated with HCV Spontaneous Clearance in Egyptian Population
February 21st (Sun)	18:05	18:10	P-0035	Epidemiology and HCV Genotypes (4)	10528	Wei-Lun	Tsai	Metformin Activates Type I Interferon Signaling against HCV Via Activation of AMPK
February 21st (Sun)	18:10	18:15	P-0036	Epidemiology and HCV Genotypes (4)	10949	Dashtseren	Bekbold	New-Estimation of Prevalence of HCV Infection in Mongolia
February 21st (Sun)	18:15	18:20	P-0037	Epidemiology and HCV Genotypes (4)	10250	Sungbum	Cho	Clinical Characteristics of Chronic Hepatitis C in the Elderly Patients
February 21st (Sun)	18:20	18:25	P-0038	Epidemiology and HCV Genotypes (4)	10003	Chung-Feng	Huang	PNPLA3 Genetic Variants Determine HCV-Related Hepatic Steatosis in Asian Non-Obese Patients
February 21st (Sun)	17:20	17:25	P-0039	Epidemiology and HCV Genotypes (5)	11360	Anita	Olczak	Genotype Distribution of Hepatitis C Virus in HIV Infected Patients in Bydgoszcz, Poland.
February 21st (Sun)	17:25	17:30	P-0040	Epidemiology and HCV Genotypes (5)	11197	Ruifeng	Yang	Performance Evaluation of the HISCL ^{reg} ; HCV Serotyping Assay in Chinese Chronic Hepatitis C Patients
February 21st (Sun)	17:30	17:35	P-0041	Epidemiology and HCV Genotypes (5)	11258	Haiying	Zhang	Prevalence and Clinical Correlates of Autoantibodies in Chinese Patients with Chronic Hepatitis C

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 21st (Sun)	17:35	17:40	P-0042	Epidemiology and HCV Genotypes (5)	10610	Channarena	Chuon	Prevalence of HCV and HBV, and Characteristics of HCV Genomes among General Population in Cambodia
February 21st (Sun)	17:40	17:45	P-0043	Epidemiology and HCV Genotypes (5)	10205	Wahyuni Lukita	Atmodjo	Prevalence of Hepatitis-C Virus Infection within Community Health Centers in Tangerang, Indonesia
February 21st (Sun)	17:45	17:50	P-0044	Epidemiology and HCV Genotypes (5)	10295	Vo Duy	Thong	Prevalence of TA Repeat, IL28B, IFNL4 and Correlation with Treatment Outcome of HCV Infection
February 21st (Sun)	17:50	17:55	P-0045	HCV and Markers	11328	Iftihar	Koksal	Results of Long-Term Monitoring of Treatment-Naive Genotype 1b Chronic Hepatitis C Patients
February 21st (Sun)	17:55	18:00	P-0046	HCV and Markers	10030	Shamardan E.	Bazeed	Serum Survivin and TIMP-1 as Non-Invasive Markers of HCV Induced Liver Fibrosis
February 21st (Sun)	18:00	18:05	P-0047	HCV and Markers	11262	Nazan	Tuna	the Relation of Serum Vitamin A Level with Chronic Hepatitis C
February 21st (Sun)	18:05	18:10	P-0048	HCV and Markers	11051	Jee-Fu	Huang	the Role of 25-Hydroxy Vitamin D in Hepatitis C Virus Replication and Treatment Viral Kinetics
February 21st (Sun)	18:10	18:15	P-0049	HCV and Markers	10930	Tajinder	Singh	Effect of Antiviral Therapy on Liver Stiffness in Patients of Chronic Hepatitis C
February 21st (Sun)	18:15	18:20	P-0050	HCV and Markers	11176	Ryo	Nakagomi	Sequential Measurement of Liver Stiffness in Patients with HCV with or without Sustained Response
February 21st (Sun)	18:20	18:25	P-0051	HCV and Markers	11054	Norihiro	Furusyo	Simeprevir- and Telaprevir-Based Therapies for Non-Responders with Genotype 1b Chronic Hepatitis C
February 21st (Sun)	18:25	18:30	P-0052	HCV and Markers	10794	Chun-i	Huang	Role of IL-28B Genetic Variants in HCV Related Liver Disease Severity
February 21st (Sun)	18:30	18:35	P-0053	HCV and Markers	10101	Yasuharu	Imai	Elasticity Modulus by Real-Time Color Mapping Shear Wave Elastography in SVR Patients of CH-C
February 21st (Sun)	17:20	17:25	P-0054	IFN-Based Therapies (1)	10493	Masakuni	Tateyama	A Randomized Study of the PegIFN-Based Regimen with Simeprevir for Chronic Hepatitis C
February 21st (Sun)	17:25	17:30	P-0055	IFN-Based Therapies (1)	11077	Anila	Kristo	Age and Gender Influences on Chronic Hepatitis C (CHC) Patients Treated with PegIFN and Ribavirin
February 21st (Sun)	17:30	17:35	P-0056	IFN-Based Therapies (1)	10443	Meng-Hsuan	Hsieh	Boceprevir-Based Triple Therapy to Rescue HCV Genotype 1/1b Dually Infected in Taiwan
February 21st (Sun)	17:35	17:40	P-0057	IFN-Based Therapies (1)	10173	Nese	Demirturk	Cases of Chronic Hepatitis C Treatment in Hemodialysis Patients
February 21st (Sun)	17:40	17:45	P-0058	IFN-Based Therapies (1)	10294	Atsushi	Suetsugu	Change in Serum Levels of M2BPGi in Patients with HCV during the Treatment of Peg-IFN and RBV
February 21st (Sun)	17:45	17:50	P-0059	IFN-Based Therapies (1)	11084	Anila	Kristo	Biochemical and Hematological Profile at Baseline Predicts Non-SVR in Chronic Hepatitis C Treatment
February 21st (Sun)	17:50	17:55	P-0060	IFN-Based Therapies (1)	10851	Baihai	Jiao	the Role of Ubiquitin Specific Protease USP18 in Interferon Resistance of HCV
February 21st (Sun)	17:55	18:00	P-0061	IFN-Based Therapies (2)	10315	Satoshi	Yamagiwa	Efficacy and Safety of SMV-Based Triple Therapy for Patients Aged 66 Years and Older with CHC
February 21st (Sun)	18:00	18:05	P-0062	IFN-Based Therapies (2)	10276	Eiichi	Ogawa	Efficacy of Second-Generation Protease Inhibitor-Based Triple Therapy for HCV Genotype 1b Patients
February 21st (Sun)	18:05	18:10	P-0063	IFN-Based Therapies (2)	10836	Andri S.	Sulaiman	Factors That Predict Pretreatment and on-Treatment SVR in CHC C Patients Treated with Dual Therapy
February 21st (Sun)	18:10	18:15	P-0064	IFN-Based Therapies (2)	10321	Young Nam	Kim	FIB-4 Can Predict HCC Development in CHC Patients with SVR to Interferon-Based Combination Therapy
February 21st (Sun)	18:15	18:20	P-0065	IFN-Based Therapies (2)	10916	Kayoko	Matsunami	Genome-Wide Association Study on Genetic Variants Associated with Interferon-Induced Depression
February 21st (Sun)	18:20	18:25	P-0066	IFN-Based Therapies (2)	11219	Qing	Shao	Cost-Effectiveness of Neutrino Regimen for CHC GT1b in China- A Real Life Study
February 21st (Sun)	17:20	17:25	P-0067	IFN-Based Therapies (3)	10568	Tri S.	Kurniasih	HCV Quasispecies Complexity and Diversity of Indonesian Chronic HCV Patients Treated with PegIFN/RBV
February 21st (Sun)	17:25	17:30	P-0068	IFN-Based Therapies (3)	10856	Norie	Yamada	HCV Reactivation and HCC Development after Achievement of HCV RNA Negative by Peg-IFN/Rbv Therapy
February 21st (Sun)	17:30	17:35	P-0069	IFN-Based Therapies (3)	10169	Eiichi	Ogawa	Impact of HCV Kinetics Differs by the Type of Real-Time Assay Used to Monitor Triple Therapy
February 21st (Sun)	17:35	17:40	P-0070	IFN-Based Therapies (3)	11326	Ahmet	Danalioglu	May Triple Therapy Still be An Alternative to Standard Therapy in Patients with Chronic Hepatitis C?
February 21st (Sun)	17:40	17:45	P-0071	IFN-Based Therapies (3)	10174	Muzzaffar	Gill	Outcomes of Sof, Riba & Peg-INF Therapy for Treatment of Chronic HEP-C G3 Treatment Naive Patients
February 21st (Sun)	17:45	17:50	P-0072	IFN-Based Therapies (3)	11159	Dr Muhammad	Imran	Paired FIB-4 Score in Successfully Treated Chronic Hepatitis C with Pegylated Interferon & Ribavirin
February 21st (Sun)	17:50	17:55	P-0073	IFN-Based Therapies (3)	10695	Hurrem	Bodur	Peg-Interferon and Ribavirin in Naive Patients with Mild to Moderate Genotype1b Chronic Hepatitis C
February 21st (Sun)	17:55	18:00	P-0074	IFN-Based Therapies (4)	10790	Chen-Hua	Liu	Peginterferon plus Ribavirin for HIV-Infected Patients with Acute or Chronic HCV Infection in Taiwan
February 21st (Sun)	18:00	18:05	P-0075	IFN-Based Therapies (4)	11225	Syed Afzal-ul-haq	Haqqi	Pegylated Interferon in HCV Genotype 3 Relapsers to Conventional Interferon in Pakistani Population
February 21st (Sun)	18:05	18:10	P-0076	IFN-Based Therapies (4)	10133	Gulnara	Aghayeva	Problems in Treatment of Cirrhotic HCV Patients in Azerbaijan- Retrospective Analyze.
February 21st (Sun)	18:10	18:15	P-0077	IFN-Based Therapies (4)	10109	Akihiro	Tamori	Randomized Trial of Two Types of Peg-IFN with Simeprevir Combined Therapy for Patients with HCV 1b
February 21st (Sun)	18:15	18:20	P-0078	IFN-Based Therapies (4)	10658	Alok	Mantri	Renal Abnormalities in Patients with Chronic Hepatitis C and Response to Therapy
February 21st (Sun)	18:20	18:25	P-0079	IFN-Based Therapies (4)	10202	Dorota	Dybowska	Resistance Analysis of Unsuccessfully Treated with Telaprevir Genotype 1 HCV Infected Patients
February 21st (Sun)	18:25	18:30	P-0080	IFN-Based Therapies (4)	11329	Suharno	Hakim	Profile of Chronic Hepatitis C Treated with Interferon Based Regimen in Sardjito General Hospital
February 21st (Sun)	18:30	18:35	P-0081	IFN-Based Therapies (4)	10626	Orhan	Yildiz	Sofosbuvir, PegIFN and Ribavirin for 12 Weeks in Treatment-Naive HCV Genotype 1b Patient
February 21st (Sun)	17:20	17:25	P-0082	IFN-Based Therapies (5)	11151	Khin M.	Win	Treatment Chronic Hepatitis C Myanmar Patients with Sofosbuvir, Pegylated Interferon and Ribavirin.

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 21st (Sun)	17:25	17:30	P-0083	IFN-Based Therapies (5)	10758	Kuo-Chin	Chang	the Effect of Peginterferon 2a and 2b in Chronic HCV Patients under Response-Guided Therapy
February 21st (Sun)	17:30	17:35	P-0084	IFN-Based Therapies (5)	10197	Miao	Zhang	the Expression of Circulating TFH Cells and CD19+B B Cells in CHC Patients with PEG-IFN Therapy
February 21st (Sun)	17:35	17:40	P-0085	IFN-Based Therapies (5)	10110	Narina	Sargsyants	Successes in Difficult-to-Treat Patient with HCV-Associated Glomerulonephritis
February 21st (Sun)	17:40	17:45	P-0086	IFN-Based Therapies (5)	10081	Bilgehan	Aygen	Telaprevir Combination Therapy in Patients Infected with Hepatitis C Virus Genotype 4
February 21st (Sun)	17:45	17:50	P-0087	IFN-Based Therapies (5)	11064	Koji	Younosumi	Telaprevir-Based Triple Therapy will be Beneficial for Patients of High Alpha-Fetoprotein Level
February 21st (Sun)	17:50	17:55	P-0088	IFN-Based Therapies (5)	10912	Zobair M.	Takayossi	Work Productivity Impairment in Asian Patients with Hepatitis C Treated with Different Regimens
February 21st (Sun)	17:55	18:00	P-0089	DAA's NS3 Inhibitor plus NS5A Inhibitor (1)	10546	Yasuhiro	Tsuda	Antiviral Effects of Daclatasvir and Asunaprevir Therapy on the Liver Function in Hepatitis C
February 21st (Sun)	18:00	18:05	P-0090	DAA's NS3 Inhibitor plus NS5A Inhibitor (1)	11001	Katsuya	Shiraki	Daclatasvir and Asunaprevir for Chronic Genotype 1 Hepatitis C Virus Infection in Japan
February 21st (Sun)	18:05	18:10	P-0091	DAA's NS3 Inhibitor plus NS5A Inhibitor (1)	10376	Chih-Wei	Lin	ABT-493 and ABT-530 Pharmacokinetics are Similar in Healthy Japanese, Chinese and Caucasian Adults
February 21st (Sun)	18:10	18:15	P-0092	DAA's NS3 Inhibitor plus NS5A Inhibitor (1)	10823	Shintaro	Takaki	Daclatasvir and Asunaprevir Improve the Baseline Parameters in Chronic Hepatitis C Patients.
February 21st (Sun)	18:15	18:20	P-0093	DAA's NS3 Inhibitor plus NS5A Inhibitor (1)	10891	Yoshihiro	Suzuki	Daclatasvir plus Asunaprevir for Hepatitis C Infected Patients in Shonai Area Yamagata Prefecture.
February 21st (Sun)	18:20	18:25	P-0094	DAA's NS3 Inhibitor plus NS5A Inhibitor (1)	10840	Seyfettin	Koklu	Daclatasvir plus Asunaprevir in Difficult to Treat HCV Gt1b Population, EAP Turkey Experience
February 21st (Sun)	18:25	18:30	P-0095	DAA's NS3 Inhibitor plus NS5A Inhibitor (1)	10430	Toshiki	Kan	Daclatasvir/Asunaprevir Treatment Reduces Liver Fibrosis
February 21st (Sun)	17:20	17:25	P-0096	DAA's NS3 Inhibitor plus NS5A Inhibitor (2)	10462	Yoshio	Tokumoto	Efficacy and Safety of Asunaprevir and Daclatasvir Therapy for Chronic Hepatitis C Patients
February 21st (Sun)	17:25	17:30	P-0097	DAA's NS3 Inhibitor plus NS5A Inhibitor (2)	10449	Nozomu	Wada	Efficacy of Combination Therapy of Daclatasvir and Asunaprevir for HCV Genotype 1
February 21st (Sun)	17:30	17:35	P-0098	DAA's NS3 Inhibitor plus NS5A Inhibitor (2)	10211	Koichi	Honda	Efficacy of Daclatasvir plus Asunaprevir for Hepatitis C in Patients Non-Positive for NS5A Variants
February 21st (Sun)	17:35	17:40	P-0099	DAA's NS3 Inhibitor plus NS5A Inhibitor (2)	10741	Tushar	Garimella	Evaluation of Daclatasvir and Asunaprevir Exposures in Non-Japanese Asians, Japanese, and Caucasians
February 21st (Sun)	17:40	17:45	P-0100	DAA's NS3 Inhibitor plus NS5A Inhibitor (2)	10521	Paul	Kwo	Elbasvir/Grazoprevir in Cirrhotic Patients with HCV Infection
February 21st (Sun)	17:45	17:50	P-0101	DAA's NS3 Inhibitor plus NS5A Inhibitor (2)	11301	I.Shyan	Sheen	Virological Breakthrough and Hepatic Toxicity in the Treatment with Daclatasvir plus Asunaprevir
February 21st (Sun)	17:50	17:55	P-0102	DAA's NS3 Inhibitor plus NS5A Inhibitor (2)	11138	Fiona	McPhee	High SVR with DCV+ASV in HCV GT-1b Chinese, Koreans & Taiwanese without Baseline NS5A Polymorphisms
February 21st (Sun)	17:55	18:00	P-0103	DAA's NS3 Inhibitor plus NS5A Inhibitor (2)	10955	Nobuyuki	Matsumoto	Hemoglobin Decrease with Iron Deficiency Induced by DCV/ASV Therapy for Chronic Hepatitis C
February 21st (Sun)	18:00	18:05	P-0104	DAA's NS3 Inhibitor plus NS5A Inhibitor (3)	11183	Hiroki	Ikeda	Impact of RAV Dominancy on Treatment Outcomes in HCV GT1B Patients for Daclatasvir and Asunaprevir
February 21st (Sun)	18:05	18:10	P-0105	DAA's NS3 Inhibitor plus NS5A Inhibitor (3)	10432	Tatsuya	Ide	Predictive Markers of Viral Response to Daclatasvir/Asunaprevir in HCV Genotype 1 Patients.
February 21st (Sun)	18:10	18:15	P-0106	DAA's NS3 Inhibitor plus NS5A Inhibitor (3)	11121	Yuuri	Yamada	the Combination Therapy of Daclatasvir and Asunaprevir for Chronic HCV Genotype 1b Infection.
February 21st (Sun)	18:15	18:20	P-0107	DAA's NS3 Inhibitor plus NS5A Inhibitor (3)	10606	Sila	Akhan	Successful Treatment with Daclatasvir/Asunaprevir of A HCV Patient after Failure of PEGIFN and RBV
February 21st (Sun)	18:20	18:25	P-0108	DAA's NS3 Inhibitor plus NS5A Inhibitor (3)	10934	Gail	DeVecchis Wygant	EQ-5D Results in Asian Patients with HCV G1b Receiving DCV+ASV Who are IFN Intolerant/Ineligible
February 21st (Sun)	18:25	18:30	P-0109	DAA's NS3 Inhibitor plus NS5A Inhibitor (3)	11133	Haruhiko	Takeda	Ultra-Deep Sequencing for Detection of Low Abundant Drug-Resistant HCV in Patients Receiving DAAs.
February 21st (Sun)	18:30	18:35	P-0110	DAA's NS3 Inhibitor plus NS5A Inhibitor (3)	10117	Satoshi	Takakusagi	Efficacy and Safety of Daclatasvir and Asunaprevir for Patients Infected with HCV Genotype 1
February 21st (Sun)	18:35	18:40	P-0111	DAA's NS3 Inhibitor plus NS5A Inhibitor (3)	10597	Tarek	Hassanein	High SVR Rates with ABT-493 + ABT-530 in Non-Cirrhotic Patients with HCV Genotypes 1, 2, 3 Infection
February 21st (Sun)	18:40	18:45	P-0112	DAA's NS3 Inhibitor plus NS5A Inhibitor (3)	10611	Elyse	Swallow	Indirect Comparison of Daclatasvir+Asunaprevir vs Sofosbuvir/Ledipasvir for HCV in Japanese Patients
February 21st (Sun)	17:20	17:25	P-0113	DAA's NS5A Inhibitor plus NS5B Inhibitor (4)	10944	Patricia	Andrade	A Prospective Evaluation of A Combination of Sofosbuvir/Ledipasvir Performance in HCV Infection
February 21st (Sun)	17:25	17:30	P-0114	DAA's NS5A Inhibitor plus NS5B Inhibitor (4)	10860	Lydia	Tang	Comparative Efficacy of Generic Sofosbuvir Versus SOVALDI with Ribavirin for Hepatitis C
February 21st (Sun)	17:30	17:35	P-0115	DAA's NS5A Inhibitor plus NS5B Inhibitor (4)	10429	Wei Wei	Hou	Cost-Effectiveness Analysis of Sofosbuvir for Treatment-Naive G1 Chronic Hepatitis C in China
February 21st (Sun)	17:35	17:40	P-0116	DAA's NS5A Inhibitor plus NS5B Inhibitor (4)	11215	Bing	Li	Cost-Effectiveness Analysis of Sofosbuvir plus Ledipasvir CHC GT1b- Real Life Practice in China
February 21st (Sun)	17:40	17:45	P-0117	DAA's NS5A Inhibitor plus NS5B Inhibitor (4)	10876	Zobair M.	Younosumi	Quality of Life of Japanese Patients with Chronic Hepatitis C Treated with Ledipasvir and Sofosbuvir
February 21st (Sun)	17:45	17:50	P-0118	DAA's NS5A Inhibitor plus NS5B Inhibitor (4)	10878	Masashi	Mizokami	Characterizing Resistance in Patients Receiving SOF or LDV/SOF in Korea, Japan, and Taiwan
February 21st (Sun)	17:50	17:55	P-0119	DAA's NS5A Inhibitor plus NS5B Inhibitor (4)	10887	Sayaka	Ito	Detection of Hepatitis C Virus NS5A L31/Y93 Mutations in Patients with Hepatitis C
February 21st (Sun)	17:55	18:00	P-0120	DAA's NS5A Inhibitor plus NS5B Inhibitor (5)	10908	P.	Atanasov	Real-World Effectiveness and Cost/SVR: Ledipasvir/Sofosbuvir(LDV/SOF) for Chronic HCV(CHC) Treatment
February 21st (Sun)	18:00	18:05	P-0121	DAA's NS5A Inhibitor plus NS5B Inhibitor (5)	10909	P.	Atanasov	Real-World Effectiveness-8 Weeks(8w) Ledipasvir/Sofosbuvir(LDV/SOF) for Chronic HCV(CHC) Treatment
February 21st (Sun)	18:05	18:10	P-0122	DAA's NS5A Inhibitor plus NS5B Inhibitor (5)	10054	Mamun-Al	Mahtab	RVR Response in HCV Related Compensated CLD with Triple Therapy Containing Sofosbuvir in Bangladesh
February 21st (Sun)	18:10	18:15	P-0123	DAA's NS5A Inhibitor plus NS5B Inhibitor (5)	10286	P. Patrick	Basu	Sofosbuvir and Ledipasvir for SVR12 in Sickle Cell Disease with HCV.SLASH C Trial

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 21st (Sun)	18:15	18:20	P-0124	DAA's NS5A Inhibitor plus NS5B Inhibitor (5)	10287	P. Patrick	Basu	Sofosbuvir, Ledipasvir in IBD Patients with Biologics Including Ribavirin for HCV: SOLATAIRE C Trial
February 21st (Sun)	18:20	18:25	P-0125	DAA's NS5A Inhibitor plus NS5B Inhibitor (5)	11128	Nicholas T.	Au	No Clinically Relevant Differences in Sofosbuvir and Ledipasvir Exposure across Various Ethnicities
February 21st (Sun)	18:25	18:30	P-0126	DAA's NS5A Inhibitor plus NS5B Inhibitor (5)	11246	Terumi	Kaishima	Cost-Effectiveness Analysis Related to HCV Treatment is Possible to be Estimated in Each Province
February 21st (Sun)	17:20	17:25	P-0127	SOF plus RBV (1)	11210	Fan	Li	Cost-Effectiveness Analysis of Sofosbuvir-Based Regimens for CHC GT2-Real Life Practice in China
February 21st (Sun)	17:25	17:30	P-0128	SOF plus RBV (1)	10917	Ataru	Igarashi	Cost-Utility Analysis of Sofosbuvir for the Treatment of Genotype 2 Chronic Hepatitis C in Japan
February 21st (Sun)	17:30	17:35	P-0129	SOF plus RBV (1)	10719	Koichi	Takaguchi	Effect of Sofosbuvir and Ribavirin Treatment in HCV Genotype 2 Japanese Patients
February 21st (Sun)	17:35	17:40	P-0130	SOF plus RBV (1)	10848	Sayuri	Nomura	Efficacy and Side Effects of SOF/RBV in Patients with Hepatitis C Virus Genotype 2 Infection.
February 21st (Sun)	17:40	17:45	P-0131	SOF plus RBV (1)	11065	Yuki	Ohta	Sofosbuvir plus Ribavirin Treatment for HCV-Infected Patients with Ulcerative Colitis
February 21st (Sun)	17:45	17:50	P-0132	SOF plus RBV (1)	10385	Masayuki	Miyazaki	Efficacy of Sofosbuvir/Ribavirin for Japanese Patients with HCV Genotype 2 Infection
February 21st (Sun)	17:50	17:55	P-0133	SOF plus RBV (2)	10094	Muzzaffar	Gill	Outcomes of SOF and RIBA Therapy for HEP C G3 Patients Who are Relapsers of Peg INF and RIBA
February 21st (Sun)	17:55	18:00	P-0134	SOF plus RBV (2)	10766	Kazuya	Ura	Rapid Decrease of the Non-Invasive Serum Liver Fibrosis Marker WFA⁺-M2BP by IFN-Free Therapy
February 21st (Sun)	18:00	18:05	P-0135	SOF plus RBV (2)	11208	Ankur	Jindal	Sofosbuvir and Ribavirin for Chronic Hepatitis C: Interim Analysis from A Real-Life Indian Cohort.
February 21st (Sun)	18:05	18:10	P-0136	SOF plus RBV (2)	11153	Masayuki	Yokoyama	Sofosbuvir plus Ribavirin for HCV Genotype 2a Reinfection after LDLT
February 21st (Sun)	18:10	18:15	P-0137	SOF plus RBV (2)	10939	Agita	Jeruma	100 % Efficacy of Hepatitis C Treatment in Cirrhotic Patients: Real Life Results in Latvia.
February 21st (Sun)	18:15	18:20	P-0138	SOF plus RBV (2)	10053	Mamun-Al	Mahtab	RVR Response in HCV Related Decompensated Cirrhosis with Sofosbuvir in Bangladesh
February 21st (Sun)	18:20	18:25	P-0139	SOF plus RBV (2)	11377	Qing-Lei	Zeng	Sofosbuvir plus Daclatasvir with Ribavirin for 12 Weeks in Chinese Refractory Hepatitis C Patients
February 21st (Sun)	17:20	17:25	P-0140	Adverse Events by DAAs	10190	Hayato	Baba	A Case of Liver Dysfunction without An Elevation of ALT Caused by A Treatment of DCV and ASV
February 21st (Sun)	17:25	17:30	P-0141	Adverse Events by DAAs	10304	Tetsuya	Hiraishi	Adverse Effects of Combined Administration of Daclatasvir and Asunaprevir
February 21st (Sun)	17:30	17:35	P-0142	Adverse Events by DAAs	10791	Etsuko	Iio	Efficacy and Adverse Events of Daclatasvir/Asunaprevir in Chronic Hepatitis C Genotype 1b
February 21st (Sun)	17:35	17:40	P-0143	Adverse Events by DAAs	10852	Yuichi	Yoshida	Frequency and Severity of Liver Injury during Daclatasvir and Asunaprevir Dual Therapy for HCV
February 21st (Sun)	17:40	17:45	P-0144	Preclinical Study	10477	Meike H.	Van der Ree	A Single Dose of RG-101 Results in Undetectable HCV-RNA Levels in Chronic Hepatitis C Patients
February 21st (Sun)	17:45	17:50	P-0145	Preclinical Study	11147	Sam	Lee	CC-31244, A Pan-Genotypic, Potent HCV NS5B Non-Nucleoside Polymerase Inhibitor
February 21st (Sun)	17:50	17:55	P-0146	Preclinical Study	10870	Nicholas T.	Au	Chinese Ethnicity does not Result in Clinically Relevant Differences in Sofosbuvir Pharmacokinetics
February 21st (Sun)	17:55	18:00	P-0147	Preclinical Study	11251	Ming-Lung	Yu	Rapid Antiviral Response with TG-2349 plus PegIFN-RBV in Naive GT-1b Subject: An Interim Analysis
February 21st (Sun)	18:00	18:05	P-0148	Preclinical Study	11269	Chau-Ting	Yeh	TG-2349 3-day Monotherapy with Significant Antiviral Activity in Caucasian and Asian HCV Subjects
February 21st (Sun)	18:05	18:10	P-0149	Preclinical Study	10384	Ahlam M.	Farghaly	Serum Extracellular Matrix Degradation Inhibitors across Stages of Liver Fibrosis in Chronic HCV
February 21st (Sun)	17:20	17:25	P-0150	Hepatitis and Fibrosis	10058	Safak	Kaya	A Case with Hepatitis C Undergoing Kidney Transplantation after Telaprevir Containing Triple Therapy
February 21st (Sun)	17:25	17:30	P-0151	Hepatitis and Fibrosis	11019	Hae Lim	Lee	Acute Hepatitis and Reactivation of Hepatitis C Virus in Patients under Immunosuppressive Therapy
February 21st (Sun)	17:30	17:35	P-0152	Hepatitis and Fibrosis	10588	Nurbanu	Sezak	Acute Hepatitis C Infection in Human Immunodeficiency Virus (HIV) Infected Case
February 21st (Sun)	17:35	17:40	P-0153	Hepatitis and Fibrosis	10583	Nesrin	Turker	Acute Hepatitis C Infection: A Case Report
February 21st (Sun)	17:40	17:45	P-0154	Hepatitis and Fibrosis	10531	Goktug	Sirin	Is There Any Impact of Thyroid Dysfunction on EVR in Patients with Acute HCV Infection?
February 21st (Sun)	17:45	17:50	P-0155	Hepatitis and Fibrosis	11191	Gamal	Shiha	Fib5: A Novel Test Differentiating between Non-significant and Significant Fibrosis in CHC Patients
February 21st (Sun)	17:50	17:55	P-0156	Hepatitis and Fibrosis	11343	Fanpu	Ji	Long-Term Clinical Outcome of HCV Decompensated Cirrhotic Patients after Antiviral Treatment
February 21st (Sun)	17:55	18:00	P-0157	Hepatitis and Fibrosis	11205	Manish Chandra	Choudhary	Progression of Liver Fibrosis in HCV Genotype 3a is Associated with Modulation in Let-7 miRNA Family
February 21st (Sun)	18:00	18:05	P-0158	Hepatitis and Fibrosis	10904	Zobair M.	Younossi	Association of SVR and All-Cause Mortality Post INF-Based Therapy for CHC in A US Community Setting
February 21st (Sun)	18:05	18:10	P-0159	HCV and HCC (1)	11238	Kazuya	Ura	Age and Female are the Risk Factors for HCC Even in Chronic Hepatitis C Patients with SVR
February 21st (Sun)	18:10	18:15	P-0160	HCV and HCC (1)	11037	Ryo	Shimizu	Efficacy and Safety of Dual Oral Therapy with DCV and ASV after Curative RFA of HCV-Related HCC
February 21st (Sun)	18:15	18:20	P-0161	HCV and HCC (1)	10572	Takashi	Kosone	Direct Acting Antiviral Agents Can be Safely Used for Hepatitis C with Hepatocellular Carcinoma.
February 21st (Sun)	18:20	18:25	P-0162	HCV and HCC (1)	10581	Mei-Hsuan	Lee	Genetic Variants Near HLA Gene were Associated with the Risk for HCC among HCV Infected Patients
February 21st (Sun)	18:25	18:30	P-0163	HCV and HCC (1)	10357	Masaru	Baba	Influence on Hepatitis C Virus Eradication on Hepatocellular Carcinogenesis.
February 21st (Sun)	18:30	18:35	P-0164	HCV and HCC (1)	10859	Satoshi	Yasuda	Risk Factor for Development of HCC in Patients Who are Eradicated Hepatitis C Virus.

Date	Start	End	Poster No.	Session Tytle	Submission No.	First Name	Last Name	Title of Abstract
February 21st (Sun)	18:35	18:40	P-0165	HCV and HCC (1)	11376	Qing-Lei	Zeng	Clinical Model for Predicting the Post-SVR of HCC in CHC Patients: A Case Control Study
February 21st (Sun)	17:20	17:25	P-0166	HCV: Others (1)	10253	Sook-Hyang	Jeong	Direct Medical Cost for Hepatitis C Virus Infection in South Korea, 2009-2013
February 21st (Sun)	17:25	17:30	P-0167	HCV: Others (1)	11058	Junko	Tanaka	Disease Burden of Chronic Hepatitis C Virus (HCV) Infection in Japan
February 21st (Sun)	17:30	17:35	P-0168	HCV: Others (1)	10515	Sameh A.	Lashen	Target of Rapamycin and Autophagy in Chronic Hepatitis C Infection:Relation to Disease Activity
February 21st (Sun)	17:35	17:40	P-0169	HCV: Others (1)	11002	Tom	Ward	Assessing the Economic Impact of New Direct-Acting Antivirals for Chronic Hepatitis C in Japan
February 21st (Sun)	17:40	17:45	P-0170	HCV: Others (1)	10504	Chien-Jen	Chen	Disease Burden of Chronic Hepatitis C Virus (HCV) Infection in Taiwan
February 21st (Sun)	17:45	17:50	P-0171	HCV: Others (1)	10320	Hironao	Okubo	Gadoxetic Acid Enhanced MRI Predicts Hyperbilirubinemia of Simeprevir in Patients with HCV
February 21st (Sun)	17:50	17:55	P-0172	HCV: Others (1)	10353	Masanori	Sato	Abnormal Iron Metabolism in Patients with Chronic Hepatitis C
February 21st (Sun)	17:55	18:00	P-0173	HCV: Others (2)	10129	Moutaz F.	Derbala	Aspartate Transaminase to Platelet Ratio Index (APRI) in HCV and Schistosomiasis Coinfection
February 21st (Sun)	18:00	18:05	P-0174	HCV: Others (2)	11207	Guofeng	Chen	Cost-Effectiveness of Response-Guided Therapy with Triple DAAs in Non-Cirrhotic CHC GT1b
February 21st (Sun)	18:05	18:10	P-0175	HCV: Others (2)	10379	Satyendra K.	Tyagi	Impact of HCV Treatment on Impoverishment in Western Uttar Pradesh, India
February 21st (Sun)	18:10	18:15	P-0176	HCV: Others (2)	10716	Rafael	Bruck	Improved HCV Disease Awareness and Screening Compliance Following A Public Media Campaign in Israel
February 21st (Sun)	18:15	18:20	P-0177	HCV: Others (2)	10498	Xiao L.	Zhang	Epidemiological Characteristics on HIV Co-Infection with HBV and/or HCV
February 21st (Sun)	18:20	18:25	P-0178	HCV: Others (2)	10248	Jun	Ito	Prevalence and Characteristics of Naturally Occurring Sofosbuvir Resistance-Associated Variants
February 21st (Sun)	17:20	17:25	P-0179	HCV: Others (3)	10259	Sungkyu	Choi	Regional Differences of HCV and Clinical Characteristics of Chronic Hepatitis C in Jeollanam-Do
February 21st (Sun)	17:25	17:30	P-0180	HCV: Others (3)	10507	Shuhe	Hige	Resistance-Associated Variants in Hepatitis C Patients Who Failed Direct Acting Antiviral Treatment
February 21st (Sun)	17:30	17:35	P-0181	HCV: Others (3)	11146	Hisamitsu	Miyaaki	Significance of Hepatic Insulin Clearance in Patients with CHC and NAFLD
February 21st (Sun)	17:35	17:40	P-0182	HCV: Others (3)	10471	Seiichi	Mawatari	the Association between the Efficacy of Dual Oral Therapy for HCV and Resistance-Associated Variants
February 21st (Sun)	17:40	17:45	P-0183	HCV: Others (3)	11113	Zobair M.	Younossi	the Value of Cure for Chronic Hepatitis C (CH‐C) to the Society
February 21st (Sun)	17:45	17:50	P-0184	HCV: Others (3)	10977	Philip	Vutien	Treatment Rates of Chronic Hepatitis C (CHC): A Meta-Analysis of 12 Studies and 307,031 Patients
February 21st (Sun)	17:50	17:55	P-0185	HCV: Others (3)	11299	Zhiyu	Yang	the Effect of DAA Antiviral Therapy on Hepatitis C Virus-Related Thrombocytopenia: A Case Report
February 21st (Sun)	17:55	18:00	P-0186	HCV: Others (3)	10747	Mohamed_Yossef	Rabea	Anti-CCP hs in Egyptian Rheumatoid Arthritis Patients Associated with Chronic HCV Infection.
February 21st (Sun)	18:00	18:05	P-0187	ALF and ACLF (1)	10000	Mathieu	Vinken	Inhibition of Pannexin1 Channels Alleviates Acetaminophen-Induced Hepatotoxicity.
February 21st (Sun)	18:05	18:10	P-0188	ALF and ACLF (1)	10155	Koki	Yamada	Predictors of Acute Liver Failure with Hepatic Coma and Its Relationships to Outcome.
February 21st (Sun)	18:10	18:15	P-0189	ALF and ACLF (1)	10533	Suharno	Hakim	Acute Liver Failure Caused by Valproic Acid
February 21st (Sun)	18:15	18:20	P-0190	ALF and ACLF (1)	10800	Noriyo	Yamashiki	Indication of Liver Transplantation for Acute Liver Failure with Pancreatitis: Report of Two Cases
February 21st (Sun)	18:20	18:25	P-0191	ALF and ACLF (1)	11044	Shin	Yasui	Factors Influencing Infectious Complications in Severe and Fulminant Hepatitis.
February 21st (Sun)	18:25	18:30	P-0192	ALF and ACLF (1)	11134	Yue	Hu	Acute Liver Failure Caused by Mushroom Poisoning A Case Report
February 21st (Sun)	18:30	18:35	P-0193	ALF and ACLF (1)	10135	Jong-Hon	Kang	Transition of Etiology in Acute Liver Failurein Hokkaido, Japan-Emerging New Cause
February 21st (Sun)	17:20	17:25	P-0194	ALF and ACLF (2)	10056	Mamun-Al	Mahtab	Comparison of Ldt vs ETV in Patients with Hepatitis B Related ACLF in Bangladesh
February 21st (Sun)	17:25	17:30	P-0195	ALF and ACLF (2)	10057	Sharker Mohammad Shahadat	Hossain	Comparison between TDF vs ETV in Patients with Hepatitis B Related ACLF in Bangladesh
February 21st (Sun)	17:30	17:35	P-0196	ALF and ACLF (2)	10088	En-Qiang	Chen	Serum apoA-V in Survival Prediction of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
February 21st (Sun)	17:35	17:40	P-0197	ALF and ACLF (2)	10152	Biplob Kumar	Saha	Comparison between TDF vs TDF plus GCSF in Patients with ACLF-B in Bangladesh
February 21st (Sun)	17:40	17:45	P-0198	ALF and ACLF (2)	10394	Dong	Xi	Down-Regulated miR-181c was Related with HBV Associated Acute-on-Chronic Liver Failure by TNFalpha
February 21st (Sun)	17:45	17:50	P-0199	ALF and ACLF (2)	10960	XiaoPing	Wu	Role of Th17 and Treg cells in the Progression of Grave Hepatitis B Infection
February 21st (Sun)	17:50	17:55	P-0200	ALF and ACLF (2)	10262	Ren	Feng	The Dysregulation of ER Stress Response in AoCLF Patients Caused by Acute Exacerbation of CHB
February 21st (Sun)	17:55	18:00	P-0201	ALF and ACLF (2)	10198	Kenta	Nakagiri	Adipose-Derived Stem Cell Administration for Cytotoxic T Lymphocyte-Mediated Liver Injury in Mice.
February 21st (Sun)	18:00	18:05	P-0202	ALF and ACLF (2)	10060	Gang	Qin	Comparison of Different Models in Predicting Prognosis of HBV-ACLF
February 21st (Sun)	17:20	17:25	P-0203	ALF and ACLF (3)	10938	Madhumita	Premkumar	Thromboelastography Accurately Interprets Coagulation Failure in Patients with ACLF
February 21st (Sun)	17:25	17:30	P-0204	ALF and ACLF (3)	10308	Go	Igarashi	A Case of Severe Sclerosing Cholangitis Following Critical Ill with Extensive Burn Injury
February 21st (Sun)	17:30	17:35	P-0205	ALF and ACLF (3)	11086	Zhujun	Cao	Acute on Chronic Liver Failure Induced by Hepatic Injury is Characterized by Massive Cell Death

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 21st (Sun)	17:35	17:40	P-0206	ALF and ACLF (3)	11348	Kouji	Kimura	A Case of Postoperative Hepatic Encephalopathy after Total Cavopulmonary Connection Conversion.
February 21st (Sun)	17:40	17:45	P-0207	ALF and ACLF (3)	10398	Yoo Li	Lim	Acute-on-Chronic Liver Failure Development Correlate with Baseline Portal Hypertension
February 21st (Sun)	17:45	17:50	P-0208	ALF and ACLF (3)	10808	Eileen L.	Yoon	Significant Factors for Mortality in Patients with Acute Decompensation of Chronic Liver Disease
February 21st (Sun)	17:50	17:55	P-0209	ALF and ACLF (3)	10700	Sanchit	Budhiraja	ACLF: Clinical Profile and Factors Affecting Outcome
February 21st (Sun)	17:55	18:00	P-0210	ALF and ACLF (3)	10392	Noriko	Itaba	Human Mesenchymal Stems-Engineered Hepatic Cell Sheets Therapy for Acute Liver Injury
February 21st (Sun)	18:00	18:05	P-0211	Treatment and Prognosis of ACLF	11259	Priyanka	Jain	Comparison of the Acute on Chronic Liver Failure Severity Score – A Need for Simple and Dynamic One
February 21st (Sun)	18:05	18:10	P-0212	Treatment and Prognosis of ACLF	10422	Fan	Zeng	Neutrophil-Lymphocyte Ratio, An Artificial Liver Support System and Prognosis
February 21st (Sun)	18:10	18:15	P-0213	Treatment and Prognosis of ACLF	10589	Guan-Huei	Lee	Liver Transplantation for Patients with Acute-on-Chronic Liver Failure in Asia.
February 21st (Sun)	18:15	18:20	P-0214	Treatment and Prognosis of ACLF	10929	Madhumita	Premkumar	Presence of SIRS and Sepsis Predicts Mortality in Patients with Acute-on-Chronic Liver Failure.
February 21st (Sun)	18:20	18:25	P-0215	Treatment and Prognosis of ACLF	11115	Eileen L.	Yoon	Impact of Grade I ACLF on 1-Year Survival in Cirrhotic Patients with First Acute Decompensation
February 21st (Sun)	18:25	18:30	P-0216	Treatment and Prognosis of ACLF	11302	Chien-Hao	Huang	the Prognosis of Patients with Acute on Chronic Liver Failure Who were Admitted to ICU
February 21st (Sun)	17:20	17:25	P-0217	Epidemiology of Autoimmune Liver Diseases	10016	Minoru	Tomizawa	Autoimmune Hepatitis Patients Positive for Anti-Mitochondrial M2 Antibody
February 21st (Sun)	17:25	17:30	P-0218	Epidemiology of Autoimmune Liver Diseases	10470	Siow-Yi	Wong	Clinical Outcomes of Autoimmune Hepatitis in North-East Scotland
February 21st (Sun)	17:30	17:35	P-0219	Epidemiology of Autoimmune Liver Diseases	10412	Kaname	Yoshizawa	Incidence and Prevalence of Autoimmune Hepatitis in the Ueda Area, Japan.
February 21st (Sun)	17:35	17:40	P-0220	Epidemiology of Autoimmune Liver Diseases	10519	Fulya	Gunsar	Clinical Presentations of Autoimmune Hepatitis
February 21st (Sun)	17:40	17:45	P-0221	Epidemiology of Autoimmune Liver Diseases	10996	Tanaka	Kazunari	Clinical Characteristics in Acute Presentation of Autoimmune Hepatitis
February 21st (Sun)	17:45	17:50	P-0222	Complication of AIH	10630	Jeong-Yeop	Song	Is There A Link between Autoimmune Hepatitis and Bronchial Asthma and Irritable Bowel Syndrome?
February 21st (Sun)	17:50	17:55	P-0223	Complication of AIH	11045	Kengo	Furutani	Aortic Aneurysm and Aortic Dissection in Patients with Autoimmune Hepatitis: A Report of Four Cases.
February 21st (Sun)	17:55	18:00	P-0224	Complication of AIH	10717	Tolga	Dogan	Successful Treatment with Steroid of Autoimmune Hepatitis in A Patient with Rectum Adenocarcinoma
February 21st (Sun)	18:00	18:05	P-0225	Complication of AIH	10749	Amey D.	Sonavane	Hepatocellular Carcinoma in Autoimmune Hepatitis : the Western India Experience
February 21st (Sun)	18:05	18:10	P-0226	Complication of AIH	10417	Hidehiro	Kamezaki	A Case of PJP Diagnosed during Treatment with 15 mg Prednisolone Daily for AIH
February 21st (Sun)	18:10	18:15	P-0227	Complication of AIH	10952	Yoko	Doi	Two Cases of Hepatocellular Carcinoma with Autoimmune Hepatitis
February 21st (Sun)	17:20	17:25	P-0228	PBC (1)	10291	Yohei	Koizumi	Usefulness of Elastography for Diagnosis of Liver Fibrosis and Disease Progression in PBC Patients
February 21st (Sun)	17:25	17:30	P-0229	PBC (1)	10950	Myungseok	Lee	A Family with Four Siblings Affected with Primary Biliary Cirrhosis
February 21st (Sun)	17:30	17:35	P-0230	PBC (1)	10293	Tomohiro	Katsumi	Up-Regulated miR-139-5p in Hepatocytes Induce TNF&Alpha Similar to Clinical Sera from PBC Cases.
February 21st (Sun)	17:35	17:40	P-0231	PBC (1)	10434	Tetsuya	Yasunaka	Laparoscopic Finding Can Predict the Progression in Patients with Primary Biliary Cirrhosis
February 21st (Sun)	17:40	17:45	P-0232	PBC (1)	11217	Qinmei	Wu	Quantitative Fibrosis Parameters Highly Predict Esophageal Varices of Primary Biliary Cirrhosis
February 21st (Sun)	17:45	17:50	P-0233	PBC (2)	10527	Kazumichi	Abe	Relationship between Serum Cytokeratin-18 (M30) and Primary Biliary Cirrhosis Pathology
February 21st (Sun)	17:50	17:55	P-0234	PBC (2)	10079	Tomohiro	Sekiguchi	Serum Cell Death Biomarkers for Prediction of Liver Fibrosis and Poor Prognosis in PBC
February 21st (Sun)	17:55	18:00	P-0235	PBC (2)	10338	Yuanyuan	Li	Risk-Factors for Mortality in PBC Patients: A Deceased Case-Living Control Study in China
February 21st (Sun)	18:00	18:05	P-0236	PBC (2)	11204	Guohui	Jiao	PD-1 as An "Immune-Check Disturbance" with Infiltrated CD8⁺/SUP>⁺/SUP>⁺/SUP> T Cells Modify PBC clinical Course
February 21st (Sun)	18:05	18:10	P-0237	PBC (2)	10783	Maki	Tobari	Clinical Significance of the Serum IgG3 in Primary Biliary Cirrhosis
February 21st (Sun)	18:10	18:15	P-0238	PBC (2)	11123	Huan	Wang	Red Cell Distribution Width is Related to Histologic Severity of Primary Biliary Cirrhosis
February 21st (Sun)	17:20	17:25	P-0239	AIH and PBC	10142	Malgorzata	Wozniak	Autoimmune Hepatitis (AIH) in Patients Transferred from Pediatric to Adult Hepatology Care
February 21st (Sun)	17:25	17:30	P-0240	AIH and PBC	10386	N	Kimura	Possible Involvement of Activating Follicular Helper T Cells in Autoimmune Hepatitis
February 21st (Sun)	17:30	17:35	P-0241	AIH and PBC	10143	Marek	Woynarowski	Long Term Follow up of AIH Children after 6-12 Months Course of Budesonide and Azathioprine Therapy
February 21st (Sun)	17:35	17:40	P-0242	AIH and PBC	10733	Taro	Shibuki	Evaluation of Factors Associated with Relapse of Type 1 AIH Patients.
February 21st (Sun)	17:40	17:45	P-0243	AIH and PBC	11206	Wanyu	Li	Liver Transplantation in Primary Biliarycirrhosis: A Retrospective Cohort Study
February 21st (Sun)	17:45	17:50	P-0244	AIH and PBC	10781	Ayako	Maruno	A Case of Autoimmune Hepatitis Successfully Treated with Ursodeoxycholic Acid
February 21st (Sun)	17:50	17:55	P-0245	AIH and PBC	10879	Junichiro	Kumagai	An Older Patient with Autoimmune Hepatitis, Which Drugs-Induced Liver Injury Probably May Trigger
February 21st (Sun)	17:55	18:00	P-0246	Intrahepatic Biliary Tumor	10265	Masahiko	Kinoshita	the Association between Non-Alcoholic Steatohepatitis and Intrahepatic Cholangiocarcinoma

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 21st (Sun)	18:00	18:05	P-0247	Intrahepatic Biliary Tumor	10595	Hiroto	Ishikawa	A Case of Mucinou Carcinoma of the Liver
February 21st (Sun)	18:05	18:10	P-0248	Intrahepatic Biliary Tumor	10776	Dae Hwan	Kang	Vorinostat-Incorporated Nanoparticles for Local Delivery into Human Cholangiocarcinoma Cells
February 21st (Sun)	18:10	18:15	P-0249	Intrahepatic Biliary Tumor	11229	Tomoharu	Yamada	Intrahepatic Cholangiocarcinoma Arising in Patients with Hepatocellular Carcinoma
February 21st (Sun)	18:15	18:20	P-0250	Intrahepatic Biliary Tumor	10842	Takafumi	Saito	A Case of Intraductal Papillary Neoplasm of the Bile Duct Associated with Autoimmune Hepatitis
February 21st (Sun)	18:20	18:25	P-0251	Hepatobiliary Cystic Disease	10765	Hiroyuki	Kanomata	A Case of Asymptomatic Mucinous Cystic Neoplasm of the Liver with Marked Calcification
February 21st (Sun)	18:25	18:30	P-0252	Hepatobiliary Cystic Disease	10677	Kadir	Ozturk	A Rare Case: An Elderly Women with Type 3 Choledochal Cyst
February 21st (Sun)	18:30	18:35	P-0253	Hepatobiliary Cystic Disease	11080	Alaa eldeen	Massry	Male Patient with Anaphylactic Shock And Hepatic Cyst
February 21st (Sun)	18:35	18:40	P-0254	Hepatobiliary Cystic Disease	10990	Takayuki	Tokunaga	Clinical Evaluation of 40 Cases with Treated Hepatic Cysts
February 21st (Sun)	17:20	17:25	P-0255	ERCP and Biliary Disease	10103	Christian D.	Fingas	Expression of PRK/PLK3 is Associated with A Less Invasive Tumor Biology in Cholangiocarcinoma
February 21st (Sun)	17:25	17:30	P-0256	ERCP and Biliary Disease	10778	Su Jim	Kim	Photosensitizer-Incorporated Chitosan Nanoparticles for Treatment of Cholangiocarcinoma
February 21st (Sun)	17:30	17:35	P-0257	ERCP and Biliary Disease	10031	Shamardan E.	Bazeed	ERCP Role in Management of Biliary Strictures in Southern Egypt
February 21st (Sun)	17:35	17:40	P-0258	ERCP and Biliary Disease	10216	Lubna	Kamani	Safety of Conscious Sedation in Patients Undergoing ERCP with HepatoBiliary Disease
February 21st (Sun)	17:40	17:45	P-0259	ERCP and Biliary Disease	10685	Muzzaffar	Gill	Outcomes of Endoscopic Retrograde Cholangiopancreatography in Patients with Cirrhosis
February 21st (Sun)	17:45	17:50	P-0260	ERC and Intervention	10381	Osman A.	Osman	Role of Fluorescence in Situ Hybridization in the Diagnosis of Malignant Biliary Stricture
February 21st (Sun)	17:50	17:55	P-0261	ERC and Intervention	10845	Hyeong Seok	Nam	Efficacy of Minor Endoscopic Sphincterotomy to Prevent Post-ERCP Pancreatitis for Biliary Stenting
February 21st (Sun)	17:55	18:00	P-0262	ERC and Intervention	11270	Lubna	Kamani	Gender Specific Etiological Spectrum of ErCP in Hepatopancreaticobiliary Diseases
February 21st (Sun)	18:00	18:05	P-0263	ERC and Intervention	11333	Ali Riza	Koksal	Relationship between Adipocytokine Levels and Post-ERCP Pancreatitis Risk.
February 21st (Sun)	18:05	18:10	P-0264	ERC and Intervention	10305	Camille Ariadne C.	Tanchanco	Role of Vit K in Prevention of Post Sphincterotomy Bleeding in Patients with Normal Prothrombin Time
February 21st (Sun)	17:20	17:25	P-0265	Cholelithiasis and Cholangitis	10974	Shen-Yung	Wang	Cooling Via A Gallbladder Drainage Tube during Radiofrequency Ablation Reduces Gallbladder Injuries
February 21st (Sun)	17:25	17:30	P-0266	Cholelithiasis and Cholangitis	10188	Ryuichi	Yamamoto	Endoscopic Management of Occcluded Biliary Stents: A Single Center Study
February 21st (Sun)	17:30	17:35	P-0267	Cholelithiasis and Cholangitis	10283	Resat	Ozaras	Psoriasis and Neutrophilic Cholangitis: More Than A Coincidence
February 21st (Sun)	17:35	17:40	P-0268	Cholelithiasis and Cholangitis	10346	Yu Jun	Wong	Management of Biliary Complications Post Liver Transplant in Singapore
February 21st (Sun)	17:40	17:45	P-0269	Cholelithiasis and Cholangitis	10487	Kiichi	Tatagawa	Multi-Planar or Curved-Planar Reconstruction in the Detailed CT Analysis of Cholelithiasis
February 21st (Sun)	17:45	17:50	P-0270	Cholelithiasis and Cholangitis	11114	Fanyin	Meng	Functional Role of microRNAs-FoxA2 Axis in Cholestatic Liver Injury
February 21st (Sun)	17:50	17:55	P-0271	Pancreaticobiliary Cancer	10601	Biröl	Baysal	Helicobacter Pylori in Pancreatic Adenocarcinoma
February 21st (Sun)	17:55	18:00	P-0272	Pancreaticobiliary Cancer	10164	Mohammad Golam	Azam	Serum Carbohydrate Antigen 19-9 (CA 19-9) in the Diagnosis of Malignant Obstructive Jaundice
February 21st (Sun)	18:00	18:05	P-0273	Pancreaticobiliary Cancer	10755	Atsushi	Kubo	A Case Report of Carcinosarcoma of the Lower Bile Duct with Polypoid Growth
February 21st (Sun)	18:05	18:10	P-0274	Pancreaticobiliary Cancer	10843	Hyeong Seok	Nam	Percutaneous Cholecystostomy as Definite Management for Acute Cholecystitis with Klartin Tumor
February 21st (Sun)	18:10	18:15	P-0275	Pancreaticobiliary Cancer	11195	Abrorjon	Yusupbekov	Liver Function Correction in Pancreatic Cancer Patients with Obstructive Jaundice
February 21st (Sun)	18:15	18:20	P-0276	Pancreaticobiliary Cancer	10043	Tharatip	Srisuk	Pancreaticoduodenectomy in A Huge Pancreatic Neuroendocrine Carcinoma of Infancy. Case Report
February 22nd (Mon)	17:40	17:45	P-0277	HBV and Immunology (1)	10203	Li	Zhang	Changes of the Humoral Immune Response in CHB Patients with PEG-IFN Therapy
February 22nd (Mon)	17:45	17:50	P-0278	HBV and Immunology (1)	10607	Satoshi	Aono	Successful Immunological Responses against Hepatitis B Virus in Immunologically Humanized Mice
February 22nd (Mon)	17:50	17:55	P-0279	HBV and Immunology (1)	10476	Ruyi	Zhang	Analysis Th17/Treg Balance and Specific Transcription Factor(ROR γ ,Foxp3) in CHB Patients
February 22nd (Mon)	17:55	18:00	P-0280	HBV and Immunology (1)	10481	Ruyi	Zhang	Analysis Th17/Treg Balance and Correlation with Liver Function,HBVDNA in CHB Patients
February 22nd (Mon)	18:00	18:05	P-0281	HBV and Immunology (1)	10813	Takuro	Uchida	CTL Mediated Acute Liver Failure and Rescue by CTLA4Ig in Human Hepatocyte Transplanted TKNOG Mice
February 22nd (Mon)	18:05	18:10	P-0282	HBV and Immunology (1)	10561	You	Jing	The Research of Th17/Treg in Patient with HBV-Infected and Its Relationship with Liver Function
February 22nd (Mon)	18:10	18:15	P-0283	HBV and Immunology (1)	11355	Masafumi	Haraguchi	Geranylgeranylacetone Exerts Anti-Hepatitis B Virus Activity by Suppressing Enhancer-1 Activity
February 22nd (Mon)	18:15	18:20	P-0284	HBV and Immunology (2)	10706	Arttrika	Ranjan	Effect of Cytokine IL-18 on Different Phases of Chronic Hepatitis B Infection. Progression.
February 22nd (Mon)	18:20	18:25	P-0285	HBV and Immunology (2)	11052	Hiroko	Miyadera	A Large Scale Screening of HLA-Binding Peptides from HBs and HBc Peptide Libraries
February 22nd (Mon)	18:25	18:30	P-0286	HBV and Immunology (2)	11150	Guiyang	Wang	Regulatory B Cells Increase in Immune Reactive Phase of Chronic Hepatitis B Virus Infection
February 22nd (Mon)	18:30	18:35	P-0287	HBV and Immunology (2)	11345	Xiangsheng	Xu	Polyclonal B Cell Activation Induced by Tfh Correlated with Th17 Mediated Liver Damage in CHB

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	18:35	18:40	P-0288	HBV and Immunology (2)	11009	Junya	Suzuki	Analyzing RNA Exosome Mediated HBV-RNA Degradation Mechanism
February 22nd (Mon)	18:40	18:45	P-0289	HBV and Immunology (2)	11361	guangying	deng	Role of TLR8 Mediated Antiviral Immunity in Chronic Hepatitis B
February 22nd (Mon)	18:45	18:50	P-0290	HBV and Immunology (2)	10303	Hang	Zhang	HBXIP Negatively Regulates Antiviral Response by Promoting Proteasomal Degradation of TBK1
February 22nd (Mon)	17:40	17:45	P-0291	Regulation of HBV Replication	10349	Kiyooki	Ito	Mechanisms of Interaction between Host Glycosylation System and Hepatitis B Virus Replication System
February 22nd (Mon)	17:45	17:50	P-0292	Regulation of HBV Replication	10096	Hussein H.	Aly	SKIV2L/RNA Exosome Mediated Regulation of Hepatitis B Virus.
February 22nd (Mon)	17:50	17:55	P-0293	Regulation of HBV Replication	10847	Reina	Sasaki	HBV blocks MG132-Induced Apoptosis in Human Hepatic Stellate Cells
February 22nd (Mon)	17:55	18:00	P-0294	Regulation of HBV Replication	11172	Jinglan	Jin	Aberrant Methylation of Inflammatory Pathways in HBV Infection
February 22nd (Mon)	18:00	18:05	P-0295	Regulation of HBV Replication	11181	Yanwei	Zhong	The Characterization of HBV ccc DNA in Placenta Tissues from Pregnant Women with Positive HBsAg
February 22nd (Mon)	18:05	18:10	P-0296	Regulation of HBV Replication	10241	Xiao-Ben	Pan	Inhibition of HBV cccDNA Transcription by CPP-PNA Conjugates Assembled on Oligonucleotide Scaffolds
February 22nd (Mon)	18:10	18:15	P-0297	miRNA and HBV	10505	Ya	Wen	Serum Level of microRNA in the Patients with ACLF Related HBV Infection
February 22nd (Mon)	18:15	18:20	P-0298	miRNA and HBV	10666	Sulin	Yu	MicroRNA-155 in Peripheral Blood Mononuclear Cells of Patients Infected with Hepatitis B Virus
February 22nd (Mon)	18:20	18:25	P-0299	miRNA and HBV	10686	Masato	Nakamura	Lower Circulating microRNA-122 Indicate Severe Hepatic Fibrosis in Chronic Hepatitis B Patients
February 22nd (Mon)	18:25	18:30	P-0300	miRNA and HBV	10718	Yao	Li	Do Unfavorable rtM204I/V and sW182stop/rtV191I Mutations Trend to Co-Mutate in Genotype C HBV?
February 22nd (Mon)	18:30	18:35	P-0301	miRNA and HBV	10830	Thananya	Jinato	Analysis of Human microRNAs Profiles in Response to HBV Transfection and Peg-IFN Treatment by NGS
February 22nd (Mon)	18:35	18:40	P-0302	miRNA and HBV	11222	Sadaf B.	Dar	Circulating mir-150 and mir-342 as Potential Biomarkers to Predict HCC Progression in HBV Patients
February 22nd (Mon)	17:40	17:45	P-0303	Epidemiology and Surveillance	10049	Md. Ashraf	Alam	Pattern of Hepato-Pancreatic Diseases in Cox's Bazar Medical College Hospital
February 22nd (Mon)	17:45	17:50	P-0304	Epidemiology and Surveillance	11096	Marina V.	Maevskaya	The Automated System for Screening of Liver Disease
February 22nd (Mon)	17:50	17:55	P-0305	Epidemiology and Surveillance	11016	Sze Hang Kevin	Liu	A Population-Based Study on the Seroprevalence of Viral Hepatitis in Hong Kong, China
February 22nd (Mon)	17:55	18:00	P-0306	Epidemiology and Surveillance	10899	Vincenzo	Messina	HBV,HVC,HIV Prevalence.Evaluation in A High Risk Population (1999-2014)
February 22nd (Mon)	18:00	18:05	P-0307	Epidemiology and Surveillance	11081	Yoona A.	Kim	Low Liver Disease Screening and Treatment Rates in Mongolia: Results from a Physician Survey
February 22nd (Mon)	18:05	18:10	P-0308	Epidemiology and Surveillance	10050	Mohammad Forhad	Abedin	Chronic Liver Disease is One of the Leading Causes of Death in Bangladesh
February 22nd (Mon)	18:10	18:15	P-0309	Epidemiology and Surveillance	10332	Kengo	Kawai	Epidemiologic Study for Acute Hepatitis in Recent Years in Toyama Area
February 22nd (Mon)	18:15	18:20	P-0310	Epidemiology and Surveillance	11306	Michelle C.	Ong-Chu	Prevalence of Hepatitis B and C and Risk Factors among Prison Inmates in Cebu, Philippines
February 22nd (Mon)	18:20	18:25	P-0311	Epidemiology and Surveillance	11327	Necla	Tulek	Seroprevalence of Hepatitis A and Hepatitis B
February 22nd (Mon)	18:25	18:30	P-0312	Vaccination of HBV	10210	<small>Dewa Palahage Chula Karishka Ananda</small>	Lal	Hepatitis B Vaccination among Dental Practitioners in Sri Lanka
February 22nd (Mon)	18:30	18:35	P-0313	Vaccination of HBV	10807	Yong	Poovorawan	Impact of Universal Hepatitis B Vaccination into Newborn as Part of Thailand EPI Program Since 1988
February 22nd (Mon)	18:35	18:40	P-0314	Vaccination of HBV	11351	Feng-cai	Zhu	Immunogenicity and Efficacy of A 10 ⁸ mug Recombinant Yeast-Derived Hepatitis B Vaccine in Newborns
February 22nd (Mon)	17:40	17:45	P-0315	HBV Genotype	10172	Rajneesh	Kumar	Similar Intrahepatic, Serum Virus-Load and HCC in Hepatitis B Genotype B&C with Advanced Fibrosis
February 22nd (Mon)	17:45	17:50	P-0316	HBV Genotype	10378	Alexis	Jose-Abrego	High Prevalence of HBV Infection, Genotypes H, F1b and G in Socially Vulnerable Mexican Risk Groups
February 22nd (Mon)	17:50	17:55	P-0317	HBV Genotype	10958	Bushra	Tanzem	Sequencing HBV Polymerase & Surface Genes Circulating in A Bangladeshi Cohort
February 22nd (Mon)	17:55	18:00	P-0318	HBsAg (1)	10041	Olga	Tarasova	HBsAg Quantity for Monitoring of Hepatitis B Virus Infection in Inactive Carriers
February 22nd (Mon)	18:00	18:05	P-0319	HBsAg (1)	10468	Itaru	Ozeki	HBsAg Analysis Using the Highly Sensitive Lumipulse HBsAg-HQ Assay in Patients with Liver Disease
February 22nd (Mon)	18:05	18:10	P-0320	HBsAg (1)	11093	Sukran	Kose	Evaluation of Serum qHBsAg Levels and Liver Biopsy in Inactive Hepatitis B Carriers
February 22nd (Mon)	18:10	18:15	P-0321	HBsAg (1)	11139	Hye Won	Lee	Distribution of Quantitative HBsAg Level According to Serum HBV DNA Level in Chronic Hepatitis B
February 22nd (Mon)	18:15	18:20	P-0322	HBsAg (1)	11357	Cunling	Yan	Detection of HBV Surface Antigen Mutations in Patients with Chronic HBV by ELECSYS HBsAg II Assay
February 22nd (Mon)	18:20	18:25	P-0323	HBsAg (1)	11232	Aiting	Yang	Dynamic Changes of HBsAg in HBV Patients: Genotype C had A Greater HBsAg Decline Than Genotype B
February 22nd (Mon)	18:25	18:30	P-0324	HBsAg (1)	10554	Chi-Ling	Chen	Plasma Adiponectin Levels and Chronic HBV Infection Characteristics and Milestones
February 22nd (Mon)	17:40	17:45	P-0325	HBsAg (2)	10021	Ahmet	Uyanikoglu	HBsAg (+) Patients Distribution, Clinical and Demographic Characteristics in Turkey Sanliurfa Region
February 22nd (Mon)	17:45	17:50	P-0326	HBsAg (2)	10563	Li	Wang	HBsAg Seroclearance after Treatment-Induced HBeAg Seroclearance in Chronic Hepatitis B Patients
February 22nd (Mon)	17:50	17:55	P-0327	HBsAg (2)	11074	Yali	Liu	High Rate of Hepatitis B Surface Antigen Mutations in Chinese Patients with Chronic HBV Infection
February 22nd (Mon)	17:55	18:00	P-0328	HBsAg (2)	11187	Ruifeng	Yang	Trace Amount of HBsAg in Samples for Pre-Surgery Testing was Detected Using An Ultra-Sensitive Assay

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	18:00	18:05	P-0329	HBsAg (2)	11091	Andrew	V	Antiviral Effect of Therapy with REP 2139-Ca and Nucleos(t)ide Analogues against HBV in Vivo
February 22nd (Mon)	18:05	18:10	P-0330	HBsAg (2)	10500	Hong	Deng	Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter and A New Algorithm
February 22nd (Mon)	18:10	18:15	P-0331	HBsAg (2)	10006	Ehab A.	Abdelatti	HBV: Challenges to Cure in the Future
February 22nd (Mon)	18:15	18:20	P-0332	HBsAg (2)	10009	Mohammad K.	Parvez	In Vitro Evaluations of Anti-Hepatitis B Activities of 60 Medicinal Plants Extracts
February 22nd (Mon)	18:20	18:25	P-0333	HBV Marker	10473	Itaru	Ozeki	Evaluation of Hepatitis B Surface Antibody and Core Antibody in Patients with HBsAg-Negative
February 22nd (Mon)	18:25	18:30	P-0334	HBV Marker	10474	Ling-bo	Liang	HBV cccDNA Correlates with Histological Inflammation Activity in Chronic Hepatitis B Infection
February 22nd (Mon)	18:30	18:35	P-0335	HBV Marker	10576	Chia-Lin	Chang	The Association between Quantitative Hepatitis B Core Antibody Level and HBV Seromarkers
February 22nd (Mon)	18:35	18:40	P-0336	HBV Marker	10438	Omer	Karasahin	Neopterin as A Marker for Immune Status in Patients with Chronic Hepatitis B
February 22nd (Mon)	18:40	18:45	P-0337	HBV Marker	11162	Chao	Wu	Red Cell Distribution Width to Albumin Ratio, A Novel Index of the Severity of Chronic HBV Infection
February 22nd (Mon)	18:45	18:50	P-0338	HBV Marker	11340	Gui-Qiang	Wang	Selected Cytokines Predicting Liver Histology in CHB Patients with Normal to Mildly Elevated ALT
February 22nd (Mon)	18:50	18:55	P-0339	HBV Marker	10427	Veena Shrivanthi	Gelli	HBV Reduces IRF3 Gene Expression Despite Increased Expression of Cellular Cytosolic DNA Sensor cGAS
February 22nd (Mon)	17:40	17:45	P-0340	HBV Mutation	10604	Shintaro	Nagashima	Characteristics of HBV Full-Length Sequences in 21 Persons among 509 Residents in Binh Thuan, Vietnam
February 22nd (Mon)	17:45	17:50	P-0341	HBV Mutation	10631	Lingyun	Zhou	Biological Characteristics and Impacts of Truncated HBsAg Mutant Expressed by HBV rtA181T Mutation
February 22nd (Mon)	17:50	17:55	P-0342	HBV Mutation	10839	Yujiao	Liang	Comparison of HBV Variants by Deep Sequencing with PCR and without PCR
February 22nd (Mon)	17:55	18:00	P-0343	HBV Mutation	11129	Yuan	Xue	Characterization of HBV Whole Genome by Ultra Deep Sequencing during Acute Infection of G145R Mutant
February 22nd (Mon)	18:00	18:05	P-0344	HBV Mutation	10270	laura Navika	Yamani	Quasispecies Variants of Surface HBV Detected by Ultra-Deep Sequencing in Indonesian Patients
February 22nd (Mon)	18:05	18:10	P-0345	HBV Mutation	10548	John Hoon	Rim	Spectrum of HBV DNA Drug Resistance Mutations in Korea: Is Heteroresistance of HBV Emerging?
February 22nd (Mon)	18:10	18:15	P-0346	HBV Mutation	11116	Qi	Zhang	Incidence of Spontaneous Resistance Mutation in Untreated Chronic Hepatitis B Patients in China
February 22nd (Mon)	18:15	18:20	P-0347	Seroconversion of HBeAg	10275	Yushi	Kimura	HBV DNA Levels on HBE Seroconversion Could Predict Clinical Course in Chronic Hepatitis B
February 22nd (Mon)	18:20	18:25	P-0348	Seroconversion of HBeAg	10329	Khairul A.	Jaafar	Hepatitis B Surface Antigen (HBsAg) Levels and Hepatitis Be Antigen (HBeAg) Seroconversion Status
February 22nd (Mon)	18:25	18:30	P-0349	Seroconversion of HBeAg	10459	Jessica	Liu	Hepatitis B Core Antibody Levels Can Predict HBeAg Seroclearance in Chronic Hepatitis B Patients
February 22nd (Mon)	18:30	18:35	P-0350	Seroconversion of HBeAg	10796	Hayriye Seda	Aydin	The Evaluation of the Factors Affecting Seroconversions in HBeAg+ Chronic Hepatitis B Patients.
February 22nd (Mon)	18:35	18:40	P-0351	Seroconversion of HBeAg	10925	Hui	Ma	HBcAg is A Predictor of HBeAg Seroconversion in CHB Patients Treated with Pegylated Interferon
February 22nd (Mon)	18:40	18:45	P-0352	Seroconversion of HBeAg	11237	Xiao L.	Chi	Baseline HBeAg and CH50 Predicts Early HBeAg Seroconversion in Chronic Hepatitis B Patients
February 22nd (Mon)	17:40	17:45	P-0353	SNP and HBV	10065	Grace	Wong	SLC10A1 Variant is Associated Liver Fibrosis in Patients with Chronic Hepatitis B
February 22nd (Mon)	17:45	17:50	P-0354	SNP and HBV	10356	Yuka	Ochi	SNPs are Associated with Pathogenesis of Chronic HBV Infection
February 22nd (Mon)	17:50	17:55	P-0355	SNP and HBV	10448	Jessica	Liu	The Association between SNPs on ADH1B and ALDH2 and HBV Related HCC is Mediated by Alcohol Drinking
February 22nd (Mon)	17:55	18:00	P-0356	SNP and HBV	11059	Hikmet	Akkiz	Association between HBV Infection and HLA Gene rs3077 and rs9277535 in the Turkish Population
February 22nd (Mon)	18:00	18:05	P-0357	SNP and HBV	11239	Seyed Reza	Mohebbi	Association between A Polymorphism in microRNA Target Site of Interleukin 16 and Chronic Hepatitis B
February 22nd (Mon)	18:05	18:10	P-0358	SNP and HBV	10159	Daiki	Miki	Japanese Genetic Study Could not Suggest the Importance of the ΔNTCP Locus for HBV Persistence
February 22nd (Mon)	18:10	18:15	P-0359	SNP and HBV	11304	Seyed Reza	Mohebbi	Lack of Association between IL-12RB1 Gene Polymorphism (rs11575934) and Chronic Hepatitis B
February 22nd (Mon)	18:15	18:20	P-0360	SNP and HBV	11331	Seyed Reza	Mohebbi	Polymorphisms of Interleukin 12 Gene are not Associated with Chronic Hepatitis B in Iranian Patients
February 22nd (Mon)	18:20	18:25	P-0361	HBV Carriers (1)	10638	Levent	Doganay	HLA DPB1*15:01 Predicts Spontaneous HBsAg Seroconversion in Chronic Hepatitis B
February 22nd (Mon)	18:25	18:30	P-0362	HBV Carriers (1)	10732	Takashi	Taida	The Clinical Difference of HBeAb-Positive Inactive Carrier among Medical Facilities in Japan.
February 22nd (Mon)	18:30	18:35	P-0363	HBV Carriers (1)	10889	Ahmet C.	Yardimci	Are We Missing Out Some of Chronic Hepatitis B Patients Who Actually Needs Treatment?
February 22nd (Mon)	18:35	18:40	P-0364	HBV Carriers (1)	10965	Takashi	Taida	The Prognosis of Hepatitis B Inactive Carrier in Japan: A Multicenter Prospective Study
February 22nd (Mon)	18:40	18:45	P-0365	HBV Carriers (1)	10153	Meliha	Meric Koc	Febrile Neutropenia Associated with Hepatitis B Infection: A Case Report
February 22nd (Mon)	18:45	18:50	P-0366	HBV Carriers (1)	10395	Yoko	Yamagiwa	Strategies to Improve Utility of Chronic Hepatitis B Therapy Based on Questionnaire Survey in Japan
February 22nd (Mon)	18:50	18:55	P-0367	HBV Carriers (1)	11277	Selma	Tosun	The Paths to Diagnosis in HBsAg Positive Individuals
February 22nd (Mon)	17:40	17:45	P-0368	HBV Carriers (2)	11287	Selma	Tosun	Evaluation of HBV Infection Status in Family Members of HBsAg-Positive Individuals
February 22nd (Mon)	17:45	17:50	P-0369	HBV Carriers (2)	10162	Jack	Wallace	Multiple Failures: Addressing the Barriers to Hepatitis B Treatment in China

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	17:50	17:55	P-0370	HBV Carriers (2)	10602	Chikako	Yamamoto	Sero-Epidemiological Study of Hepatitis Viral Infections among 2,105 Employees in Hiroshima, Japan
February 22nd (Mon)	17:55	18:00	P-0371	HBV Carriers (2)	10744	Nazish	Butt	Clinical Characteristics and Management Status of Hepatitis B: A Cross-Sectional Study.
February 22nd (Mon)	18:00	18:05	P-0372	HBV Carriers (2)	11318	Selma	Tosun	Are Hepatitis Patients Hiding Their Disease ?
February 22nd (Mon)	18:05	18:10	P-0373	HBV Carriers (2)	10040	Myung Jin	Oh	Differentiation in Patients with Acute Hepatitis B and Chronic Hepatitis B with Acute Exacerbation
February 22nd (Mon)	18:10	18:15	P-0374	HBV Carriers (3)	10167	Amrish	Mishra	Hep B Prevention
February 22nd (Mon)	18:15	18:20	P-0375	HBV Carriers (3)	10282	Muhammad	Adnan	To Determine the Prevalence of Hepatitis B Disease Stages
February 22nd (Mon)	18:20	18:25	P-0376	HBV Carriers (3)	10788	Esmeray	Mutlu Yilmaz	Stigma, Discrimination and Living with Hepatitis B in Turkey
February 22nd (Mon)	17:40	17:45	P-0377	Co-Infection and HBV (1)	10512	Erwin	Ho	China on the Scheldt:HBV and HCV in the Chinese Population in Belgium and Study of Screening Methods
February 22nd (Mon)	17:45	17:50	P-0378	Co-Infection and HBV (1)	10857	Guoli	Lin	the Virological Data of the Patients with HBV-HCV Co-Infection
February 22nd (Mon)	17:50	17:55	P-0379	Co-Infection and HBV (1)	10896	Prasad_Ashok	Bhate	Cross Sectional Study of Prevalence and Risk Factors of Hepatitis B and C Infection in Rural India
February 22nd (Mon)	17:55	18:00	P-0380	Co-Infection and HBV (1)	10861	Guoli	Lin	The Virological Response of the Patients with HBV-HCV Co-Infection after Accepting Anti-HCV Therapy
February 22nd (Mon)	18:00	18:05	P-0381	Co-Infection and HBV (1)	10354	Hsing Yu	Chen	Impact of Occult Hepatitis B on the Clinical Outcomes of Patients with Chronic Hepatitis C Infection
February 22nd (Mon)	18:05	18:10	P-0382	Co-Infection and HBV (2)	11305	Yi-Cheng	Chen	Patients with Active HBV had Worse Clinical Features Than Active HCV Alone in Dual HBV/HCV Infection
February 22nd (Mon)	18:10	18:15	P-0383	Co-Infection and HBV (2)	10798	Guoli	Lin	The Epidemiological Characters of the Patients with HBV HCV Co-Infection
February 22nd (Mon)	18:15	18:20	P-0384	Co-Infection and HBV (2)	11163	Cagdas	Kalkan	Sustained Virological Response in Dual Infection of Chronic Hepatitis B and C
February 22nd (Mon)	18:20	18:25	P-0385	Co-Infection and HBV (2)	11103	Seyed Reza	Mohebbi	Detection of TTV in Iranian Patients with HBV or HCV Mono-infection, HIV and HCV Coinfection
February 22nd (Mon)	18:25	18:30	P-0386	Co-Infection and HBV (2)	10873	Ozgun	Gunal	HBV-HIV Co-Infection, A Case Report
February 22nd (Mon)	18:30	18:35	P-0387	Co-Infection and HBV (2)	11236	Mohamed_Yossef	Rabea	The Risk of HBV and HIV Transmission in Long-Haul Truck Drivers in Egypt
February 22nd (Mon)	18:35	18:40	P-0388	Co-Infection and HBV (2)	10890	Ian	Baudi	Co-Infection of Hepatitis B Virus with HIV and Viral Characteristics in Zimbabwe.
February 22nd (Mon)	17:40	17:45	P-0389	Co-Infection and HBV (3)	11029	Zulkhuu	Delgersaikhan	Alarming High Prevalence of HDV Infection in Mongolia
February 22nd (Mon)	17:45	17:50	P-0390	Co-Infection and HBV (3)	11155	Lin	Wang	Prevalence of HDV in Chinese Active CHB is Low, with Similar Clinical Profiles as Non-HDV Patients
February 22nd (Mon)	17:50	17:55	P-0391	Co-Infection and HBV (3)	11293	Erkin	Musabaev	Diagnostic Importance of ccc DNA in Patients with Chronic Hepatitis D
February 22nd (Mon)	17:55	18:00	P-0392	Co-Infection and HBV (3)	10440	Meng-Hsuan	Hsieh	The HDV Infections among Injecting Drug Users with and without HIV Infection in Taiwan
February 22nd (Mon)	18:00	18:05	P-0393	Co-Infection and HBV (3)	11135	Ozcan	Aydogdu	Prevalence of Anti-HDV in Patients with Chronic Hepatitis B in Bafra County, Samsun Province, Turkey
February 22nd (Mon)	18:05	18:10	P-0394	Co-Infection and HBV (3)	10284	Fehmi	Tabak	Epidemiology of HBV Subgenotypes D
February 22nd (Mon)	18:10	18:15	P-0395	Co-Infection and HBV (3)	10520	Ilker	Sen	An Engrossing Case of Delta Hepatitis
February 22nd (Mon)	18:15	18:20	P-0396	Fibrosis in HBV (1)	11161	Yameng	Sun	Neglected Significant Fibrosis in Young HBV Patients: Evidence from China Registry of Hepatitis B
February 22nd (Mon)	18:20	18:25	P-0397	Fibrosis in HBV (1)	10170	Angelo B.	Lozada	Antifibrotic Effect of Oral NUCs in Chronic Hepatitis B Infection Assessed by Transient Elastography
February 22nd (Mon)	18:25	18:30	P-0398	Fibrosis in HBV (1)	10388	Wai Kay Walter	Seto	Determinants for Persistent Fibrosis during Nucleoside Analogue Therapy in Chronic Hepatitis B
February 22nd (Mon)	18:30	18:35	P-0399	Fibrosis in HBV (1)	10905	Taeheon	Lee	Assessment of Response by Elastography during the Tenofovir Treatment in Hepatitis B Patients
February 22nd (Mon)	18:35	18:40	P-0400	Fibrosis in HBV (1)	11157	Hong	You	Dynamic Changes of Liver Stiffness to Define Reverse of HBV-Related Fibrosis after Antiviral Therapy
February 22nd (Mon)	18:40	18:45	P-0401	Fibrosis in HBV (1)	10311	Weiquan James	Li	Assessing Fibrosis Regression in Treated Hep B Using Transient Elastography and LiFa-HBV Score
February 22nd (Mon)	18:45	18:50	P-0402	Fibrosis in HBV (1)	10351	Anlin	Ma	Liver Stiffness Measured by Transient Elastography is Superior to APRI and FIB-4 in CHB Patients
February 22nd (Mon)	17:40	17:45	P-0403	Fibrosis in HBV (2)	10689	Kerstina	Boctor	<U>Retrospective Analysis of CHB Patients Referred to An Ontario Based FibroScan® Referral Program.</U>
February 22nd (Mon)	17:45	17:50	P-0404	Fibrosis in HBV (2)	10973	Gaofeng	Chen	Correlational Studies of Fibrotouch, Fibroscan and Ishak Score in Patients with Chronic Hepatitis B
February 22nd (Mon)	17:50	17:55	P-0405	Fibrosis in HBV (2)	10863	Ryuichi	Noguchi	Serum ACE Level as A New Non-Invasive Fibrosis Marker Could be Possible for HBV Patients
February 22nd (Mon)	17:55	18:00	P-0406	Fibrosis in HBV (2)	11033	Seung Ha	Park	Added Value of New Biomarkers Over APRI in Hepatitis B-Related Fibrosis
February 22nd (Mon)	18:00	18:05	P-0407	Fibrosis in HBV (2)	11109	Fatma	Yavuz	Serum Ischemia Modified Albumin Level in Chronic Hepatitis B and ITS Relation with Fibrosis
February 22nd (Mon)	18:05	18:10	P-0408	Fibrosis in HBV (2)	11226	Xiao L	Chi	A Noninvasive Assessment Model Based on Fibroscan is Good at Predicting Liver Fibrosis Progression
February 22nd (Mon)	18:10	18:15	P-0409	IFN for HBV (3)	10336	Natthaya	Chuaypen	HBsAg and cccDNA Reduction in HBeAg-Positive and HBeAg-Negative CHB Treated with Peginterferon
February 22nd (Mon)	18:15	18:20	P-0410	IFN for HBV (3)	10389	Yong	Li	IFN&alpha Mediated Excision Repair Pathway Correlates with Antiviral Response Against HBV Infection

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	18:20	18:25	P-0411	IFN for HBV (3)	10865	Yin Chen	Wang	The Impact of on-Treatment ALT Flares on Response to Peginterferon Alpha-2a in CHB Patients
February 22nd (Mon)	18:25	18:30	P-0412	IFN for HBV (3)	11166	Natthaya	Chuaypen	Quantification of cccDNA and pgRNA in Patients with HBeAg-Negative CHB Treated with Peg-IFN
February 22nd (Mon)	18:30	18:35	P-0413	IFN for HBV (3)	11227	Natthaya	Chuaypen	Kinetics of Serum HBcAg during PEG-IFN Therapy in Patients with HBeAg-Negative CHB
February 22nd (Mon)	18:35	18:40	P-0414	IFN for HBV (3)	11311	Necla	Tulek	Chronic Hepatitis B Treatment; Real Life Data, an Experience of a Centre
February 22nd (Mon)	18:40	18:45	P-0415	IFN for HBV (3)	10824	Ching-Lung	Lai	Placebo-Controlled Trial of Antibody to Connective Tissue Growth Factor (CTGF) in HBV Liver Fibrosis
February 22nd (Mon)	17:40	17:45	P-0416	NUC for HBV (1)	10567	Marlinang D.	Siburian	Lamivudine Resistance Mutations in Indonesian Chronic Hepatitis B Patients
February 22nd (Mon)	17:45	17:50	P-0417	NUC for HBV (1)	10786	Dzmitry	Danilau	Comparative Study of Efficacy of Lamivudine and Tenofovir in Treatment for Chronic Hepatitis B
February 22nd (Mon)	17:50	17:55	P-0418	NUC for HBV (1)	10940	Alpay	Ari	The Results of Long Term Lamivudine Therapy in Anti-HBe Positive Chronic Hepatitis B Patients
February 22nd (Mon)	17:55	18:00	P-0419	NUC for HBV (1)	11042	Keng	Lai	Cost-Effectiveness of Rescue Therapies for LAM-Resistant Patients with HBeAg-Positive CHB
February 22nd (Mon)	18:00	18:05	P-0420	NUC for HBV (1)	10328	Hong	Shi	Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive CHB Patients with High HBV DNA
February 22nd (Mon)	18:05	18:10	P-0421	NUC for HBV (1)	10363	Xiaoling	Chi	Evaluating eGFR Changes in Chronic Hepatitis B Patients with Adefovir Add-on Therapy
February 22nd (Mon)	18:10	18:15	P-0422	NUC for HBV (2)	10837	Young-Suk	Lim	Tenofovir Monotherapy up to 96-Weeks in Patients with Adefovir-Resistant Chronic Hepatitis B
February 22nd (Mon)	18:15	18:20	P-0423	NUC for HBV (2)	10359	Byung Seok	Kim	Prolonged Tenofovir Monotherapy for Partial Virologic Response to Tenofovir in Chronic Hepatitis B
February 22nd (Mon)	18:20	18:25	P-0424	NUC for HBV (2)	10651	So Young	Kwon	Tenofovir Disoproxil Fumarate is Effective and Safe for Lamivudine-Resistant HBV Infection
February 22nd (Mon)	18:25	18:30	P-0425	NUC for HBV (2)	10942	Henry L.Y.	Chan	Flares in Patients Treated with Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG)
February 22nd (Mon)	18:30	18:35	P-0426	NUC for HBV (2)	10136	Selcuk	Aksoz	The Efficacy of Tenofovir in Patients with Chronic Hepatitis B
February 22nd (Mon)	18:35	18:40	P-0427	NUC for HBV (2)	10154	Mingxing	Huang	Comparison of the Effectiveness of Tenofovir in Nucleoside Analogue Naive and Experienced in CHB
February 22nd (Mon)	18:40	18:45	P-0428	NUC for HBV (2)	10702	Shou-Wu	Lee	Two-Year Real Life Data of Tenofovir Disoproxil Fumarate to Chronic Hepatitis B Patients in Taiwan
February 22nd (Mon)	17:40	17:45	P-0429	NUC for HBV (3)	10918	Nurcan	Baykam	Efficacy and Safety of Tenofovir in Patients with Chronic Hepatitis B: Four Year Real-Life Data
February 22nd (Mon)	17:45	17:50	P-0430	NUC for HBV (3)	10066	Chi	Zhang	Cost-Effectiveness of Lamivudine plus Adefovir Combination Therapy in Chronic Hepatitis B Patients
February 22nd (Mon)	17:50	17:55	P-0431	NUC for HBV (3)	10496	Chien-Hung	Chen	HBV Relapse and HBsAg Loss after LAM and ETV Therapy in HBeAg-Negative Patients with HBsAg \geq 200 IU/mL
February 22nd (Mon)	17:55	18:00	P-0432	NUC for HBV (3)	11285	Xiangyong	Li	Combination of LdT and ADV is Efficacious and Safe for CHB Patients Who Failed LAM/ADV/LdT Treatment
February 22nd (Mon)	18:00	18:05	P-0433	NUC for HBV (3)	10397	Wei	Gou	Efficacy of LdT+ADV Combination Therapy and ETV Monotherapy for CHB Patients with High Viral Load
February 22nd (Mon)	18:05	18:10	P-0434	NUC for HBV (3)	11184	Xiaoning	Wu	Clinical Effects of Entecavir vs Lamivudine plus Adefovir on HBV-Related Compensated Cirrhosis
February 22nd (Mon)	18:10	18:15	P-0435	NUC for HBV (3)	11275	Xiangyong	Li	Combination of ADV and ETV Therapy is Effective in CHB Patients Who Failed to ADV Monotherapy
February 22nd (Mon)	18:15	18:20	P-0436	NUC for HBV (4)	11185	Cagdas	Kalkan	Telbivudin Treatment Experience of A Single Center
February 22nd (Mon)	18:20	18:25	P-0437	NUC for HBV (4)	11255	Chao Wei	Hsu	Telbivudine Treatment in Chronic Hepatitis B Patients: A Prospective, Real World Experienced Study
February 22nd (Mon)	18:25	18:30	P-0438	NUC for HBV (4)	11282	Xiangyong	Li	Combination of LdT and ADV is Efficacious and Safe for CHB Patients with LAM/LdT Experience
February 22nd (Mon)	18:30	18:35	P-0439	NUC for HBV (4)	10089	Jihye	Park	Effects of ETV or TDF on Renal Function in Patients with HBV-Related Cirrhosis: Outcome at 2 Years
February 22nd (Mon)	18:35	18:40	P-0440	NUC for HBV (4)	10090	Bircan	Kayaaslan	Entecavir Versus Tenofovir in Treatment of Nucleoside Analogue-Naive Chronic Hepatitis B Patients
February 22nd (Mon)	18:40	18:45	P-0441	NUC for HBV (4)	11359	Asli	Okan	The Reduction of HBV DNA Levels at the Third Month for Predicting Virological Response
February 22nd (Mon)	18:45	18:50	P-0442	NUC for HBV (4)	10511	Aylin	Calica Utku	Comparison of Entecavir and Tenofovir Effectiveness in Treatment-Naive Chronic Hepatitis B Patients
February 22nd (Mon)	17:40	17:45	P-0443	NUC for HBV (5)	10452	Kyu Sik	Jung	Long Term Entecavir Treatment Results in Viral Suppression and Fibrosis Regression
February 22nd (Mon)	17:45	17:50	P-0444	NUC for HBV (5)	11314	Isil	Tuzcuoglu	HBsAg Loss in Patients with Chronic HBV Treated with Entecavir : A Retrospective Case Series
February 22nd (Mon)	17:50	17:55	P-0445	NUC for HBV (5)	10215	Yue	Qi	Effect of Telbivudine on Intrahepatic cccDNA in HBeAg-Positive Patients with Chronic Hepatitis B
February 22nd (Mon)	17:55	18:00	P-0446	NUC for HBV (5)	10255	Guangdong	Tong	Effect of Switching to or Adding on Ldt on Renal Function in CHB with Suboptimal Response to ADV
February 22nd (Mon)	18:00	18:05	P-0447	NUC for HBV (5)	10330	Fan	Mo	Efficacy and Safety of Telbivudine in Treatment Naive or ADV Treated HBeAg Positive CHB Patients
February 22nd (Mon)	18:05	18:10	P-0448	NUC for HBV (5)	11021	Si Hyun	Bae	Prepartum Use of Telbivudine on Preventing Mother-to-Child Transmission of Hepatitis B Virus
February 22nd (Mon)	18:10	18:15	P-0449	NUC for HBV (5)	10120	Xu	Li	The Changes of Liver Stiffness and Its Associated Factors for CHB Patients with Antiviral Therapy
February 22nd (Mon)	18:15	18:20	P-0450	NUC for HBV (6)	10362	Taesuk	Kim	Assessment of Insufficient Viral Response during Entecavir Therapy in Treatment-naïve CHB
February 22nd (Mon)	18:20	18:25	P-0451	NUC for HBV (6)	10894	Rachel Wen-Juei	Jeng	Elevation of ALT during Nuc Treatment Enhances HBsAg Decline

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	18:25	18:30	P-0452	NUC for HBV (6)	11179	Xiaoning	Wu	Regression of HBV-Induced Liver Cirrhosis: A Preliminary Data of A Randomized, Prospective Study
February 22nd (Mon)	18:30	18:35	P-0453	NUC for HBV (6)	11067	Vipul	Mahajan	Meta-Analysis: Geographical Variation in Treatment Rates of Chronic Hepatitis B (CHB) Patients.
February 22nd (Mon)	18:35	18:40	P-0454	NUC for HBV (6)	11165	Tianhui	Liu	Reversion of Liver Fibrosis after Anti-HBV Treatment for 52 Weeks is Closely Related to HBV Genotype
February 22nd (Mon)	18:40	18:45	P-0455	NUC for HBV (6)	10271	Huashan	Li	The Impact of Nucleos(t)ides Analogues on the Renal Function in Patients with Chronic Hepatitis B.
February 22nd (Mon)	18:45	18:50	P-0456	NUC for HBV (6)	10540	Sung Eun	Kim	Mutations at rtS202, rtM250 May Cause Poor Viral Response to Tenofovir Rescue in Chronic Hepatitis B
February 22nd (Mon)	18:50	18:55	P-0457	NUC for HBV (6)	10838	Jin-Woo	Lee	Impact of Antiviral Treatment on Clinical Outcome after Curative Therapy for Hepatitis B Related HCC
February 22nd (Mon)	17:40	17:45	P-0458	NUC for HBV (7)	11279	Xiangyong	Li	Entecavir Treatment for Patients with Hepatitis B-Related Cirrhosis is Efficacious and Safe
February 22nd (Mon)	17:45	17:50	P-0459	NUC for HBV (7)	11346	Li	Wang	Long-Term Outcomes after Nucleos(t)ide Analogue Withdrawal in Patients with HBeAg-Positive CHB
February 22nd (Mon)	17:50	17:55	P-0460	NUC for HBV (7)	10063	Yuri	Miyazoe	Relation of the Nucleoside Analogues Therapy and HBsAg in Patient with Hepatitis B Virus Related HCC
February 22nd (Mon)	17:55	18:00	P-0461	NUC for HBV (7)	10064	Mingxing	Huang	Tenofovir Added on Other Nucleoside-Analogues was not Superior to TDF Monotherapy
February 22nd (Mon)	18:00	18:05	P-0462	NUC for HBV (7)	10426	Joo H.	Chang	Current Treatment Cost of Chronic Hepatitis B in China, Compared to Cost Based on Standard Guideline
February 22nd (Mon)	18:05	18:10	P-0463	NUC for HBV (7)	10869	Widya	Wasityastuti	Quasispecies of Antiviral-Resistant in Naive and Undertreated HBV Infected Patients in Indonesian
February 22nd (Mon)	18:10	18:15	P-0464	NUC for HBV (7)	11364	Yuhua	Gao	An Early Decrease of HBeAg in CHB Patients Strongly Predicted Treatment Response during NAs Therapy
February 22nd (Mon)	18:15	18:20	P-0465	NUC for HBV (8)	11378	Jian	Sun	Baseline Vitamin D Level Predict Virologic Response in Hepatitis B Patients Treated with Telbivudine
February 22nd (Mon)	18:20	18:25	P-0466	NUC for HBV (8)	10652	Muhammet	Kutu	Hepatitis B Surface Antigen Monitorization during Oral Antiviral Therapy
February 22nd (Mon)	18:25	18:30	P-0467	NUC for HBV (8)	10919	Ting	Shen	The Changes in the Balance of Treg and Th17 after Entecavir Therapy
February 22nd (Mon)	18:30	18:35	P-0468	NUC for HBV (8)	10712	Jung Gil	Park	Tenofovir and Entecavir for Patients with Chronic Hepatitis Resistant to Adefovir and Entecavir
February 22nd (Mon)	18:35	18:40	P-0469	NUC for HBV (8)	10586	Jong Seok	Joo	Treatment Efficacy of Tenofovir in Treating Drug-Resistant Chronic Hepatitis B
February 22nd (Mon)	18:40	18:45	P-0470	NUC for HBV (8)	11038	Wei	Lu	Optimized Therapy with Domestic Lamivudine and Adefovir in HBeAg-Positive Chronic Hepatitis B
February 22nd (Mon)	18:45	18:50	P-0471	NUC for HBV (8)	11280	Xiangyong	Li	De Novo LAM and ADV Combination Treatment in CHB Patients with High HBV DNA Level is Efficacious
February 22nd (Mon)	17:40	17:45	P-0472	Interferon and NUC for HBV	10435	Jeong	Heo	HBsAg Decline after Pegylated-Interferon-Alpha in HBeAg Positive with Nucleoside Maintenance
February 22nd (Mon)	17:45	17:50	P-0473	Interferon and NUC for HBV	11102	Murat	Aladag	Eight Years of PEG INF and Entecavir Therapy on HBsAg Loss and Seroconversion with Chronic HBV
February 22nd (Mon)	17:50	17:55	P-0474	Interferon and NUC for HBV	11211	Natthaya	Chuaypen	HBsAg and cccDNA Reduction in Patients with CHB Receiving PEG-IFN with or without Entecavir
February 22nd (Mon)	17:55	18:00	P-0475	Interferon and NUC for HBV	10634	Masataka	Tsuge	Nucleotide Analogues Improve Interferon Responsiveness in HBV-Infected Human Hepatocytes
February 22nd (Mon)	18:00	18:05	P-0476	Interferon and NUC for HBV	11310	Yiqi	Yu	Sequential Combination of PegIFN in ETV-Experienced Patients and PegIFN in Treatment-Naive Patients
February 22nd (Mon)	18:05	18:10	P-0477	Interferon and NUC for HBV	10822	Won-Young	Tak	Comparison of Asians vs. Non-Asians Treated with TDF Plus Peginterferon (PEG)
February 22nd (Mon)	18:10	18:15	P-0478	Interferon and NUC for HBV	10926	Peng	Hu	The Pharmacoeconomics Value for HBeAg-Positive CHB Patients to Switch from NUCs to PEG-IFN- α ;2a
February 22nd (Mon)	18:15	18:20	P-0479	Cessation of NUC for HBV	10086	Wenxiong	Xu	48 Weeks Follow-up in CHB Patients after NAs Treatments Cessation
February 22nd (Mon)	18:20	18:25	P-0480	Cessation of NUC for HBV	10609	Seong Hee	Kang	Long Term Follow up of Chronic Hepatitis B Patients after Oral Antiviral Treatment Discontinuation
February 22nd (Mon)	18:25	18:30	P-0481	Cessation of NUC for HBV	10770	Wenxiong	Xu	24 Weeks Follow-up in CHB Patients after NAs Treatments Discontinuation
February 22nd (Mon)	18:30	18:35	P-0482	Cessation of NUC for HBV	10571	Liang	Wu	Durability of Telbivudine Efficacy off-Treatment in Chronic Hepatitis B Patients
February 22nd (Mon)	17:40	17:45	P-0483	Reactivation of HBV	11101	Antonio	Izzi	Functional Cure of HBV in A Severe Immunocompromised Patient with CLL Treated with Entecavir
February 22nd (Mon)	17:45	17:50	P-0484	Reactivation of HBV	11284	Selma	Tosun	Testing of Kidney Transplantation Candidates for HBV Infection and the Importance of Monitoring
February 22nd (Mon)	17:50	17:55	P-0485	Reactivation of HBV	10062	Min-Yue	Zhang	Network Meta-Analysis of Nucleotide Analogues for Preventing HBV Reactivation during Chemotherapy
February 22nd (Mon)	17:55	18:00	P-0486	Reactivation of HBV	10436	Aytac	Erdem	Follow-up of the Chronic HBV Infected Patients Planned Chemotherapy Due to Solid Organ Malignancy
February 22nd (Mon)	18:00	18:05	P-0487	Reactivation of HBV	10574	Shih-Hao	Young	Entecavir to Prevent HBV Reactivation by Chemotherapy for CHB Patients with Non-Hematological Cancer
February 22nd (Mon)	18:05	18:10	P-0488	Reactivation of HBV	10742	Yukitomo	Urata	Cessation of Pre-Empive Therapy for Patients with Rheumatic Disease with Previously Resolved HBV
February 22nd (Mon)	18:10	18:15	P-0489	Reactivation of HBV	10945	Takeshi	Matsui	The Efficacy of Warning Popu System in Electronic Medical Chart in Screening for HBV Reactivation
February 22nd (Mon)	18:15	18:20	P-0490	Reactivation of HBV	11350	Ya-Lin	Liu	A Prospective Evaluation of Occult HBV Infection in Immunized Infants Born to HBsAg-Positive Mothers
February 22nd (Mon)	18:20	18:25	P-0491	Reactivation of HBV	10819	Duygu	Mert	In A Patient Who is HBsAg-Negative and AntiHBs Positive , Reactivation of Hepatitis B Infection
February 22nd (Mon)	18:25	18:30	P-0492	HBV and Renal Function	10592	Mei	Li	The Value of HBV-PreS1 and Other HBV Antigens for Hepatitis B Virus Associated Glomerulonephritis

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	18:30	18:35	P-0493	HBV and Renal Function	10593	Mei	Li	Expression and Significance of HBeAg, HBV-DNA in the Patients with HBV Associated Nephropathy
February 22nd (Mon)	18:35	18:40	P-0494	HBV and Renal Function	10598	Mei	Li	Change in Renal Pathological of HBV-GN and NHBV-GN
February 22nd (Mon)	18:40	18:45	P-0495	HBV and Renal Function	10629	Baek Gyu	Jun	Lamivudine with Adefovir Dipivoxil Therapy does not Worsen Renal Function in Chronic Hepatitis B
February 22nd (Mon)	18:45	18:50	P-0496	HBV and Renal Function	10675	Ming-Jen	Chen	Comparison of Telbivudine and Entecavir on Maintenance of eGFR in off-Treatment after 3-Years
February 22nd (Mon)	18:50	18:55	P-0497	HBV and Renal Function	11379	Ling	Ning	Prevalence of Chronic Kidney Disease in Patients with Chronic Hepatitis B: A Cross-Sectional Survey
February 22nd (Mon)	17:40	17:45	P-0498	Pregnancy in HBV Carriers	10599	Gule	Aydin	Prevalence of Hepatitis B Virus Serologic Markers in Pregnant Patients in A State Hospital in Turkey
February 22nd (Mon)	17:45	17:50	P-0499	Pregnancy in HBV Carriers	10600	Gule	Aydin	How does Maternal Hepatitis B Surface Antigen Carrier Status Impact the Preterm Delivery?
February 22nd (Mon)	17:50	17:55	P-0500	Pregnancy in HBV Carriers	11061	Koji	Takahashi	Tenofovir Treatment for A Japanese Female with Chronic Hepatitis B and Pregnancy
February 22nd (Mon)	17:55	18:00	P-0501	Pregnancy in HBV Carriers	11240	Ayşe	Batirel	Hepatitis B Virus in Pregnancy: Antiviral Treatment Efficacy and Risk of Perinatal Transmission
February 22nd (Mon)	18:00	18:05	P-0502	HCC and HBV	10001	Abu Saleh Mohammad Sadequl	Islam	Diagnostic Utility of AFP in Hepatitis B Related Hepatocellular Carcinoma
February 22nd (Mon)	18:05	18:10	P-0503	HCC and HBV	10347	Katsunori	Yoshida	Reversible pSmad3 Signaling between Tumor Suppression and Fibrocarcinogenesis in Chronic Hepatitis B
February 22nd (Mon)	18:10	18:15	P-0504	HCC and HBV	10451	Kyu Sik	Jung	Partial Virological Response with Entecavir is not Risk Factor of HCC Occurrence.
February 22nd (Mon)	18:15	18:20	P-0505	HCC and HBV	10656	Kazunori	Kawaguchi	Notch Ligand DNA Copy Number Variation is Enhanced in HBV-Related Liver Cancer
February 22nd (Mon)	18:20	18:25	P-0506	HCC and HBV	10764	Noboru	Shinkai	WFA+- Mac-2 Binding Protein is A Predicting Biomarker for HCC in Hepatitis B Patients
February 22nd (Mon)	18:25	18:30	P-0507	HCC and HBV	10914	Umme	Shahera	IP-10, p53 and Foxp3 Expression in Hepatitis B Patients with Cirrhosis and Hepatocellular Carcinoma.
February 22nd (Mon)	18:30	18:35	P-0508	HCC and HBV	11070	Yu-Ju	Chu	Elevated Aflatoxin B₁-Albumin Adducts Increase Cirrhosis and Cirrhotic Hepatocellular Carcinoma Risk
February 22nd (Mon)	17:40	17:45	P-0509	Hepatitis A and E	10650	Pattaratida	Sa-nguanmoo	Assessing HAV Antibody in the Thai Population
February 22nd (Mon)	17:45	17:50	P-0510	Hepatitis A and E	10627	Ermil R.	Magsino	Corticosteroid Therapy in Relapsing Hepatitis A: A Case Report
February 22nd (Mon)	17:50	17:55	P-0511	Hepatitis A and E	10644	Resat	Ozars	Acute Hepatitis A May Trigger Development of Autoimmune Hepatitis
February 22nd (Mon)	17:55	18:00	P-0512	Hepatitis A and E	11024	Ananta	Shrestha	Asymptomatic Hepatitis E Viremia in Bloods Donors in Nepal
February 22nd (Mon)	18:00	18:05	P-0513	Hepatitis A and E	11202	Sahaj	Rathi	Chronic Genotype 1 HEV Infection in An Immunosuppressed Liver-Transplant Recipient in India
February 22nd (Mon)	18:05	18:10	P-0514	Hepatitis A and E	11303	Birendra Prasad	Gupta	Three Novel Amino Acid Substitutions in RNA Dependent RNA Polymerase Accelerates HEV Infection
February 22nd (Mon)	18:10	18:15	P-0515	Hepatitis A and E	10558	Mohammad Sayedul	Haque	Sero-Prevalence of Acute Hepatitis Caused by HAV and HEV in Gazipur, Bangladesh
February 22nd (Mon)	18:15	18:20	P-0516	Hepatitis A and E	11297	Dr. Jayanta	Borkakoti	Is HEV Screening Necessary in Patients of Cirrhosis of Liver?
February 22nd (Mon)	18:20	18:25	P-0517	Basic Research (1)	11010	Zdenko	Herceg	Epigenome Deregulation in Liver Carcinoma
February 22nd (Mon)	18:25	18:30	P-0518	Basic Research (1)	10183	Qiang	Gao	Deep-Sequencing Reveals Clonal Evolution and Genomic Heterogeneity in Multifocal Liver Cancer
February 22nd (Mon)	18:30	18:35	P-0519	Basic Research (1)	10647	Neung Hwa	Park	Genetic Alterations of the SIAH-1 Gene in Hepatocellular Carcinomas
February 22nd (Mon)	18:35	18:40	P-0520	Basic Research (1)	11118	Magdalena A.	Budzinska	Genomic Landscape of Precancerous Liver Disease
February 22nd (Mon)	18:40	18:45	P-0521	Basic Research (1)	10076	Koichi	Fujisawa	Adenylate Kinase 4 Modulates Drug Sensitivity and Mitochondrial Activity
February 22nd (Mon)	18:45	18:50	P-0522	Basic Research (1)	10948	Shingo	Nakamoto	Association between Sirtuins Expression and Hepatocellular Carcinoma
February 22nd (Mon)	18:50	18:55	P-0523	Basic Research (1)	10639	Sen-Yung	Hsieh	Functional Genomics Identified A Novel EMT-MET Regulator for Human Hepatoma Invasion
February 22nd (Mon)	17:40	17:45	P-0524	Basic Research (2)	11374	Jing Min	Zhao	Effect of Raft-Associated TLR7 Activation on Proliferation and Migration of Hepatocellular Carcinoma
February 22nd (Mon)	17:45	17:50	P-0525	Basic Research (2)	11053	Daniel	Huang	Human Amniotic Epithelial Cell Exosomes Reduce Proliferation of Hepatocellular Carcinoma Cell Lines
February 22nd (Mon)	17:50	17:55	P-0526	Basic Research (2)	10371	Qifan	Yang	Increased Expression of Mitochondrial Dynamics Protein Drp1 in Hepatocellular Carcinoma
February 22nd (Mon)	17:55	18:00	P-0527	Basic Research (2)	10199	Sze Keong	Tey	Nuclear Met Regulates Liver Cancer Metastasis Via NF-↑B/MMP2 Pathway.
February 22nd (Mon)	18:00	18:05	P-0528	Basic Research (2)	11332	Fanping	Meng	PTP-PEST Controls Liver Cancer Cell Migration Through Regulation of RhoA and Rac1
February 22nd (Mon)	18:05	18:10	P-0529	Basic Research (2)	11370	Byung Il	Yeh	Inhibition Effect for the Growth of Hepatocellular Cell Line Fibroblast Growth Factor (FGF) 5
February 22nd (Mon)	18:10	18:15	P-0530	Basic Research (2)	11132	Chun	Tang	ASPH Disrupts Mitochondrial DNA Stability and Mitochondrial Function in Hepatocellular Carcinoma
February 22nd (Mon)	18:15	18:20	P-0531	Basic Research (3)	11173	Nawin	Chanthra	Association of STAT3 and STAT4 Polymorphisms and Hepatocellular Carcinoma
February 22nd (Mon)	18:20	18:25	P-0532	Basic Research (3)	10171	Trai-Ming	Yeh	Molecular Mechanism of Concanavalin A-Induced Autophagic Cell Death of Human Hepatoma Cells
February 22nd (Mon)	18:25	18:30	P-0533	Basic Research (3)	11367	Jingmin	Zhao	ANGPTL6 Inhibites Hepatocarcinoma Metastasis by Promoting Wnt Pathway Through Macrophages

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	18:30	18:35	P-0534	Basic Research (3)	10322	Hyo Jung	Cho	Genetic Polymorphisms in the Wnt Pathway as Prognostic Predictors in HBV-Associated HCC
February 22nd (Mon)	18:35	18:40	P-0535	Basic Research (3)	10536	Chian-Feng	Chen	Identification of Novel Liver Cancer Fusion Genes Using Chromosome Breakpoints Screening
February 22nd (Mon)	18:40	18:45	P-0536	Basic Research (3)	10220	Frankie C.F.	Ko	Study of DLC1 Regulates Oxidative Stress for Tumor Suppression
February 22nd (Mon)	18:45	18:50	P-0537	Basic Research (3)	10023	Hsiang-Hsuan	Fan	In Vivo Study on the Roles of HBx and HCP in Pathogenesis by Conditional Mouse Models
February 22nd (Mon)	17:40	17:45	P-0538	Basic Research (4)	11294	Chi-Tan	Hu	Screening of c-Met-Positive Hepatocellular Carcinoma for c-Met-Based Target Therapy
February 22nd (Mon)	17:45	17:50	P-0539	Basic Research (4)	10044	Sohji	Nishina	DPP-4 Inhibitor, Anagliptin Suppresses the Progression of Hepatocellular Carcinoma
February 22nd (Mon)	17:50	17:55	P-0540	Basic Research (4)	10224	Hayato	Hikita	Chronic Apoptotic Stimuli in Hepatocytes Induces Oxidative Stress Leading to Development of HCC
February 22nd (Mon)	17:55	18:00	P-0541	Basic Research (4)	10646	Neung Hwa	Park	Inactivating Mechanism of ATBF1 Gene in Hepatocellular Carcinomas
February 22nd (Mon)	18:00	18:05	P-0542	Basic Research (4)	11369	Alexandre	Tavartkiladze	Clinical Characteristics of Glycine and Taurine Exchange in Patients with Liver Cancer
February 22nd (Mon)	18:05	18:10	P-0543	Basic Research (4)	10461	Takao	Watanabe	Protein Kinase R Modulates DNA Methylation in Hepatocellular Carcinoma with HCV Infection
February 22nd (Mon)	18:10	18:15	P-0544	Basic Research (4)	11148	Ge	Yu	An ssDNA Aptamer Selectively Delivers Cytotoxic Drug to Hepatocellular Carcinoma Cells
February 22nd (Mon)	18:15	18:20	P-0545	Basic Research (5)	10711	Xia	Jiang	Effects of Lin28B on Human Colorectal Carcinoma and HBV-Associated Hepatocellular Carcinoma
February 22nd (Mon)	18:20	18:25	P-0546	Basic Research (5)	10192	Ka Yin	Lui	LncRNA INTS6P1, A Prognostic Factor in HCC, Induces Apoptosis Via Intrinsic Mitochondrial Pathway
February 22nd (Mon)	18:25	18:30	P-0547	Basic Research (5)	10165	Tong-Hong	Wang	LncRNA GPS1-IT1 Suppresses Hepatocellular Carcinoma Metastasis by Regulating HIF-1 α ; Activity
February 22nd (Mon)	18:30	18:35	P-0548	Basic Research (5)	11152	Robert	Cheng	Differential Gene Expression of miRNA in Plasma MV of Patients with Hepatocellular Carcinoma
February 22nd (Mon)	18:35	18:40	P-0549	Basic Research (5)	11170	Takayuki	Kogure	Involvement of Autophagy in Resistance to Sorafenib Induced by Hypoxia in Hepatocellular Carcinoma
February 22nd (Mon)	18:40	18:45	P-0550	Basic Research (5)	10020	Kwang-Huei	Lin	Thyroid Hormone-Activated DAPK2 Suppresses Hepatocarcinogenesis Through Autophagy
February 22nd (Mon)	18:45	18:50	P-0551	Basic Research (5)	11335	Junliang	Fu	BTLA Up-Regulation Impaired CD8 ⁺ T-Cell Function and Accelerated Disease Progression of HCC Patients
February 22nd (Mon)	17:40	17:45	P-0552	Basic Research (6)	10502	Jijia	Zhou	NANOG Modulates Chemoresistance of Liver Cancer Stem Cells by Activating Stat3/ABCB1 Pathway
February 22nd (Mon)	17:45	17:50	P-0553	Basic Research (6)	10457	Lee-Won	Chong	Saturated Fatty Acid Induces Cancer Stem Cell-Like Properties in Human Hepatoma Cells
February 22nd (Mon)	17:50	17:55	P-0554	Basic Research (6)	10178	Mariko	Yoshida	Sorafenib Targets CD90 ⁺ Cancer Stem Cells and Controls Distant Metastasis
February 22nd (Mon)	17:55	18:00	P-0555	Basic Research (6)	10976	Na Ri	Park	TGF- β 1 Enhances EMT in CD44 HCC Cell Lines, Leading to Cancer Progression and Metastasis.
February 22nd (Mon)	18:00	18:05	P-0556	Basic Research (6)	10358	Atsunori	Tsuchiya	An EpCAM/NCAM Expressing HCC in Which Progenitor Marker Positive Cells are Important for Metastasis
February 22nd (Mon)	18:05	18:10	P-0557	Basic Research (6)	11018	Stephanie	Ma	Functional Role of TP53INP1 in HCC Metastasis
February 22nd (Mon)	18:10	18:15	P-0558	Basic Research (7)	10212	Xiaowen	Mao	Functional Role of Caveolin-1-Mediated S100P Signaling in Liver Cancer Metastasis under Hypoxia
February 22nd (Mon)	18:15	18:20	P-0559	Basic Research (7)	10226	Judy W.	Yam	Nuclear Met-Derived Exosomes Promote HCC Metastasis and Formation of Lung Premetastatic Niche
February 22nd (Mon)	18:20	18:25	P-0560	Basic Research (7)	10344	Yohei	Shirakami	Preventive Effects of Pentoxifylline on Liver Tumorigenesis in A NASH-Related Liver Cancer Model
February 22nd (Mon)	18:25	18:30	P-0561	Basic Research (7)	11144	Zhenhua	Sun	Characterization of Circulating and Intrahepatic NK, NKT, CD4 ⁺ and CD8 ⁺ T Cells in HBV-Related HCC
February 22nd (Mon)	18:30	18:35	P-0562	Basic Research (7)	10681	Ryosuke	Muroyama	Fusion HBx from HBV Integrant Might Affect ER Stress Response and be Associated with HCC
February 22nd (Mon)	18:35	18:40	P-0563	Basic Research (7)	10415	Takayasu	Ideta	NASH-Related Hepatocarcinogenesis is Suppressed in Mice Lacking Hepatic Retinoid Storage
February 22nd (Mon)	18:40	18:45	P-0564	Basic Research (7)	10472	Lingyao	Du	Hepatitis C Virus Might Regulate Suppressor of Cytokine Signaling-1 Gene Methylation to Tumorigenesis
February 22nd (Mon)	17:40	17:45	P-0565	Basic Research (8)	11022	Terence	Lee	C-Terminal Truncated Hepatitis B Virus X Protein Regulates Stemness Via Stat3/Nanog Pathway
February 22nd (Mon)	17:45	17:50	P-0566	Basic Research (8)	10508	Shintaro	Sawada	Preventive Effect of Geraniol on Hepatocarcinogenesis in Diethylnitrosamine-Induced Rats
February 22nd (Mon)	17:50	17:55	P-0567	Basic Research (8)	10849	Yuka	Futsukaichi	The Significance of Immune Cells in Peripheral Blood with Hepatocellular Carcinoma
February 22nd (Mon)	17:55	18:00	P-0568	Basic Research (8)	11193	Kai-Wen	Huang	Endostatin Gene Delivery after Irreversible Electroporation for Hepatocellular Carcinoma
February 22nd (Mon)	18:00	18:05	P-0569	Basic Research (8)	11368	Alexandre	Tavartkiladze	The Role of Cellular Immunity in the Pathogenesis and Treatment of Patients with Liver Cancer
February 22nd (Mon)	18:05	18:10	P-0570	Basic Research (8)	10665	HuiGuo	Ding	PI3K/Akt/mTOR Signaling Pathway Mediates Hepatoma Cell Autophagy Induced by Hydrogen Sulfide
February 22nd (Mon)	18:10	18:15	P-0571	Epidemiology and Country-Particularity in HCC	10956	Mamun-Al	Mahtab	Hepatitis B Virus Remains the Leading Cause of HCC in Bangladesh
February 22nd (Mon)	18:15	18:20	P-0572	Epidemiology and Country-Particularity in HCC	10966	Alina	Kutsenko	Heterogeneity among Asians with Hepatocellular Carcinoma (HCC): A Single Center Study in California
February 22nd (Mon)	18:20	18:25	P-0573	Epidemiology and Country-Particularity in HCC	10969	Imelda M.	Loho	Survival Rate of HCC Patients after Fifteen Years in A Tertiary Referral Hospital in Indonesia
February 22nd (Mon)	18:25	18:30	P-0574	Epidemiology and Country-Particularity in HCC	11094	Mamdouh	Gabr	Aflatoxin B1 as A Preventable Risk Factor in the Development of HCC in Egyptian Patients

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	18:30	18:35	P-0575	Epidemiology and Country-Particularity in HCC	10005	Ehab A.	Abdelatti	Prevalence and Risk Factors of Hepatocellular Carcinoma in Egyptian Cirrhotic Patients
February 22nd (Mon)	18:35	18:40	P-0576	Epidemiology and Country-Particularity in HCC	10643	Ehab A.	Abdelatti	HCC Burden in Egypt
February 22nd (Mon)	17:40	17:45	P-0577	Markers for HCC (1)	10688	Ka Shing	Cheung	Relationship between HCC and Serum Markers in NA-Treated Patients with Undetectable HBV DNA
February 22nd (Mon)	17:45	17:50	P-0578	Markers for HCC (1)	10281	Tarek	Korah	Role of Serum Glypican-3 in the Diagnosis of Small Hepatocellular Carcinoma
February 22nd (Mon)	17:50	17:55	P-0579	Markers for HCC (1)	10068	Engin	Altintas	Serum Chitotriosidase Levels in Malignant Diseases of Liver: Is It A New Tumor Marker?
February 22nd (Mon)	17:55	18:00	P-0580	Markers for HCC (1)	10182	Mohamed	El-Kassas	Serum Fibrosis Biomarkers Can Predict Presence of Hepatocellular Carcinoma in Chronic Hepatitis C
February 22nd (Mon)	18:00	18:05	P-0581	Markers for HCC (1)	10263	Cho	Hyo Jung	Serum Interleukin-6 Levels as A Predictive Marker in Patients with Hepatocellular Carcinoma
February 22nd (Mon)	18:05	18:10	P-0582	Markers for HCC (1)	10922	Celina H.	Adraneda	AFP as Predictor of Survival Rather Than Diagnostic Marker in Patients W/ HCC (Retrospective Cohort)
February 22nd (Mon)	18:10	18:15	P-0583	Markers for HCC (1)	10691	Dongkai	Zhou	The Clinical Significance of HINT2 Expression in Hepatocellular Carcinoma
February 22nd (Mon)	18:15	18:20	P-0584	Markers for HCC (1)	11264	Hyun Chin	Cho	Clinical Significance of Circulating Endothelial Progenitor Cells in Patients with Liver Cirrhosis
February 22nd (Mon)	18:20	18:25	P-0585	Markers for HCC (2)	11312	Mingjie	Yao	AFP Still is A Valuable Diagnostic and Prognosis Predicting Biomarker in HBV Infection-Related HCC
February 22nd (Mon)	18:25	18:30	P-0586	Markers for HCC (2)	10614	Hideaki	Naoe	Proteomics Analyses Identified A Phosphoprotein Relevant to Apoptosis Resistance in Human Hepatoma
February 22nd (Mon)	18:30	18:35	P-0587	Markers for HCC (2)	11079	XiuHong	Liu	Evaluation of the Diagnostic Value of Plasma GP73 and AFP in HCC Patients Infected with HBV
February 22nd (Mon)	18:35	18:40	P-0588	Markers for HCC (2)	10317	Omer	Ekinci	Factors Associated with A Higher Alfa-Fetoprotein Level in Patients with Hepatocellular Carcinoma
February 22nd (Mon)	18:40	18:45	P-0589	Markers for HCC (2)	10238	Masanori	Tokoro	The Impact of Alpha Fetoprotein (AFP) Level during IFN Free Treatment for Hepatitis C.
February 22nd (Mon)	18:45	18:50	P-0590	Markers for HCC (2)	10999	Mayuko	Kondo	The Characteristics of Hepatocellular Carcinoma with Elevated AFP-L3 Level and Normal AFP Level
February 22nd (Mon)	18:50	18:55	P-0591	Markers for HCC (2)	10301	Masato	Yoshikawa	Elevated Preoperative Serum CEA Levels in Patients with HCC is Associated with Prognosis and EMT.
February 22nd (Mon)	17:40	17:45	P-0592	Markers for HCC (3)	11130	Hyeseung	Lee	ELK4, SIRT7 and H3K18ac Expressions in Hepatocellular Carcinoma with Prognostic Implication
February 22nd (Mon)	17:45	17:50	P-0593	Markers for HCC (3)	10620	Takehisa	Watanabe	Lymphotoxin- β ; Regulated by NF- κ B is A Biomarker of Poor Prognosis in Hepatocellular Carcinoma.
February 22nd (Mon)	17:50	17:55	P-0594	Markers for HCC (3)	10730	Hui Ting	Hsu	The Diagnostic Accuracy for Early Stage Hepatocellular Carcinoma by Combined Use of AFP and PIVKA-II
February 22nd (Mon)	17:55	18:00	P-0595	Markers for HCC (3)	10682	Toan B.	Nguyen	Value of AFP, AFP-L3 and DCP in Early Detection of Hepatocellular Carcinoma in Vietnamese Patients
February 22nd (Mon)	18:00	18:05	P-0596	Markers for HCC (3)	11120	Zhiying	Xin	Expression of SALL4 in Hepatocellular Carcinoma and Its Clinical Significance
February 22nd (Mon)	18:05	18:10	P-0597	Markers for HCC (3)	10032	Kazuto	Tajiri	The Impact of Neutrophil/Lymphocyte Ratio for the Recurrence of HCC after RFA
February 22nd (Mon)	18:10	18:15	P-0598	Markers for HCC (3)	10234	Dipu	Bharali	Expression Analysis of Plasma Apolipoprotein AI and AIV in Hepatocellular Carcinoma
February 22nd (Mon)	18:15	18:20	P-0599	Imaging Diagnosis	10608	Seong Hee	Kang	Diagnostic Performance for Small Hepatocellular Carcinoma Measuring Less Than 2cm
February 22nd (Mon)	18:20	18:25	P-0600	Imaging Diagnosis	10193	Yoshiaki	Tanaka	SPIO-Enhanced MRI is Useful in Predicting Hypervascularization of Hypointense Hypovascular Nodules
February 22nd (Mon)	18:25	18:30	P-0601	Imaging Diagnosis	10306	Akihiro	Deguchi	Usefulness of Angio CT for the Diagnosis and Treatment of Early Hepatocellular Carcinoma
February 22nd (Mon)	18:30	18:35	P-0602	Imaging Diagnosis	10775	Chihiro	Dohi	A Strategy to Diagnose Hepatocellular Carcinoma by EOB-MRI
February 22nd (Mon)	18:35	18:40	P-0603	Imaging Diagnosis	10042	Sandi A.	Kwee	Specific Phosphatidylcholine Species are Associated with Liver Tumors Detected by 18F-Choline PET/CT
February 22nd (Mon)	18:40	18:45	P-0604	Imaging Diagnosis	10901	Brian K.	Goh	Importance of Tumor Size as A Prognostic Factor after Liver Resection for Solitary HCC
February 22nd (Mon)	18:45	18:50	P-0605	Imaging Diagnosis	10350	Suk Bae	Kim	The Necessity of Computed Tomography to Hepatic Lesions Detected on Private Clinic Sonography
February 22nd (Mon)	18:50	18:55	P-0606	Imaging Diagnosis	10219	Hiroshi	Yoshida	Preoperative Liver Functional Volumetry Performed by 3D-99mTc-GSA Scintigraphy/Vascular Fused Images
February 22nd (Mon)	18:55	19:00	P-0607	Imaging Diagnosis	11375	Ye Eun	Kwak	Lack of Contrast Washout in Delayed Phases in Hepatocellular Carcinoma with Portal Vein Occlusion
February 22nd (Mon)	17:40	17:45	P-0608	Novel US Technology	11137	Takeshi	Nihei	Comparison of 'Low MI THI' Mode and CHI Mode in Contrast-Enhanced Ultrasonography of Liver Tumors
February 22nd (Mon)	17:45	17:50	P-0609	Novel US Technology	10753	Hironori	Tanaka	Comparison of the Latest Fusion Technology
February 22nd (Mon)	17:50	17:55	P-0610	Novel US Technology	10456	Masashi	Hirooka	Usefulness of A Three-Dimensional Simulator System for Multipolar Ablation
February 22nd (Mon)	17:55	18:00	P-0611	Novel US Technology	10454	Tomohiro	Minami	US-US Fusion Imaging in Radiofrequency Ablation Therapy for Liver Cancer
February 22nd (Mon)	18:00	18:05	P-0612	Novel US Technology	10998	Tomoko	Aoki	Which is Useful for Liver Carcinogenesis Prediction Needle Biopsy or Liver Stiffness Measurement?
February 22nd (Mon)	18:05	18:10	P-0613	Novel US Technology	10900	Junya	Nuta	Kupffer Images of Contrast Ultrasound and Recurrence after Hepatectomy for Hepatocellular Carcinoma
February 22nd (Mon)	18:10	18:15	P-0614	Novel US Technology	10442	Akinori	Miyata	Detection of Small Liver Tumors Using Intraoperative Real-Time Virtual Sonography
February 22nd (Mon)	18:15	18:20	P-0615	New Scoring System for HCC	10242	Chau-Ting	Yeh	A Risk Score for Predicting Future Occurrence of Hepatocellular Carcinoma in Cirrhotic Patients

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	18:20	18:25	P-0616	New Scoring System for HCC	10831	Anthony W.H.	Chan	Integration of Albumin-Bilirubin (ALBI) Score into CLIP Staging for Hepatocellular Carcinoma
February 22nd (Mon)	18:25	18:30	P-0617	New Scoring System for HCC	10423	Takamasa	Kawakami	Prognostic Scoring System for Radiofrequency Ablation: Usefulness of ALBI-Grade.
February 22nd (Mon)	18:30	18:35	P-0618	New Scoring System for HCC	11268	Andrea	Casadei Gardini	SII Index Predicts Outcome in HCC Patients Treated with Sorafenib
February 22nd (Mon)	18:35	18:40	P-0619	New Scoring System for HCC	10663	HuiGuo	Ding	Comparison of Different Screening Schemes for Patients with Hepatitis B Associated Cirrhosis
February 22nd (Mon)	18:40	18:45	P-0620	New Scoring System for HCC	10439	Issei	Saeki	Efficacy of A New Therapeutic Assessment Score (ACTH score) for Advanced HCC Patients Receiving HAIC
February 22nd (Mon)	18:45	18:50	P-0621	New Scoring System for HCC	10618	Yuki	Kitano	E-PASS Scoring System is A Good Predictor of Prognosis in HCC Patients Underwent Major Hepatectomy
February 22nd (Mon)	18:50	18:55	P-0622	New Scoring System for HCC	10762	Hyun	Yang	Korean Validation and Comparison of Prognostic Scores for Transarterial Chemoembolization
February 22nd (Mon)	17:40	17:45	P-0623	HCC Treatment (1)	10769	Ching-Sheng	Hsu	Impact of Antiviral Therapy on Hepatitis C Patients After Curative Hepatocellular Carcinoma Therapy
February 22nd (Mon)	17:45	17:50	P-0624	HCC Treatment (1)	10189	Naoya	Kanogawa	SVR of Interferon-Based Therapy as A Prognostic Factor for HCV-Related Hepatocellular Carcinoma
February 22nd (Mon)	17:50	17:55	P-0625	HCC Treatment (1)	10407	Yang Jae	Yoo	Influence of HBV DNA on Recurrence of HCC after Surgical Resection and Role of Antiviral Therapy
February 22nd (Mon)	17:55	18:00	P-0626	HCC Treatment (1)	11049	Ryo	Shimizu	Radiofrequency Ablation in Very Elderly Patients (85 years old or older) with Liver Tumors
February 22nd (Mon)	18:00	18:05	P-0627	HCC Treatment (1)	10503	Mari	Mandai	Usefulness of Radiofrequency Ablation for the Elderly with Hepatocellular Carcinoma
February 22nd (Mon)	18:05	18:10	P-0628	HCC Treatment (1)	10019	Takeshi	Hatanaka	Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Located in the Caudate Lobe
February 22nd (Mon)	18:10	18:15	P-0629	HCC Treatment (1)	10010	Naoki	Hotta	Usefulness of 4D Us to Evaluate Effects Therapeutic RFA for HCC
February 22nd (Mon)	18:15	18:20	P-0630	HCC Treatment (2)	10149	Naoki	Morimoto	Evaluation of Laparoscopic Multipolar Radiofrequency Ablation for Localized Hepatocellular Carcinoma
February 22nd (Mon)	18:20	18:25	P-0631	HCC Treatment (2)	10061	Kuo Chao	Yew	Hepatocellular Carcinoma Tumour Ablation Procedures – Less is More ?
February 22nd (Mon)	18:25	18:30	P-0632	HCC Treatment (2)	11046	Ryo	Shimizu	Radiofrequency Ablation by New Adjustable Electrode: Initial Experience
February 22nd (Mon)	18:30	18:35	P-0633	HCC Treatment (2)	10098	Wei-Yu	Kao	Ten-Year Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma
February 22nd (Mon)	18:35	18:40	P-0634	HCC Treatment (2)	11190	Koki	Sato	The Risk Factors for Percutaneous Radiofrequency Ablation under Monitored Anesthesia Care
February 22nd (Mon)	18:40	18:45	P-0635	HCC Treatment (2)	10566	Masaaki	Kitahara	OK432-Stimulated Monocyte-Derived Dendritic Cell Injection into HCC after RFA
February 22nd (Mon)	17:40	17:45	P-0636	HCC Treatment (3)	11273	Yoshihiko	Ooka	The Benefit of Balloon Occluded TACE Compared with Conventional TACE for BCLC Stage B HCC Patients
February 22nd (Mon)	17:45	17:50	P-0637	HCC Treatment (3)	10701	Toru	Ishikawa	Double Platinum Therapy TAI and TACE for BCLC B Hepatocellular Carcinoma
February 22nd (Mon)	17:50	17:55	P-0638	HCC Treatment (3)	10754	Kazuo	Okumoto	Efficacy and Safety of Cisplatin vs Doxorubicin in TACE for HCC
February 22nd (Mon)	17:55	18:00	P-0639	HCC Treatment (3)	10431	Atsushi	Hiraoka	Interventional Radiology for Hepatocellular Carcinoma in Patients with Child-Pugh C
February 22nd (Mon)	18:00	18:05	P-0640	HCC Treatment (3)	10888	Wei	Teng	Response at First Chemoembolization Plays A Favorable Outcome in Hepatocellular Carcinoma
February 22nd (Mon)	18:05	18:10	P-0641	HCC Treatment (3)	11201	Abrorjon	Yusupbekov	The Results of Chemoembolization and Endoarterial Chemotherapy in Primary Hepatic Carcinoma
February 22nd (Mon)	18:10	18:15	P-0642	HCC Treatment (3)	11108	Jingjing	Zhou	Two Cases of Bile Duct Injury after TACE
February 22nd (Mon)	18:15	18:20	P-0643	HCC Treatment (4)	11014	Manabu	Morimoto	Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma: Short-Term Efficacy
February 22nd (Mon)	18:20	18:25	P-0644	HCC Treatment (4)	11188	Yong Kang	Lee	Clinical Outcomes of DEB-TACE Versus Conventional TACE in Hepatocellular Carcinoma
February 22nd (Mon)	18:25	18:30	P-0645	HCC Treatment (4)	10166	Ky Doan	Thai	Long-Term Survival Results of HCC Patients after Drug-Eluting Beads TACE
February 22nd (Mon)	18:30	18:35	P-0646	HCC Treatment (4)	10964	Takayoshi	Oikawa	The Short-Term Effectiveness of TACE Using Cisplatin-Eluting Hepasphere for Unresectable HCC
February 22nd (Mon)	18:35	18:40	P-0647	HCC Treatment (4)	11220	Jui-Wen	Kang	Comparison of the Effects of TACE with T-ACE Beads and Other Microspheres – A Porcine Study
February 22nd (Mon)	17:40	17:45	P-0648	HCC Treatment (5)	10445	Futa	Koga	Bolus Administration of CDDP with 5FU in Hepatic Arterial Infusion Chemotherapy for Advanced HCC
February 22nd (Mon)	17:45	17:50	P-0649	HCC Treatment (5)	10641	Niizeki	Takashi	Efficacy of Hepatic Arterial Chemotherapy of CDDP Suspension in Lipiodol and 5-FU for Advanced HCC.
February 22nd (Mon)	17:50	17:55	P-0650	HCC Treatment (5)	10787	Shinpei	Sato	Hepatic Arterial Infusion Chemotherapy for Sorafenib Failure on Advanced HCC
February 22nd (Mon)	17:55	18:00	P-0651	HCC Treatment (5)	10437	Kenichiro	Murayama	Hepatic Arterial Infusion Chemotherapy vs Sorafenib for cTACE-Refractory HCC
February 22nd (Mon)	18:00	18:05	P-0652	HCC Treatment (5)	10140	Masaaki	Kondo	Hepatic Arterial Infusion Chemotherapy with Cisplatin and Sorafenib in Hepatocellular Carcinoma
February 22nd (Mon)	18:05	18:10	P-0653	HCC Treatment (5)	10501	Kazuhiro	Izumi	Clinical Evaluation of Sorafenib Treatment and HAIC for Advanced HCC
February 22nd (Mon)	18:10	18:15	P-0654	HCC Treatment (6)	10785	Yuichi	Honma	Sorafenib Enhances Cytotoxicity Via Inhibition of Cellular Defense Mechanisms
February 22nd (Mon)	18:15	18:20	P-0655	HCC Treatment (6)	10131	Pengfei	Huang	Sorafenib Resistance Can be Overcome by Mfn2 Through Inhibiting HIF-1 α ; Expression in HCC
February 22nd (Mon)	18:20	18:25	P-0656	HCC Treatment (6)	10669	Chikara	Himoto	Efficiency of Sorafenib in Japanese Patients with Hepatocellular Carcinoma: A Multicenter Experience

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	18:25	18:30	P-0657	HCC Treatment (6)	10396	Masahito	Nakano	Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma with Extrahepatic Metastasis
February 22nd (Mon)	18:30	18:35	P-0658	HCC Treatment (6)	10298	Daigo	Matsui	Sorafenib Might Inhibit Liver Fibrogenesis in Patients with Cirrhosis and Hepatocellular Carcinoma
February 22nd (Mon)	18:35	18:40	P-0659	HCC Treatment (6)	10779	Yoshinari	Asaoka	The Improved Prognosis of Hepatocellular Carcinoma with Extrahepatic Spread Treated by Sorafenib
February 22nd (Mon)	18:40	18:45	P-0660	HCC Treatment (6)	11266	Andrea	Casadei Gardini	Meld Score Predicts Outcome of Patients with HCC Treated with Sorafenib
February 22nd (Mon)	18:45	18:50	P-0661	HCC Treatment (6)	10832	Shuntaro	Obi	NLR is Predictive Factor for Survival in Patients with Advanced HCC Treated by Sorafenib.
February 22nd (Mon)	18:50	18:55	P-0662	HCC Treatment (6)	10319	Takanori	Mukoizu	Molecular Target Drug (Sorafenib) Might Cause the Activation of Kupffer Cell.
February 22nd (Mon)	17:40	17:45	P-0663	HCC Treatment (7)	10433	Yotaro	Iino	RT Combined with TACE in Advanced HCC Patient Having Hepatic Vein Invasion
February 22nd (Mon)	17:45	17:50	P-0664	HCC Treatment (7)	10383	Hong Soo	Kim	Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma as A Local Salvage Treatment
February 22nd (Mon)	17:50	17:55	P-0665	HCC Treatment (7)	10335	Filiz	Akyuz	Clinical Yield of Radioembolization in Hepatocellular Carcinoma?
February 22nd (Mon)	17:55	18:00	P-0666	HCC Treatment (7)	10594	Chao-Hung	Hung	Combined Resection plus Radiofrequency Ablation Versus Transarterial Embolization for BCLC-B HCC
February 22nd (Mon)	18:00	18:05	P-0667	HCC Treatment (7)	10962	Jung Il	Lee	The Effect of Additional TACE after Combined Chemoradiation for Locally Advanced HCC with PVT
February 22nd (Mon)	18:05	18:10	P-0668	HCC Treatment (7)	10257	Takamasa	Ohki	TACE Followed by Sorafenib Improves Progression Free Survival in Patients with Advanced HCC
February 22nd (Mon)	18:10	18:15	P-0669	HCC Treatment (7)	11073	Jennielyn C.	Agcaoili	RFA is Comparable to RFA and TACE among Patients with Intermediate Stage Hepatocellular Carcinoma
February 22nd (Mon)	18:15	18:20	P-0670	HCC Treatment (8)	10883	Manabu	Hayashi	Frequency of Surgical Site Infection after RFA without Maximal Sterile Barrier Precautions
February 22nd (Mon)	18:20	18:25	P-0671	HCC Treatment (8)	11050	Toru	Wakamatsu	Glisson's Capsule Injury after Radiofrequency Ablation in Patients with Hepatocellular Carcinoma
February 22nd (Mon)	18:25	18:30	P-0672	HCC Treatment (8)	11043	Taijiro	Wake	Hepatic Infarction after Percutaneous Radiofrequency Ablation for Liver Tumors
February 22nd (Mon)	18:30	18:35	P-0673	HCC Treatment (8)	10002	Abu Saleh Mohammad Sadeequl	Islam	Terminal Stage of Hepatitis B Related Hepatocellular Carcinoma is Unsuitable for Treatment
February 22nd (Mon)	18:35	18:40	P-0674	HCC Treatment (8)	10033	Szu-Yuan	Wu	Hepatocellular Carcinoma Received Palliative Treatments with Statin
February 22nd (Mon)	18:40	18:45	P-0675	HCC Treatment (8)	10637	Masaki	Kaibori	Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing HCC Resection
February 22nd (Mon)	18:45	18:50	P-0676	HCC Treatment (8)	11338	Rintaro	Mikata	EUS-Guided Ethanol Injection for Hepatocellular Carcinoma in S1 Region
February 22nd (Mon)	18:50	18:55	P-0677	HCC Treatment (8)	11265	Tsang-En	Wang	ADI-PEG-20 as Salvage Therapy in A Patient with Advanced Hepatocellular Carcinoma
February 22nd (Mon)	17:40	17:45	P-0678	Clinical Course and Prognosis in HCC (1)	10127	Keiko	Yamane	Prognostic Analyses of Progressive Disease Patients with Advanced Hepatoma Treated with Sorafenib
February 22nd (Mon)	17:45	17:50	P-0679	Clinical Course and Prognosis in HCC (1)	10018	Takeshi	Hatanaka	Prediction of Response to Transarterial Chemotherapy with GDDP Powder for Hepatocellular Carcinoma
February 22nd (Mon)	17:50	17:55	P-0680	Clinical Course and Prognosis in HCC (1)	11047	Yi-Chung	Hsieh	Predictors of Refractory Chemoembolization in Patients with Hepatocellular Carcinoma
February 22nd (Mon)	17:55	18:00	P-0681	Clinical Course and Prognosis in HCC (1)	10518	Nozomu	Wada	Prognostic Factors of the Patients with TACE -Refractory Hepatocellular Carcinoma
February 22nd (Mon)	18:00	18:05	P-0682	Clinical Course and Prognosis in HCC (1)	10111	Yukiyasu	Okamura	The FIB-4 Index is A Prognostic Predictor for Non-B Non-C Hepatocellular Carcinoma
February 22nd (Mon)	18:05	18:10	P-0683	Clinical Course and Prognosis in HCC (1)	10927	Celina H.	Adraneda	The FHCC-Pro:Prognostic Stratification Index of Filipino Patients with HCC- A Validation Study
February 22nd (Mon)	18:10	18:15	P-0684	Clinical Course and Prognosis in HCC (2)	10985	Rino A.	Gani	Role of VEGF as A Predictor of Survival in HCC Patients Receiving Supportive Treatment
February 22nd (Mon)	18:15	18:20	P-0685	Clinical Course and Prognosis in HCC (2)	10217	Masahiko	Koda	Predictive Factors for Local Tumor Progression after Radiofrequency Ablation for HCC
February 22nd (Mon)	18:20	18:25	P-0686	Clinical Course and Prognosis in HCC (2)	10622	Masaya	Sato	ADOPT-LC Score: A Novel Score for In-Hospital Mortality of Surgical Procedure in Cirrhotic Patients
February 22nd (Mon)	18:25	18:30	P-0687	Clinical Course and Prognosis in HCC (2)	10373	Takayoshi	Kaida	Preoperative Platelet-to-Lymphocyte Ratio (PLR) Predicts Recurrence Status after Initial Hepatectomy
February 22nd (Mon)	18:30	18:35	P-0688	Clinical Course and Prognosis in HCC (2)	10232	Satoshi	Oeda	Surveillance of Viral Hepatitis Affects not Only the Detection of Early-Stage HCC but Also Survival
February 22nd (Mon)	17:40	17:45	P-0689	Health, Prevention and Medical Economy	10007	Amr	Amin	Saffron-Based Crocin Prevents Liver Cancer: in Vivo, in Vitro and in Silico Insights
February 22nd (Mon)	17:45	17:50	P-0690	Health, Prevention and Medical Economy	11199	Athina	Chounta	A Cost of Illness Analysis of HCC in the Setting of Severe Financial Constraints
February 22nd (Mon)	17:50	17:55	P-0691	Health, Prevention and Medical Economy	10114	Chih-Wen	Lin	Alcoholism Concomitant with Viral Hepatitis Increases the Prevalence of HCC in Taiwan
February 22nd (Mon)	17:55	18:00	P-0692	Health, Prevention and Medical Economy	10339	Shiu-Feng	Huang	Introduction of Taiwan Liver Cancer Network
February 22nd (Mon)	18:00	18:05	P-0693	Others	10591	Chun	Gao	Effect of Type-2 Diabetes Mellitus on Blood Pressure in Hepatocellular Carcinoma
February 22nd (Mon)	18:05	18:10	P-0694	Others	10923	Hayato	Baba	Insulin Treatment Can Accelerate the Recurrence of Hepatocellular Carcinoma after Surgery
February 22nd (Mon)	18:10	18:15	P-0695	Others	10867	Long	Fang	Effect of Type-2 Diabetes Mellitus on Platelet Count in Hepatocellular Carcinoma
February 22nd (Mon)	17:40	17:45	P-0696	Liver Tumors (1)	10835	Takahisa	Sato	38 Cases of Brain Metastases from Hepatocellular Carcinoma
February 22nd (Mon)	17:45	17:50	P-0697	Liver Tumors (1)	11223	Anne B.	Hu	Failure to Detect: Late Hepatocellular Carcinoma (HCC) Recurrence after Liver Transplantation (LT)

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 22nd (Mon)	17:50	17:55	P-0698	Liver Tumors (1)	10209	<small>Dowa Palashige Chula Karishia Anandi</small> Lal	Lal	Hepatic Actinomycosis Mimicking Hepatocellular Carcinoma
February 22nd (Mon)	17:55	18:00	P-0699	Liver Tumors (1)	11323	R. Fernanda	Zaragoza-Organista	Fibrolamellar HCC Hepatectomy and Postoperative Acute Vena Cava Syndrome and Successful Thrombectomy
February 22nd (Mon)	18:00	18:05	P-0700	Liver Tumors (1)	11349	Tomoo	Nakagawa	A Case of Liver Tumors Caused by Lymphoproliferative Disorder in Crohn's Disease Clinical Course
February 22nd (Mon)	18:05	18:10	P-0701	Liver Tumors (1)	10590	Naoki	Akizue	A Case of Metachronous Spontaneous Regression of Hepatocellular Carcinoma
February 22nd (Mon)	18:10	18:15	P-0702	Liver Tumors (2)	10978	Hiroshi	Maeno	A Case of the Large Hepatocellular Carcinoma Effective Treatment with Modified NEW FP Method.
February 22nd (Mon)	18:15	18:20	P-0703	Liver Tumors (2)	10557	Byoung Kwan	Son	Clinical Features and Antibiotic Sensitivity to Causative Microorganisms of Pyogenic Liver Abscess
February 22nd (Mon)	18:20	18:25	P-0704	Liver Tumors (2)	10555	Seok Hyun	Kim	Two Cases of Spontaneous Intramuscular Hematoma Survived in Liver Cirrhosis Patients
February 22nd (Mon)	18:25	18:30	P-0705	Liver Tumors (2)	10261	Chunghwan	Jun	A Case of Hepatic Hemangioma with Kasabach-Merritt Syndrome in An Adult Patient
February 22nd (Mon)	18:30	18:35	P-0706	Liver Tumors (2)	10522	Ilker	sen	Exophytic and Pediculated Hemangioma of Liver: A Rare Entity
February 22nd (Mon)	18:35	18:40	P-0707	Liver Tumors (2)	11189	Aaron TM.	Gan	An Unusual Hepatic Tumour in an Patient with Chronic Hepatitis B
February 22nd (Mon)	17:40	17:45	P-0708	Liver Tumors (3)	10532	Dewi Norwani	Basir	Extra-Renal Malignant Rhabdoid Tumour in An Adult: A Rare Case of A Liver Tumor
February 22nd (Mon)	17:45	17:50	P-0709	Liver Tumors (3)	10862	Salih	Boga	Hepatobiliary Cystadenoma Which Misdiagnosed as Hydatid Cyst: A Case Report
February 22nd (Mon)	17:50	17:55	P-0710	Liver Tumors (3)	11119	Koji	Saito	Heterogeneity of Histological Features of Benign Hepatocellular Nodular Lesions.
February 22nd (Mon)	17:55	18:00	P-0711	Liver Tumors (3)	11180	Abrorjon	Yusupbekov	The Results of Treatment of Gastric Cancer with Liver Metastases
February 22nd (Mon)	18:00	18:05	P-0712	Liver Tumors (3)	10535	Goichi	Nakayama	A Case of Hematogenous Metastatic Small Intestinal Tumor of Hepatocellular Carcinoma
February 22nd (Mon)	18:05	18:10	P-0713	Liver Tumors (3)	10570	Yusaku	Date	A Case of Small Hepatocellular Carcinoma with Bile Duct Tumor Thrombus
February 23rd (Tue)	17:40	17:45	P-0714	Cirrhosis:Basic Research (1)	10316	Juanjuan	Zhao	Antifibrotic Activity of NK Cells is Impaired by TGF- β -Dependent Emperipolesis in Liver Cirrhosis
February 23rd (Tue)	17:45	17:50	P-0715	Cirrhosis:Basic Research (1)	10668	Hiroyasu	Ito	Deficiency of Indoleamine 2,3-Dioxygenase Aggravates the Development of CCl ₄ -Induced Liver Fibrosis
February 23rd (Tue)	17:50	17:55	P-0716	Cirrhosis:Basic Research (1)	11224	Sheetalnath	Rooge	Growth Factor Mobilized CD34+ BMSCs Rescue the Loss of Regenerative Microenvironment in Cirrhosis
February 23rd (Tue)	17:55	18:00	P-0717	Cirrhosis:Basic Research (1)	10850	Hsin-Ling	Ho	Homocysteine Deteriorates Intrahepatic Derangement and Portal-Systemic Collaterals in Cirrhotic Rats
February 23rd (Tue)	18:00	18:05	P-0718	Cirrhosis:Basic Research (1)	11337	Ming	Shi	Human Mesenchymal Stem Cell Therapy is Feasible for Liver Cirrhosis Associated with HBV Infection.
February 23rd (Tue)	18:05	18:10	P-0719	Cirrhosis:Basic Research (1)	11336	Jinsheng	Guo	Identification of Axon Guidance Signaling Pathway in Hepatic Stellate Cells and Liver Fibrogenesis
February 23rd (Tue)	18:10	18:15	P-0720	Cirrhosis:Basic Research (1)	11271	Xiao F.	Shi	Inhibition of TGF- β and TIMP1/2 by siRNA Showed A Different Prevention of Hepatic Fibrosis
February 23rd (Tue)	18:15	18:20	P-0721	Cirrhosis:Basic Research (1)	10059	Jiamei	Chen	Enhancement of Hepatocyte Differentiation from Human Embryonic Stem Cells by Chinese Medicine FZHY
February 23rd (Tue)	18:20	18:25	P-0722	Cirrhosis:Basic Research (1)	10475	Toshihiko	Matsumoto	Collagen Matrix Modulates Macrophage Expression of MMPs in Part by Controlling Cell Shape.
February 23rd (Tue)	18:25	18:30	P-0723	Cirrhosis:Basic Research (1)	10767	Xiao F.	Shi	In Vivo Expression of TIMP-1/2 siRNA Promotes Apoptosis of HSC and Smad Protein Expression in Liver
February 23rd (Tue)	18:30	18:35	P-0724	Cirrhosis:Basic Research (1)	11261	Chen	Long	The Protective Role of TGF- β ; Induced Upregulation of Follistatin against Mice Hepatic Fibrosis
February 23rd (Tue)	18:35	18:40	P-0725	Cirrhosis:Basic Research (1)	10972	Christine	Yee	CD147 in the Immune Response to Liver Injury in A Novel Conditional Knockout Mouse Model.
February 23rd (Tue)	18:40	18:45	P-0726	Cirrhosis:Basic Research (1)	10399	Soon Koo	Baik	Effect of Decorin Expressing Adenovirus Infected Mesenchymal Stem Cells on Cirrhosis Rat Model
February 23rd (Tue)	18:45	18:50	P-0727	Cirrhosis:Basic Research (1)	10947	Askhat	Isbambetov	Systemic Administration of MSCs for Hepatic Ischemia Reperfusion Injury in A Rat Model
February 23rd (Tue)	18:50	18:55	P-0728	Cirrhosis:Basic Research (1)	10979	Jung Hoon	Cha	WT1 is the Key Regulatory of Hepatic Differentiation from Bone Marrow Mesenchymal Stem Cells
February 23rd (Tue)	17:40	17:45	P-0729	Cirrhosis:Basic Research (2)	10067	Rafael	Bruck	Sortilin Deficiency Affects Fibrosis Differently in Hepatocyte vs. Cholangiocyte Models of Injury
February 23rd (Tue)	17:45	17:50	P-0730	Cirrhosis:Basic Research (2)	10573	Tung-Hung	Su	The Activation of SH2 Domain-Containing Phosphatase-1 by SC-43 Ameliorates Hepatic Fibrosis
February 23rd (Tue)	17:50	17:55	P-0731	Cirrhosis:Basic Research (2)	10603	Muhammad Babar	Khawar	Hepatotoxicity of Industrial Leachate; Histopathology and Heavy Metal Contents in Liver
February 23rd (Tue)	17:55	18:00	P-0732	Cirrhosis:Basic Research (2)	11213	Tasleem	Akhtar	Tacrolimus Induced Acute Hepatotoxicity in Wistar Rats
February 23rd (Tue)	18:00	18:05	P-0733	Cirrhosis:Basic Research (2)	10200	Tomomi	Ohara	Therapeutic Effects of Ghrelin and Leptin on Experimental Acute Liver Injury in Mice.
February 23rd (Tue)	18:05	18:10	P-0734	Cirrhosis:Basic Research (2)	10201	Torsten	Wuestefeld	A Dynamic Relationship between Cellular Senescence and Liver Regeneration.
February 23rd (Tue)	18:10	18:15	P-0735	Cirrhosis:Basic Research (2)	10710	Hongbo	Shi	Protective Effect of Ganshuang Granules on Liver Cirrhosis by Suppressing Regulatory T Cells
February 23rd (Tue)	18:15	18:20	P-0736	Cirrhosis:Basic Research (2)	11313	Yujia	Wang	Characterization of Crosslinked Porcine Extracellular Matrix as Scaffold for Thepatic Bioengineering
February 23rd (Tue)	18:20	18:25	P-0737	Cirrhosis:Basic Research (2)	10750	Feng	Zhang	TWEAK Suppresses Activated Hepatic Stellate Cell Senescence in Vitro Via Regulating SIRT1 and p53
February 23rd (Tue)	17:40	17:45	P-0738	Cirrhosis:Basic Research (3)	11158	Rui	Huang	B Cells May Play A Pathological Role in Hepatic Inflammation in Chronic Liver Diseases

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 23rd (Tue)	17:45	17:50	P-0739	Cirrhosis:Basic Research (3)	10151	Hokahiro	Katayama	Generation of Transgene-Free Hepatocyte Like Cell with Transposon Mediated Direct Reprogramming
February 23rd (Tue)	17:50	17:55	P-0740	Cirrhosis:Basic Research (3)	10380	Dominik	Huster	Impact of Atp7b Deficiency on Hepatic Cholesterol Metabolism and Atherosclerosis in Atp7b^{-/-}Mice
February 23rd (Tue)	17:55	18:00	P-0741	Cirrhosis:Basic Research (3)	10391	Shinji	Oe	Involvement of Endoplasmic Reticulum Stress in Excess Copper-Induced Hepatotoxicity
February 23rd (Tue)	18:00	18:05	P-0742	Cirrhosis:Basic Research (3)	10720	Ebrahim	Sakhinia	Make the Best Decision Facing Suspected Progressive Familial Intrahepatic Cholestasis in Fetal Cases
February 23rd (Tue)	18:05	18:10	P-0743	Cirrhosis:Basic Research (3)	11145	Ting-Xia	Lv	Mutation Analysis of HFE Gene in A Small Cohort of Hereditary Hemochromatosis Cases from North China
February 23rd (Tue)	18:10	18:15	P-0744	Cirrhosis:Basic Research (3)	10880	Hye-Young	Seo	Protective Effect of Clusterin on Hepatic Fibrosis
February 23rd (Tue)	18:15	18:20	P-0745	Cirrhosis:Basic Research (3)	10773	Yuan	Peng	Salvia Miltiorrhiza Enhances NK Cell Versus HSC Effect Via Modulating PD-L1/PD-1 Axis
February 23rd (Tue)	18:20	18:25	P-0746	Cirrhosis:Basic Research (3)	10400	Jhen-Jyun	Chen	Antioxidative Activity of Deferasirox (DFX) in Iron-Induced Oxidative Stress of Hepatocytes
February 23rd (Tue)	18:25	18:30	P-0747	Cirrhosis:Basic Research (3)	11107	Ping	Wang	Hepatic Stem/Progenitor Cells are Sox9 and AFP Double Positive in Human Cirrhosis Liver
February 23rd (Tue)	17:40	17:45	P-0748	Noninvasive Diagnosis of Liver Fibrosis (1)	10746	Kerstina	Boctor	<u>Retrospective Analysis of An Ontario Based Diagnostic Referral Program Using Transient Elastography.</U>
February 23rd (Tue)	17:45	17:50	P-0749	Noninvasive Diagnosis of Liver Fibrosis (1)	10993	Syed Afzal-ul-haq	Haqqi	Fibroscan:A Novel Modality; Initial Results from Low Cost Tertiary Care Centres of Pakistan.
February 23rd (Tue)	17:50	17:55	P-0750	Noninvasive Diagnosis of Liver Fibrosis (1)	10123	George S.	Gherlan	Fibroscan–are 10 Valid Measurements Mandatory?
February 23rd (Tue)	17:55	18:00	P-0751	Noninvasive Diagnosis of Liver Fibrosis (1)	10921	Mahesh K.	Goenka	ARFI Elastography Correlation with Liver Biopsy in the Evaluation of Staging of Fibrosis.
February 23rd (Tue)	18:00	18:05	P-0752	Noninvasive Diagnosis of Liver Fibrosis (1)	10401	Mizuki	Endo	Noninvasive Assessment of Liver Fibrosis Using RTE and A Novel Serum Marker:WFA+</sup>-M2BP
February 23rd (Tue)	18:05	18:10	P-0753	Noninvasive Diagnosis of Liver Fibrosis (1)	11117	Kerstina	Boctor	<U>The Correlation of RDW to Liver and Spleen Stiffness in Patients with Chronic Liver Disease.</U>
February 23rd (Tue)	18:10	18:15	P-0754	Noninvasive Diagnosis of Liver Fibrosis (1)	11131	Jialing	Zhou	Diagnosis Model of HBV Related Compensated Cirrhosis by Ultrasonography and Transient Elastography
February 23rd (Tue)	18:15	18:20	P-0755	Noninvasive Diagnosis of Liver Fibrosis (2)	10674	Kerstina	Boctor	Further Exploration of the Effect of Body Positioning on Spleen Stiffness in Cirrhotic Patients.
February 23rd (Tue)	18:20	18:25	P-0756	Noninvasive Diagnosis of Liver Fibrosis (2)	11017	Syed Zea-ul-Islam	Farrukh	Body Mass Index in Hepatitis B & C Related Liver Disease:First Fibroscan Based Study from Pakistan.
February 23rd (Tue)	18:25	18:30	P-0757	Noninvasive Diagnosis of Liver Fibrosis (2)	11196	Gamal	Shiha	Transient Elastography is not Useful in the Diagnosis of Schistosomal Hepatic Peri-Portal Fibrosis
February 23rd (Tue)	18:30	18:35	P-0758	Noninvasive Diagnosis of Liver Fibrosis (2)	10743	Pik Eu	Chang	Optimal Liver Stiffness Values for Diagnosis of Liver Fibrosis and Cirrhosis
February 23rd (Tue)	18:35	18:40	P-0759	Noninvasive Diagnosis of Liver Fibrosis (2)	10107	Wang	Rongqi	FibroTouch is Good for Evaluation of Liver Fibrosis in Chinese Patients with Chronic Viral Hepatitis
February 23rd (Tue)	18:40	18:45	P-0760	Noninvasive Diagnosis of Liver Fibrosis (2)	10340	Jeong Han	Kim	Predictive Value of MELD, APRI, and FIB-4 for Mortality and Development of HCC in Cirrhotic Patients
February 23rd (Tue)	18:45	18:50	P-0761	Noninvasive Diagnosis of Liver Fibrosis (2)	11075	Deepak N.	Amarapurkar	Acoustic Radiation Force Impulse Elastography (ARFI) in the Diagnosis of Hepatic Fibrosis.
February 23rd (Tue)	17:40	17:45	P-0762	Noninvasive Diagnosis of Liver Fibrosis (3)	10292	Tamami	Abe	Noninvasive Assessment of Liver Fibrosis Using Shear Wave Elastography in Patients with CLD
February 23rd (Tue)	17:45	17:50	P-0763	Noninvasive Diagnosis of Liver Fibrosis (3)	10748	George S.	Gherlan	The Agreement of Transient Elastography (TE) and Acoustic Radiation Force Impulse Imaging(ARFI)
February 23rd (Tue)	17:50	17:55	P-0764	Noninvasive Diagnosis of Liver Fibrosis (3)	11005	Masaaki	Takamura	Value of VTTQ Measurements for the Risk Assessment of HCC Development in Viral Hepatitis Patients
February 23rd (Tue)	17:55	18:00	P-0765	Noninvasive Diagnosis of Liver Fibrosis (3)	11372	Li-Wei	Chen	The Association between NAFLD Fibrosis Score, FIB4 Index and Serum Vitamin D
February 23rd (Tue)	18:00	18:05	P-0766	Noninvasive Diagnosis of Liver Fibrosis (3)	10236	Yuan-Hung	Kuo	Using Non-Invasive Apri, FIB4-Score and Liver Stiffness to Identify Cirrhosis in the Community
February 23rd (Tue)	18:05	18:10	P-0767	Noninvasive Diagnosis of Liver Fibrosis (3)	10147	Tadashi	Sekimoto	Significant Relationship between Liver Stiffness and Waveform Patterns in the Hepatic Vein
February 23rd (Tue)	18:10	18:15	P-0768	Cirrhosis: Complication and Outcome (1)	11228	Wang Yong	Choi	Change of Liver Cirrhotic Patients during 15 Years : Retrospective Multi-Center Study in Korea
February 23rd (Tue)	18:15	18:20	P-0769	Cirrhosis: Complication and Outcome (1)	10797	Rafael	Torres-Valadez	Early Diagnosis and Biological Markers in Advanced Liver Damage of Different Etiologies
February 23rd (Tue)	18:20	18:25	P-0770	Cirrhosis: Complication and Outcome (1)	11160	Necati	Ormeci	Natural Course and Etiology of End-Stage Liver Disease in Turkey
February 23rd (Tue)	18:25	18:30	P-0771	Cirrhosis: Complication and Outcome (1)	11104	Beytullah	Yildirim	Possible Role of Hepatitis B Virus in the Etiology of Cryptogenic Cirrhosis
February 23rd (Tue)	18:30	18:35	P-0772	Cirrhosis: Complication and Outcome (1)	10625	Chau-Ting	Yeh	Distinct Circulatory miRNA Profiles between Cirrhotic Patients Infected with Hepatitis B and C Virus
February 23rd (Tue)	18:35	18:40	P-0773	Cirrhosis: Complication and Outcome (1)	10122	Yu Jun	Wong	Baseline Liver Stiffness Measurement Can Predict Liver Related Events in Chronic Liver Disease
February 23rd (Tue)	18:40	18:45	P-0774	Cirrhosis: Complication and Outcome (1)	11122	Yameng	Sun	Reversion of HBV-Related Liver Fibrosis/Cirrhosis Starts from Septal Area Assessed by SHG Images
February 23rd (Tue)	17:40	17:45	P-0775	Cirrhosis: Complication and Outcome (2)	10156	Ferzan	Aydin	Dose Serum Urotensin-II Have Role on Pathogenesis at Compensated and Decompensated Liver Cirrhosis?
February 23rd (Tue)	17:45	17:50	P-0776	Cirrhosis: Complication and Outcome (2)	10714	Mehmet	Demir	Fragmented QRS and Decompensated Cirrhosis
February 23rd (Tue)	17:50	17:55	P-0777	Cirrhosis: Complication and Outcome (2)	10095	Yi-Chun	Chou	Higher Mortality during Intensive Care Unit and Associated Factors in Patients with Liver Cirrhosis
February 23rd (Tue)	17:55	18:00	P-0778	Cirrhosis: Complication and Outcome (2)	10661	Asem A.	Elfert	Is Microwave Ablation A Good Alternative to Partial Splenic Embolization to Treat Hypersplenism?
February 23rd (Tue)	18:00	18:05	P-0779	Cirrhosis: Complication and Outcome (2)	10004	Gelina H.	Adraneda	Predictive Upper Gastrointestinal Bleeding Score for Triaging Patients-Multicenter Validation Study

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 23rd (Tue)	18:05	18:10	P-0780	Cirrhosis: Complication and Outcome (2)	10078	Mohammad Shahed	Ashraf	Alteration of Serum Lipid Profile with Severity of Liver Damage in Cirrhotic Patients
February 23rd (Tue)	18:10	18:15	P-0781	Cirrhosis: Complication and Outcome (2)	10464	Madhumita	Premkumar	A/H1N1/09 Influenza is Associated with High Mortality in Liver Cirrhosis
February 23rd (Tue)	18:15	18:20	P-0782	Portal Hypertension (1)	10529	Takafumi	Sugimoto	Prophylaxis for Esophageal Varices Can Improve the QOL in Patients with PVTT.
February 23rd (Tue)	18:20	18:25	P-0783	Portal Hypertension (1)	10722	Kerstina	Boctor	Spleen Stiffness Alone vs. Liver to Spleen Stiffness in the Prediction of Portal Hypertension.
February 23rd (Tue)	18:25	18:30	P-0784	Portal Hypertension (1)	10269	Reiichiro	Kondo	Pathological Characteristics of Spleen in Liver Cirrhosis and Idiopathic Portal Hypertension
February 23rd (Tue)	18:30	18:35	P-0785	Portal Hypertension (1)	10052	Mamun-Al	Mahtab	Fibroscan is Superior to HVPG in Assessing Advanced Hepatic Fibrosis
February 23rd (Tue)	18:35	18:40	P-0786	Portal Hypertension (1)	10158	Soichiro	Kiyono	Yearly Variation in the Portal Hemodynamic Parameters on Doppler Sonography
February 23rd (Tue)	18:40	18:45	P-0787	Portal Hypertension (1)	10046	Ahmed	Abdulghany	Esophageal Varices and Platelet Sequestration, Effect of Variceal Eradication on Platelet Count
February 23rd (Tue)	18:45	18:50	P-0788	Portal Hypertension (1)	10179	Eslam	Habba	Correlation of Platelets Count with Endoscopic Findings in Egyptian Patients with Liver Cirrhosis
February 23rd (Tue)	17:40	17:45	P-0789	Portal Hypertension (2)	10545	Hidekatsu	Kuroda	Visualization of the Vascular Architecture Using SMI Reflects the Fibrosis in Patients with HCV
February 23rd (Tue)	17:45	17:50	P-0790	Portal Hypertension (2)	10051	Mamun-Al	Mahtab	Comparison between HVPG and Endoscopy of UGIT in Assessing Severity of Portal HTN in Cirrhotics
February 23rd (Tue)	17:50	17:55	P-0791	Portal Hypertension (2)	11013	Takashi	Nishimura	Pathogenesis of Portal Hypertension and the Intrahepatic Hemodynamics in Liver Cirrhosis
February 23rd (Tue)	17:55	18:00	P-0792	Portal Hypertension (2)	10146	Jae Yoon	Jeong	Both Elevation of HVPG and LS Can Predict Mortality in Non-Critically Ill Patients with Cirrhosis
February 23rd (Tue)	18:00	18:05	P-0793	Portal Hypertension (2)	10251	Yasunori	Sato	Enhanced VASH1 Expression in Splenic Sinus Lining Cells Relates to Splenomegaly in IPH
February 23rd (Tue)	18:05	18:10	P-0794	Portal Hypertension (2)	10128	Om	Parkash	Clinical Characteristics and Outcome of Budd-Chiari Syndrome at A Tertiary Care Hospital in Pakistan
February 23rd (Tue)	18:10	18:15	P-0795	Portal Hypertension (2)	11274	Vanessa O.	Co	Endoscopic Ligation and Beta Blocker Versus Monotherapy in Primary Prophylaxis of Variceal Bleeding
February 23rd (Tue)	18:15	18:20	P-0796	Portal Hypertension (2)	10047	Yoshitaka	Takuma	Diagnostic Accuracy of Spleen Stiffness for the Portal Hypertension in Patients with Liver Cirrhosis
February 23rd (Tue)	18:20	18:25	P-0797	Portal Vein Thrombosis	10368	Yuko	Nagaoki	Efficacy and Safety of Danaparoid Sodium Followed by Warfarin or Edoxaban for Treatment of PVT
February 23rd (Tue)	18:25	18:30	P-0798	Portal Vein Thrombosis	10342	Toshihiro	Kawai	EVL Following Variceal Rupture in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis
February 23rd (Tue)	17:40	17:45	P-0799	Portal Hypertension (3)	10524	Tahiri Joutei Hassani	Mohammed	VBT: A New Test of Variceal Source among Patients Presenting with Upper GI Bleeding
February 23rd (Tue)	17:45	17:50	P-0800	Portal Hypertension (3)	10784	PY	Loh	Audit of the Practice of Elective Endoscopic Variceal Ligation and Its Complication in Singapore
February 23rd (Tue)	17:50	17:55	P-0801	Portal Hypertension (3)	10704	Sien-Sing	Yang	Statins Reduce Esophageal Variceal Rebleeding in Post-Endoscopic Variceal Ligation Patients
February 23rd (Tue)	17:55	18:00	P-0802	Portal Hypertension (3)	10280	Muhammad	Adnan	To Determine the Frequency of Upper GI Bleeding and Its Predicting Factors in CLD
February 23rd (Tue)	18:00	18:05	P-0803	Portal Hypertension (3)	10017	Takahiro	Sato	Treatments of Bleeding Portal Hypertensive Duodenopathy
February 23rd (Tue)	18:05	18:10	P-0804	Portal Hypertension (3)	10071	Medhat A.	Abdel motelleb	Comorbidity of Diabetes Mellitus and Bleeding Esophageal Varices -Short Term Outcome .
February 23rd (Tue)	18:10	18:15	P-0805	Portal Hypertension (3)	10820	Ryuta	Shigefuku	Hepatic Hemodynamics and Liver Function before and after Endoscopic Injection Sclerotherapy
February 23rd (Tue)	18:15	18:20	P-0806	Portal Hypertension (3)	10707	Kerstina	Boctor	Spleen Stiffness: the Missing Link in Detection of Clinically Significant Portal Hypertension
February 23rd (Tue)	18:20	18:25	P-0807	Portal Hypertension (4)	11358	Nazish	Butt	Histoacryl&Reg Therapy of Bleeding Gastric Varices;the Experience of Tertiary Care Hospitals
February 23rd (Tue)	18:25	18:30	P-0808	Portal Hypertension (4)	10584	Muhammad_Mansoor UL	Haq	Outcome of Patients Treated with N-Butyl-2-Cyanoacrylate in Gastric Variceal Bleeding
February 23rd (Tue)	18:30	18:35	P-0809	Portal Hypertension (4)	10218	Shivakumar	Varakanahalli	Gastric Varices in Cirrhosis vs EHPVO and Response to Endoscopic N-Butyl-2-Cyanoacrylate Injection
February 23rd (Tue)	18:35	18:40	P-0810	Portal Hypertension (4)	11027	Hisashi	Hidaka	Long-Term Outcomes of B-RTO for Prevention of First or Second Bleeding of Gastric Fundal Varices
February 23rd (Tue)	18:40	18:45	P-0811	Portal Hypertension (4)	10982	Hyung Joon	Yim	Endoscopic Variceal Obliteration vs BRTO as A Prophylactic Treatment for Gastric Varices
February 23rd (Tue)	18:45	18:50	P-0812	Portal Hypertension (4)	10119	Takeshi	Hatanaka	Gastric Varices Successfully Treated by Shunt Occlusion-Endoscopic Injection Therapy: A Case Report
February 23rd (Tue)	18:50	18:55	P-0813	Portal Hypertension (4)	10543	Shinhee	Kim	Comparison of Obliteration of Gastric Varices and Technical Success between BRTO vs PARTO
February 23rd (Tue)	17:40	17:45	P-0814	Portal Vein Thrombosis	11006	Hiroaki	Haga	The Efficacy of Danaparoid Sodium on Portal Thrombosis in Patients with Hepatic Cirrhosis
February 23rd (Tue)	17:45	17:50	P-0815	Portal Vein Thrombosis	10231	Etsushi	Kawamura	Danaparoid Sodium Thrombolytic Therapy Followed by Warfarin in Cirrhotic Portal Vein Thrombosis
February 23rd (Tue)	17:50	17:55	P-0816	Portal Vein Thrombosis	10039	Dimitrios N.	Samonakis	Treatment of Portal Vein Thrombosis in Cirrhosis: A Multicenter Real Life Study
February 23rd (Tue)	17:55	18:00	P-0817	Portal Hypertension (5)	10585	Chang Chuen	Cheah	Liver Stiffness Measurement $\leq 12\text{kPa}$ Excludes Large Varices in Patients with Early Cirrhosis
February 23rd (Tue)	18:00	18:05	P-0818	Portal Hypertension (5)	10045	Soichiro	Shibata	LSPS Identifies Esophageal Varices in Chronic Liver Disease
February 23rd (Tue)	18:05	18:10	P-0819	Portal Hypertension (5)	11371	Su Jin	Kim	Effect of Time Interval for Prevention of Variceal Rebleeding in Patients without Active Bleeding
February 23rd (Tue)	18:10	18:15	P-0820	Portal Hypertension (5)	10214	Kayoko	Sugawara	Long-Term Outcome of Cirrhotic Patients with Bleeding Esophageal and Gastric Varices

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 23rd (Tue)	18:15	18:20	P-0821	Portal Hypertension (5)	10587	Sang Jun	Suh	What Predicts Short Term Mortality in Patient with Variceal Bleeding?
February 23rd (Tue)	18:20	18:25	P-0822	Portal Hypertension (5)	10272	Il Han	Song	Clinical Implication of Portal Hypertensive Colopathy Accompanied by Cirrhotic Patients
February 23rd (Tue)	18:25	18:30	P-0823	Portal Hypertension (5)	10181	Jennifer	Lai	Non-Selective Beta-Blockers and Physical Function
February 23rd (Tue)	17:40	17:45	P-0824	Ascites	11267	Takeharu	Asano	Heart Failure and Liver Cirrhosis in Patients with Ascites.
February 23rd (Tue)	17:45	17:50	P-0825	Ascites	10115	Christos	Triantos	Natural History of Grade 1 Ascites in Patients with Liver Cirrhosis
February 23rd (Tue)	17:50	17:55	P-0826	Ascites	10564	HyunJung	Chung	N-Terminal Pro B-Type Natriuretic Peptide is Useful Diagnostic Markers for the New Onset Ascites.
February 23rd (Tue)	17:55	18:00	P-0827	Ascites	11106	Naoki	Matsumoto	Renal Vein Dilation Predicts the Prognosis of Cirrhotic Ascites
February 23rd (Tue)	18:00	18:05	P-0828	Ascites	10102	Syed Abul	Foez	Ascitic Fluid Cholesterol May be A Good Parameter to Asses the Severity of Liver Cirrhosis
February 23rd (Tue)	18:05	18:10	P-0829	Ascites	10906	Toru	Arano	Denver Peritoneovenous Shunt Selectively Enriches Life of Cirrhotic Patients with Refractory Ascites
February 23rd (Tue)	18:10	18:15	P-0830	Ascites	10553	Fauzi	Yusuf	A Female with Massive Ascites: A Diagnostic Dilemma of Unknown Primary
February 23rd (Tue)	18:15	18:20	P-0831	Ascites	10077	Md.Jahangir Alam	Sarker	Variant of Ascitic Fluid Bacterial Infections in Patients of Liver Cirrhosis
February 23rd (Tue)	18:20	18:25	P-0832	Hepatic Encephalopathy	10632	Mohammad golam	Azam	Minimal Hepatic Encephalopathy among Patients with Cirrhosis of Liver: What is the Burden?
February 23rd (Tue)	18:25	18:30	P-0833	Hepatic Encephalopathy	10924	Bayarmaa	Ochirkhuree	Assessment of Minimal Hepatic Encephalopathy in Mongolia
February 23rd (Tue)	18:30	18:35	P-0834	Hepatic Encephalopathy	10815	Karim S.	Elnoemany	Combination of Lactulose, Rifaximin and LOLA in Treatment of Minimal Hepatic Encephalopathy
February 23rd (Tue)	18:35	18:40	P-0835	Hepatic Encephalopathy	10313	Masanori	Hododuka	Minimal Hepatic Encephalopathy Diagnosed with Neurophysiological Test in Cirrhotic Patients
February 23rd (Tue)	18:40	18:45	P-0836	Hepatic Encephalopathy	10943	El-Sayed S.	Tharwa	Correlation Between Character of Portal Blood Flow and Post-TIPS Incidence of Hepatic Encephalopathy
February 23rd (Tue)	18:45	18:50	P-0837	Hepatic Encephalopathy	11322	Nauman A.	Jadoon	Presence of Anemia Predicts Advanced Grade at Presentation in Patients with Hepatic Encephalopathy
February 23rd (Tue)	18:50	18:55	P-0838	Hepatic Encephalopathy	10509	Rie	Osaki	A Summary of Using Levocarnitine with Liver Cirrhosis in Our Hospital
February 23rd (Tue)	17:40	17:45	P-0839	Cirrhosis: Management (1)	11056	Vaibhav S.	Somani	Comparing the TEG with Conventional Coagulation Tests in Cirrhotics Undergoing Invasive Procedures.
February 23rd (Tue)	17:45	17:50	P-0840	Cirrhosis: Management (1)	10105	Md. Ashrafal	Alam	Correlation of Hepatic Cirrhosis with Severity of Bone Changes Measured by BMD
February 23rd (Tue)	17:50	17:55	P-0841	Cirrhosis: Management (1)	10207	Young E.	Chon	Serial Assessment of Fibrosis Regression Using Fibroscan in CHB Patients Receiving Antiviral Therapy
February 23rd (Tue)	17:55	18:00	P-0842	Cirrhosis: Management (1)	10414	Shahid	Sarwar	Hepatorenal Syndrome: Response to Terlipressin and Albumin and Its Determinants
February 23rd (Tue)	18:00	18:05	P-0843	Cirrhosis: Management (1)	10738	Omer	Ozbakir	Endothelial Dysfunction in Cirrhosis and Hepatorenal Syndrome
February 23rd (Tue)	18:05	18:10	P-0844	Cirrhosis: Management (1)	11309	Nauman A.	Jadoon	Relationship of Child-Pugh and Meld Scores with in-Hospital Mortality in Decompensated Cirrhosis
February 23rd (Tue)	18:10	18:15	P-0845	Cirrhosis: Management (1)	11315	Nauman A.	Jadoon	Prevalence and Predictors of Thrombocytopenia in Advanced Liver Disease
February 23rd (Tue)	18:15	18:20	P-0846	Cirrhosis: Management (2)	11071	Jennielyn C.	Agcaoili	Left Ventricular Dysfunction Among Cirrhotic with Beta Blocker Therapy
February 23rd (Tue)	18:20	18:25	P-0847	Cirrhosis: Management (2)	10959	Yuu	Shimozuma	Predictive Factors for Therapeutic Effects of Tolvaptan to Patients with Refractory Ascites
February 23rd (Tue)	18:25	18:30	P-0848	Cirrhosis: Management (2)	10300	Rika	Aso	Tolvaptan Reduces Refractory Ascites in Patients with Advanced Liver Cirrhosis.
February 23rd (Tue)	18:30	18:35	P-0849	Cirrhosis: Management (2)	10846	Hideo	Yoshida	Hepatic Ascites Treatment with Novel Diuretic - Vasopressin V2 Receptor Antagonist (Tolvaptan)
February 23rd (Tue)	18:35	18:40	P-0850	Cirrhosis: Management (2)	10858	Norio	Itokawa	Serum M2BPGi and HVPG are Useful Factors Predicting the Effect of Tolvaptan on Hepatic Edema
February 23rd (Tue)	18:40	18:45	P-0851	Cirrhosis: Management (2)	10768	Pik Eu	Chang	Portosystemic Gradient is Significantly Different on Day 5 Compared to Immediately Post-TIPS
February 23rd (Tue)	18:45	18:50	P-0852	Cirrhosis: Management (2)	10804	Vaibhav S.	Somani	Role of Von Willebrand Factor Levels in Predicting Severity of Cirrhosis
February 23rd (Tue)	17:40	17:45	P-0853	Cirrhosis: Management (3)	10444	Aiko	Fukui	Factors Related to Skeletal Muscle Volume in Patients with Chronic Hepatitis C
February 23rd (Tue)	17:45	17:50	P-0854	Cirrhosis: Management (3)	10372	Akira	Hiramatsu	Measurement of Muscle Mass Using CT is Useful to Diagnose Sarcopenia in Patients with Cirrhosis
February 23rd (Tue)	17:50	17:55	P-0855	Cirrhosis: Management (3)	10659	Sudhir	Maharshi	Effects of Nutritional Therapy on Complications and Outcome in Cirrhosis - Randomized Trial
February 23rd (Tue)	17:55	18:00	P-0856	Cirrhosis: Management (3)	11366	Sandeep S.	Kulkarni	Nutritional Assessment in Cirrhosis of Liver
February 23rd (Tue)	18:00	18:05	P-0857	Cirrhosis: Management (3)	10662	Teruo	Miyazaki	Serum 3-Hydroxyisobutyrate as A Biomarker of Muscular BCAA Catabolism in Liver Cirrhosis Patients
February 23rd (Tue)	18:05	18:10	P-0858	Cirrhosis: Management (3)	10148	Tadashi	Sekimoto	Prediction of the Response to Branched-Chain Amino Acid Medication by Liver Stiffness in Cirrhosis
February 23rd (Tue)	18:10	18:15	P-0859	Cirrhosis: Management (3)	10124	Cheng-Hung	Chien	The Association between Hepatitis B/C Infection and Metabolic Syndrome in Northern Taiwan
February 23rd (Tue)	18:15	18:20	P-0860	Cirrhosis: Management (3)	10771	Kamil	Ozdil	Comparison the Accuracy of Clinical Assessment Tools to Diagnose Malnutrition in Cirrhosis
February 23rd (Tue)	18:20	18:25	P-0861	Cirrhosis: Management (4)	10757	Tatsuya	Osuga	Aspirin Administration May be A Therapeutic Option for Cirrhosis-Related Thrombocytopenia

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 23rd (Tue)	18:25	18:30	P-0862	Cirrhosis: Management (4)	10995	Young Mi	Hong	The Prescription Pattern of Acetaminophen and NSAIDs in Patients with Liver Cirrhosis
February 23rd (Tue)	18:30	18:35	P-0863	Cirrhosis: Management (4)	11069	Jennielyn C.	Agcaoili	Prognostic Indicators of Mortality among Cirrhotics Admitted at the Intensive Care Unit
February 23rd (Tue)	18:35	18:40	P-0864	Cirrhosis: Management (4)	10803	Andree	Kurniawan	Clostridium Difficile Infection in Liver Cirrhosis Patients Increased Risk of Malnutrition
February 23rd (Tue)	18:40	18:45	P-0865	Cirrhosis: Management (4)	10014	Ragaa A.	Ramadan	Nitric Oxide: the Link between Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome
February 23rd (Tue)	18:45	18:50	P-0866	Cirrhosis: Management (4)	10072	Medhat A.	Abdel motelleb	Combined Norfloxacin and Rifaximine as Primary Prophylaxis for Spontaneous Bacterial Peritonitis .
February 23rd (Tue)	18:50	18:55	P-0867	Cirrhosis: Management (4)	10341	Jeong Han	Kim	Clinical Features of Spontaneous Bacterial Peritonitis; Ten Years Single Center Experience
February 23rd (Tue)	18:55	19:00	P-0868	Cirrhosis: Management (4)	10055	Mamun-Al	Mahtab	Safety and Efficacy of Stem Cell Stimulating Therapy in Decompensated Cirrhosis of Liver
February 23rd (Tue)	17:40	17:45	P-0869	Cirrhosis: Management (5)	10801	Mohd Harun Or	Rashid	Dermatological Manifestations of Chronic Liver Disease
February 23rd (Tue)	17:45	17:50	P-0870	Cirrhosis: Management (5)	10036	Saira	Baloch	Hematological Changes and Occurrence of Anemia in Chronic Liver Disease
February 23rd (Tue)	17:50	17:55	P-0871	Cirrhosis: Management (5)	10698	Mingxing	Huang	Artificial Liver Support System with Recombinant Human Growth Hormone in Chronic Liver Failure
February 23rd (Tue)	17:55	18:00	P-0872	Cirrhosis: Management (5)	10872	Mikio	Kajihara	Detection of Blood Microbiota and Dysbiosis in Patients with Liver Cirrhosis
February 23rd (Tue)	18:00	18:05	P-0873	Cirrhosis: Management (5)	10642	Hiroko	Setoyama	Reduced Human Serum Albumin is A Useful Biomarker of Progression in Chronic Liver Disease
February 23rd (Tue)	18:05	18:10	P-0874	Cirrhosis: Management (5)	10022	Huriye	Camlibel	Serum Visfatin, HBA1C, Insulin, C Peptide and Glucose Levels in Patients with Liver Cirrhosis
February 23rd (Tue)	18:10	18:15	P-0875	Cirrhosis: Management (5)	10307	Anatol	Panasiuk	Serum Transferrin Isoforms in Liver Diseases
February 23rd (Tue)	18:15	18:20	P-0876	Cirrhosis: Management (6)	10728	JeongSuk	Jeon	Effect of Vitamin B6, Vitamin B12 and Folic Acid on Serum Homocysteine Level
February 23rd (Tue)	18:20	18:25	P-0877	Cirrhosis: Management (6)	10530	Aubrey Q.	Taguba	Vitamin D Deficiency in Chronic Liver Disease Patients of the Philippine General Hospital
February 23rd (Tue)	18:25	18:30	P-0878	Cirrhosis: Management (6)	10721	Bikha Ram	Devrajani	Vitamin D Levels in Cirrhosis and Chronic Liver Disease
February 23rd (Tue)	18:30	18:35	P-0879	Cirrhosis: Management (6)	10082	Dilip	Sharma	Prevalence of Vitamin D Deficiency in Patients with Chronic Viral Hepatitis: A Nepalese Study
February 23rd (Tue)	18:35	18:40	P-0880	Cirrhosis: Management (6)	10708	Lei	Yu	Copper Deficiency in Liver Disorders: Implications for Disease Mechanism and Clinical Management
February 23rd (Tue)	18:40	18:45	P-0881	Cirrhosis: Management (6)	10037	Mohsin Ali	Baloch	Zinc and Copper Concentration in Children with Chronic Liver Disease
February 23rd (Tue)	18:45	18:50	P-0882	Cirrhosis: Management (6)	10318	Yu-Tung	Lin	The Correlation between Serum Zinc Level and Dysgeusia in Cirrhotic Patients
February 23rd (Tue)	18:50	18:55	P-0883	Cirrhosis: Management (6)	11233	Nadeem	Sheikh	Impact of Acute Fe & Cu Administration on Hematology and Biochemistry in <D>Rattus Norvegicus</D>
February 23rd (Tue)	17:40	17:45	P-0884	NASH/NAFLD:Basic Research (1)	10793	Shan	Zhong	OD36 Deficiency Aggravates the Development of NASH Via Up-Regulating MCP-1 Expression in Hepatocytes
February 23rd (Tue)	17:45	17:50	P-0885	NASH/NAFLD:Basic Research (1)	10913	Francois	Briand	Cyclodextrin Promotes Liver Inflammation and Fibrosis in High Fat/Cholesterol/Cholate Diet Fed Mice
February 23rd (Tue)	17:50	17:55	P-0886	NASH/NAFLD:Basic Research (1)	10802	Hiroshi	Yokoyama	Distribution of Hepatic Stellate Cells Which Express LRAT and/or CRBP-1 in NASH Patients
February 23rd (Tue)	17:55	18:00	P-0887	NASH/NAFLD:Basic Research (1)	10984	Takahiro	Tsuchiya	Duodenal Jejunal Bypass Improves Non-Alcoholic Steatohepatitis in Rats
February 23rd (Tue)	18:00	18:05	P-0888	NASH/NAFLD:Basic Research (1)	10795	Shoichiro	Yara	Dysregulation of Hepatic 27-Hydroxycholesterol in Steatohepatitis Model Mice with Hyperglycemia
February 23rd (Tue)	18:05	18:10	P-0889	NASH/NAFLD:Basic Research (1)	11186	Linda	Ban	Extracellular Vesicles: Exploring A Novel Biomarker in Nonalcoholic Fatty Liver Disease Pathogenesis
February 23rd (Tue)	18:10	18:15	P-0890	NASH/NAFLD:Basic Research (1)	10196	Dariusz M.	Lebensztejn	Fibroblast Growth Factor 21 Concentration in Obese Children with Nonalcoholic Fatty Liver Disease
February 23rd (Tue)	18:15	18:20	P-0891	NASH/NAFLD:Basic Research (2)	10497	Mei	Li	Effect of Polydatin to ApoE-/- Mices the Expression of MDA/T-SOD and Liver Function
February 23rd (Tue)	18:20	18:25	P-0892	NASH/NAFLD:Basic Research (2)	10424	Norihisa	Nishimura	Ipragliflozin Ameliorates Liver Fibrosis Development in Diabetic OLETF Rats
February 23rd (Tue)	18:25	18:30	P-0893	NASH/NAFLD:Basic Research (2)	10239	Koichiro	Miyagawa	Lipid-Induced Endoplasmic Reticulum Stress Impairs Selective Autophagy in Hepatocytes
February 23rd (Tue)	18:30	18:35	P-0894	NASH/NAFLD:Basic Research (2)	10099	Saut	Nababan	Ether Phospholipid Profile in Mice with Non-Alcoholic Steatohepatitis
February 23rd (Tue)	18:35	18:40	P-0895	NASH/NAFLD:Basic Research (2)	10991	Ayaka	Kinoshita	Rapid Progression of Hepatocellular Carcinoma in Neuropeptide Y Knockout Mice under High Fat Diet
February 23rd (Tue)	18:40	18:45	P-0896	NASH/NAFLD:Basic Research (2)	10087	Fehmi	Ates	The Importance of MTHFR A1298C and C677T Gene Polymorphisms in Non-Obese NASH Patients
February 23rd (Tue)	18:45	18:50	P-0897	NASH/NAFLD:Basic Research (2)	10992	Suguru	Ogura	The Role of Hematopoietic Stem Cells in Liver Pathogenesis
February 23rd (Tue)	17:40	17:45	P-0898	NASH/NAFLD:Basic Research (3)	10299	Masanori	Abe	Characterization of Liver Myeloid-Derived Suppressor Cells in Nonalcoholic Fatty Liver Disease
February 23rd (Tue)	17:45	17:50	P-0899	NASH/NAFLD:Basic Research (3)	10699	Kyoung Min	Sohn	Adipolysis Efficacy of Aged Black Garlic Extract in 3T3-L1 Adipocytes
February 23rd (Tue)	17:50	17:55	P-0900	NASH/NAFLD:Basic Research (3)	10404	Masami	Minemura	Analysis of the Direct Interaction between Macrophages and Microbiota
February 23rd (Tue)	17:55	18:00	P-0901	NASH/NAFLD:Basic Research (3)	10229	Kang-Yu	Peng	Fatty Acid-Overloaded Steatotic Hepatocytes Display Altered Phospholipidome and Membrane Integrity
February 23rd (Tue)	18:00	18:05	P-0902	NASH/NAFLD:Basic Research (3)	10411	Sang Bong	Ahn	Fermented Soymilk Prevent Free Fatty Acid-Induced Lipogenesis in Hepatocellular Steatosis Model

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 23rd (Tue)	18:05	18:10	P-0903	NASH/NAFLD:Basic Research (3)	10097	Dipendra R.	Pandeya	Gut Microbiota and Their Metabolic Influence in Neonatal Intestine by Early Colonization
February 23rd (Tue)	18:10	18:15	P-0904	NASH/NAFLD:Basic Research (3)	10168	Yuhan	Liu	Identification of SENP3 as A Potential Modulator in the Lipid Metabolism Pathway in NAFLD
February 23rd (Tue)	18:15	18:20	P-0905	NASH/NAFLD: Fibrosis (1)	10327	Le T.T.	Thuy	Protective Role of Cytoglobin in Liver Inflammation and Fibrogenesis in Mouse Steatohepatitis Model
February 23rd (Tue)	18:20	18:25	P-0906	NASH/NAFLD: Fibrosis (1)	10208	Ming Han	Lim	Reliability of Transient Elastography for the Detection of Fibrosis in Severely Obese Patients.
February 23rd (Tue)	18:25	18:30	P-0907	NASH/NAFLD: Fibrosis (1)	11278	Wang	Qianyi	Comparison of FibroTouch and FibroScan for the Assessment of Liver Steatosis in NAFLD Patients
February 23rd (Tue)	18:30	18:35	P-0908	NASH/NAFLD: Fibrosis (1)	10713	Keiko	Korenaga	Usefulness of the FibroScan® XL Probe in Patients with Nonalcoholic Fatty Liver Disease
February 23rd (Tue)	18:35	18:40	P-0909	NASH/NAFLD: Fibrosis (1)	11257	Stephen A.	Harrison	Novel Quantitative Assessment of Liver Fibrosis in NAFLD
February 23rd (Tue)	18:40	18:45	P-0910	NASH/NAFLD: Fibrosis (1)	10075	Noritaka	Wakui	Utility of Heartbeat-Induced Strain Elastography (S-Map) in Staging Fibrosis in NASH
February 23rd (Tue)	17:40	17:45	P-0911	NASH/NAFLD: Novel Therapy (1)	11023	Shigekazu	Takemura	S-Allyl Cysteine Improves Fatty Liver Disease and Diabetes in Otsuka Long-Evans Tokushima Fatty rats
February 23rd (Tue)	17:45	17:50	P-0912	NASH/NAFLD: Novel Therapy (1)	11078	Bryan	Laffitte	Anti-Fibrotic Effect A Novel, Non-Bile Acid FXR Agonist in A Model of Non-Alcoholic Steatohepatitis
February 23rd (Tue)	17:50	17:55	P-0913	NASH/NAFLD: Novel Therapy (1)	10911	Francois	Briand	Obese Insulin Resistant Diet-Induced NASH (DIN) Mouse as A Model for Evaluating Drugs Targeting NASH
February 23rd (Tue)	17:55	18:00	P-0914	NASH/NAFLD: Novel Therapy (1)	11048	Ronald	Barbaras	P2Y13 Receptor Agonist CER-209 Decreases Both Atherosclerosis and Liver Steatosis in Vivo
February 23rd (Tue)	18:00	18:05	P-0915	NASH/NAFLD: Novel Therapy (1)	11062	Ronald	Barbaras	P2Y13 Receptor Agonist CER-209, An Anti-Atherosclerotic Compound, Decreases Liver Steatosis in Vivo
February 23rd (Tue)	18:05	18:10	P-0916	NASH/NAFLD: Novel Therapy (2)	10551	Tsuneyuki	Miyazaki	Sodium Alginate Prevents NASH Progression and Liver Carcinogenesis in Obese and Diabetic Mice
February 23rd (Tue)	18:10	18:15	P-0917	NASH/NAFLD: Novel Therapy (2)	10874	Cansel	Turkay	Echocardiographic Findings in Patients with Non-Alcoholic Fatty Liver Disease
February 23rd (Tue)	18:15	18:20	P-0918	NASH/NAFLD: Novel Therapy (2)	10759	Keitaro	Sofue	Stability of Liver Proton Density Fat Fraction and Changes in R2* Induced by Gd-EOB-DTPA.
February 23rd (Tue)	18:20	18:25	P-0919	NASH/NAFLD: Novel Therapy (2)	11298	Haiyan	Song	New Effect and Mechanism of Protopanaxadiol in Improving Nonalcoholic Fatty Liver Disease
February 23rd (Tue)	18:25	18:30	P-0920	NASH/NAFLD: Novel Therapy (2)	10447	Toshiaki	Okamoto	The Antifibrotic Effects of Endothelin Type A Receptor Antagonist in NASH Model FLS-ob/ob Mice
February 23rd (Tue)	17:40	17:45	P-0921	NASH/NAFLD:Epidemiology and Natural History (1)	10777	Mohd Harun Or	Rashid	Impaired Liver Functions in Patients with Diabetes Mellitus in Bangladesh
February 23rd (Tue)	17:45	17:50	P-0922	NASH/NAFLD:Epidemiology and Natural History (1)	11040	Jonathan C. F.	Leung	Histological Severity and Clinical Outcomes of Non-Obese Non-Alcoholic Fatty Liver Disease
February 23rd (Tue)	17:50	17:55	P-0923	NASH/NAFLD:Epidemiology and Natural History (1)	10723	Wataru	Tomeno	Major Depressive Disorder Adversely Affect Treatment Outcomes of Non-Alcoholic Fatty Liver Disease
February 23rd (Tue)	17:55	18:00	P-0924	NASH/NAFLD:Epidemiology and Natural History (1)	10337	Mara Teresa T.	Panlilio	NAFLD in Type 1 Diabetes Mellitus: Prevalence and Association with Metabolic Syndrome and CVD
February 23rd (Tue)	18:00	18:05	P-0925	NASH/NAFLD:Epidemiology and Natural History (1)	10310	Pochamana	Phisalprapa	Association between Caffeine Consumption and Nonalcoholic Fatty Liver Disease in Metabolic Syndrome
February 23rd (Tue)	18:05	18:10	P-0926	NASH/NAFLD:Epidemiology and Natural History (1)	10343	Yasunori	Yamamoto	Upregulated Intestinal Absorption of Dietary Saturated Fatty Acids in Non-Alcoholic Steatohepatitis
February 23rd (Tue)	18:10	18:15	P-0927	NASH/NAFLD:Epidemiology and Natural History (1)	10774	Risky I.	Riani	The Role of Nutritions to Incidence and Severity of Non Alcoholic Fatty Liver Disease
February 23rd (Tue)	18:15	18:20	P-0928	NASH/NAFLD:Epidemiology and Natural History (2)	10015	Alfonso Syoei R.	Yoshida	Profile of Patients Diagnosed with Fatty Liver Disease at Seamen's Hospital
February 23rd (Tue)	18:20	18:25	P-0929	NASH/NAFLD:Epidemiology and Natural History (2)	10678	Shou-Wu	Lee	The Association of Non-Alcoholic Fatty Liver Disease with Metabolic Syndrome
February 23rd (Tue)	18:25	18:30	P-0930	NASH/NAFLD:Epidemiology and Natural History (2)	10104	Kadir	Ozturk	The Association of Non-Alcoholic Fatty Liver Disease with Obesity and Apolipoproteins
February 23rd (Tue)	18:30	18:35	P-0931	NASH/NAFLD:Epidemiology and Natural History (2)	10390	Jung Hee	Kim	The Risk of Preclinical Atherosclerosis in Non-Diabetic, Non-Hypertensive Adults by NAFLD
February 23rd (Tue)	18:35	18:40	P-0932	NASH/NAFLD:Epidemiology and Natural History (2)	10556	Xiao	Hu	PPAR&Alpha Can Attenuate Dietary Trans-Fatty Acid-Induced Liver Changes
February 23rd (Tue)	18:40	18:45	P-0933	NASH/NAFLD:Epidemiology and Natural History (2)	11088	Ieva	Tolmane	Relationship between Patient Lifestyle and Development of Fatty Liver Disease
February 23rd (Tue)	17:40	17:45	P-0934	NASH/NAFLD:Biomarker (1)	10465	Hakan	Demirci	Is Serum Uric Acid Risk Factor for Non-Alcoholic Fatty Liver Disease?
February 23rd (Tue)	17:45	17:50	P-0935	NASH/NAFLD:Biomarker (1)	10048	Sheikh Mohammad	Noor-E-Alam	Limited Implication of Ratio of Serum AST to Serum ALT for Diagnosis of NASH
February 23rd (Tue)	17:50	17:55	P-0936	NASH/NAFLD:Biomarker (1)	10854	Junya	Okabe	Measurement of Liver Fat Volume by Multi-Material Decomposition Method with Dual Energy CT in NAFLD
February 23rd (Tue)	17:55	18:00	P-0937	NASH/NAFLD:Biomarker (1)	10074	Fusun	Bolukbas	Relationship between Vitamin B12 Levels and Hepatic Fibrosis Detected with Fibroscan in NAFLD
February 23rd (Tue)	18:00	18:05	P-0938	NASH/NAFLD:Biomarker (1)	10871	Cansel	Turkay	Role of Paraoxonase-1, Caspase Cleaved Cytokeratin 18 and Pentraxin-3 Levels in Nafld
February 23rd (Tue)	18:05	18:10	P-0939	NASH/NAFLD:Biomarker (1)	11365	Jingmin	Zhao	Serum PEDF as An Independent Biomarker in Non-Invasive Diagnosis of NASH
February 23rd (Tue)	18:10	18:15	P-0940	NASH/NAFLD:Biomarker (2)	10841	Taeang	Arai	Serum 25(OH)D3 Levels are Related to the Severity of Liver Fibrosis in Patients with NAFLD
February 23rd (Tue)	18:15	18:20	P-0941	NASH/NAFLD:Biomarker (2)	11008	Gasser	El-Azab	Serum Apelin as A Non-Invasive Marker for Nonalcoholic Steatohepatitis
February 23rd (Tue)	18:20	18:25	P-0942	NASH/NAFLD:Biomarker (2)	10499	Kohei	Oda	The Association between sAIM and the Clinical Features of Non-Obese Patients with NAFLD
February 23rd (Tue)	18:25	18:30	P-0943	NASH/NAFLD:Biomarker (2)	10137	Omer	Kurt	The Relationship of Pentraxin 3 with Atherosclerosis in Non-alcoholic Fatty Liver Disease

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 23rd (Tue)	17:40	17:45	P-0944	NASH/NAFLD:Biomarker (3)	10268	Naoto	Kawabe	The Usefulness of Markers for Diagnosis of NAFLD Comparing with Chronic Hepatitis C
February 23rd (Tue)	17:45	17:50	P-0945	NASH/NAFLD:Biomarker (3)	10488	Maricruz	Sepulveda-Villegas	Use of Biochemical and Metabolic Markers for the Detection of Nonalcoholic Steatohepatitis (NASH)
February 23rd (Tue)	17:50	17:55	P-0946	NASH/NAFLD:Biomarker (3)	10756	Shahinul	Alam	Changes of Alanine Aminotransferase and Gamma Glutamyl Transpeptidase with Histology of Fatty Liver
February 23rd (Tue)	17:55	18:00	P-0947	NASH/NAFLD:Biomarker (3)	10895	Koji	Takayama	Controlled Attenuation Parameters is Efficient in the Quantification of Hepatic Steatosis
February 23rd (Tue)	18:00	18:05	P-0948	NASH/NAFLD:Biomarker (3)	10549	Kyoung Min	Sohn	Relation of Risk Factors between Metabolic Syndrome and Nafld in Apparently Healthy Young Adults
February 23rd (Tue)	18:05	18:10	P-0949	NASH/NAFLD:Biomarker (4)	10562	Peter P.	Liu	Metabolic Syndrome as Predictors for Severity of NAFLD Detected by Ultrasonography in Taiwanese
February 23rd (Tue)	18:10	18:15	P-0950	NASH/NAFLD:Biomarker (4)	10619	Ferdane	Sapmaz	Which is More Important for Development of Endothelial Dysfunction: Steatosis or Fibrosis?
February 23rd (Tue)	18:15	18:20	P-0951	NASH/NAFLD:Biomarker (4)	11164	Chiharu	Yoshida	Possible Gender Difference of NAFLD in Adolescence Evaluated by Elevated Liver Enzyme Levels
February 23rd (Tue)	18:20	18:25	P-0952	NASH/NAFLD:Biomarker (4)	10494	Salih	Boga	Serum Immunoglobulin A Level is A Predictor for Fibrosis in Non-Alcoholic Fatty Liver Disease
February 23rd (Tue)	18:25	18:30	P-0953	NASH/NAFLD:Biomarker (4)	10751	Zia H.	Bosunia	To Evaluate Non-Invasive Predictors in Diagnosis of Nonalcoholic Steatohepatitis
February 23rd (Tue)	17:40	17:45	P-0954	NASH and Other Diseases (2)	10664	HuiGuo	Ding	Effects of Liver Steatosis on the Progression and the Antiviral Response in Chronic Hepatitis B
February 23rd (Tue)	17:45	17:50	P-0955	NASH and Other Diseases (2)	10760	Mamun-Al	Mahtab	NASH Challenges HBV as the Leading Cause of Chronic Hepatitis in Bangladesh
February 23rd (Tue)	17:50	17:55	P-0956	NASH and Other Diseases (2)	11292	Deniz Guney	Duman	Nonalcoholic Fatty Liver Disease is Associated with Erectile Dysfunction: A Prospective Pilot Study
February 23rd (Tue)	17:55	18:00	P-0957	NASH and Other Diseases (2)	11004	Matsuki	Umehara	Non-Invasive Assessment of Hepatic Steatosis in Patients with Anorexia Nervosa Using Elastography
February 23rd (Tue)	18:00	18:05	P-0958	NASH and Other Diseases (3)	10028	Metin	Basaranoglu	Nonalcoholic Fatty Liver Disease Needs More Metabolic Abnormalities Than Polycystic Ovary Syndrome
February 23rd (Tue)	18:05	18:10	P-0959	NASH and Other Diseases (3)	10826	Asem	Elfert	Study of Hepatic Steatosis Index in Patients with Chronic HCV Infection
February 23rd (Tue)	18:10	18:15	P-0960	NASH and Other Diseases (3)	10696	Murat T.	Gulsen	The Association between Chronic Hepatitis b/c Infection and Metabolic Syndrome
February 23rd (Tue)	18:15	18:20	P-0961	NASH and Other Diseases (3)	10080	Kazuhisa	Kodama	Comparison of Complications between Nonalcoholic Fatty Liver Disease vs Alcoholic Liver Disease
February 23rd (Tue)	18:20	18:25	P-0962	Alcoholic Liver Disease	10213	Masahiro	Kikuchi	Utility of Quantitative Controlled Attenuation Parameter to Diagnose Alcoholic Liver Disease.
February 23rd (Tue)	18:25	18:30	P-0963	Alcoholic Liver Disease	10419	Young-Sun	Lee	Systematic Review : Steroid, Pentoxifylline or Combined Therapy for Acute Alcoholic Hepatitis
February 23rd (Tue)	18:30	18:35	P-0964	Alcoholic Liver Disease	10885	Dae Hee	Choi	Clinical Factors Correlated to Alcohol Withdrawal in Patients with Alcoholic Liver Disease
February 23rd (Tue)	18:35	18:40	P-0965	Alcoholic Liver Disease	11140	Masateru	Miura	The Comparison Examination with A Serum Sodium Level and Varicose Recurrence in Alcoholic Cirrhosis.
February 23rd (Tue)	18:40	18:45	P-0966	Alcoholic Liver Disease	11221	Varsha	Shasthry	BIA is in Proximate Agreement with CT Based Assessment of Sarcopenia in ALD Patients
February 23rd (Tue)	18:45	18:50	P-0967	Alcoholic Liver Disease	11241	Petr	Tkachenko	Prednisolone plus S-Adenosil-L-Methionine in Severe Alcoholic Hepatitis.
February 23rd (Tue)	17:40	17:45	P-0968	Surgery: Imaging	10112	Jaiyoung	Cho	Remnant Liver Ischemia is Associated with Early Recurrence and Poorer Survival after Hepatectomy
February 23rd (Tue)	17:45	17:50	P-0969	Surgery: Innovation	10130	Toshio	Shikano	Successful Laparoscopic Deroofing for Liver Cysts: Our Technique and Outcome
February 23rd (Tue)	17:50	17:55	P-0970	Surgery: Innovation	10636	Masaki	Kaibori	Effect of Introducing An ERAS for Patients Undergoing Resection of HCC
February 23rd (Tue)	17:55	18:00	P-0971	Surgery: Innovation	10113	Jaiyoung	Cho	Validation of A Complexity Classification to Define Surgical Difficulty in Patients with HCC
February 23rd (Tue)	18:00	18:05	P-0972	Surgery: Innovation	11214	Rahiman	Faiyaz	C3a Receptor Blockade Reduces Liver Regeneration Post-Hepatectomy in LPS-Hyporesponsive C3h/HeJ Mice
February 23rd (Tue)	18:05	18:10	P-0973	Liver Transplantation (1)	10931	Deeplaxmi P.	Borle	HBIG Free Regimen for Preventing Post Transplant Hepatitis B Recurrence
February 23rd (Tue)	18:10	18:15	P-0974	Liver Transplantation (1)	10118	Harvey	Ho	Modelling of Hepatic Flow Variations Due to Liver Resection and Transplantation
February 23rd (Tue)	18:15	18:20	P-0975	Liver Transplantation (1)	10302	Mark D	Muthiah	Reducing the Rates of Invasive CMV Disease in Post Liver Transplant Patients.
February 23rd (Tue)	18:20	18:25	P-0976	Liver Transplantation (1)	10613	Hae Won	Lee	The Start of Liver Transplantation at the Public Hospital in Korea
February 23rd (Tue)	18:25	18:30	P-0977	Liver Transplantation (1)	10180	Jennifer	Lai	Polypharmacy and Medication Adherence in Liver Transplant Candidates
February 23rd (Tue)	18:30	18:35	P-0978	Liver Transplantation (1)	10811	Min-Su	Park	The Association between Tumor Necrosis Factor-Alpha Polymorphism and Acute Solid Organ Rejection
February 23rd (Tue)	17:40	17:45	P-0979	Liver Transplantation (2)	11032	Yang Won	Nah	Surgical Results of Outflow Reconstruction in Living Donor Liver Transplantation
February 23rd (Tue)	17:45	17:50	P-0980	Liver Transplantation (2)	10274	Khue Kim	Dang	Liver Transplantation in Adults in Viet Duc University Hospital: A Single-Center Experience
February 23rd (Tue)	17:50	17:55	P-0981	Liver Transplantation (2)	11036	Byeong Ju	Kang	Acute Kidney Injury after Liver Transplantation does not Affect the Patients' Mortality
February 23rd (Tue)	17:55	18:00	P-0982	Liver Transplantation (2)	10008	Moamed H.	Badr	Urinary-NGAL as A Predictor of Acute Kidney Injury in Post-Liver Transplant Recipients
February 23rd (Tue)	18:00	18:05	P-0983	Liver Transplantation (2)	10450	Koichi	Kimura	Exacerbation of Fatty Liver Ischemic Reperfusion Injury Through NADPH Oxidase Signal Transduction
February 23rd (Tue)	18:05	18:10	P-0984	Case Report, LT	10393	Joo S.	Kim	A Rare Infectious Complication after Living Donor Liver Transplantation

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 23rd (Tue)	18:10	18:15	P-0985	Case Report, LT	10703	Raman K.	Gupta	Donor Derived Dengue Infection in Living Donor Livertransplantation Recipient: Case Report
February 23rd (Tue)	18:15	18:20	P-0986	Case Report, LT	11319	Natalia	Rodriguez- Payan	Successful Percutaneous Thrombectomy for Portal Vein Thrombosis Following Liver Transplant
February 23rd (Tue)	18:20	18:25	P-0987	Case Report, LT	11127	Kengo	Sasaki	Successful Living Domino Liver Transplantation Using Liver from A Maple Syrup Urine Disease Patient
February 23rd (Tue)	18:25	18:30	P-0988	Case Report, LT	10184	Sunhawit	Junrungsee	Super Marginal Liver Graft; Lacerated Liver in Open Abdomen Setting; A Case Report
February 23rd (Tue)	17:40	17:45	P-0989	GI	10139	Talat	Ayyildiz	Coexistence of Gastrointestinal Stromal Tumor of the Stomach and Small Bowel Adenocarcinoma
February 23rd (Tue)	17:45	17:50	P-0990	GI	10289	Mansoor A.	Kalwar	Endoscopic Findings around Gastroesophageal Junction. Experience from Tertiary Hospital in Pakistan
February 23rd (Tue)	17:50	17:55	P-0991	GI	10138	Talat	Ayyildiz	The Expression of Adipor1/R2 in Gastric Intestinal Metaplasia and Gastric Carcinoma
February 23rd (Tue)	17:55	18:00	P-0992	GI	10994	Mohammad Hossein	Somi	Upper Gastrointestinal Endoscopic Findings in More Than 8500 Patients
February 23rd (Tue)	18:00	18:05	P-0993	GI	10864	Chen-Wang	Chang	Evaluate the Effects of Bacillus Coagulans in Functional Bowel Disorders
February 23rd (Tue)	18:05	18:10	P-0994	GI	10705	Jong In	Yang	Enteral Parasite Detection by Stool Exam, Abdominal US/CT, & Colonoscopy during Health Checkup
February 23rd (Tue)	18:10	18:15	P-0995	Drug Induced Liver Injury (2)	10560	Madeeha	Arshad	Adverse Effects of Sodium Arsenate Exposure to Gestational Mothers
February 23rd (Tue)	18:15	18:20	P-0996	Drug Induced Liver Injury (2)	11182	Xijing	Xu	A Case of Fanconi Syndrome Induced by TCM in A Chronic Drug Induced Liver Disease Patient
February 23rd (Tue)	18:20	18:25	P-0997	Drug Induced Liver Injury (2)	10029	Pin-Der	Duh	The Protective Effect of Djulis and Its Bioactive Compounds against CCl4-Induced Liver Injury
February 23rd (Tue)	18:25	18:30	P-0998	Drug Induced Liver Injury (2)	10100	Nella	Suhuyanly	Tuberculostatic Hepatotoxicity : Focused on NAT2 Enzyme Status and Polymorphism of CYP 2E1
February 23rd (Tue)	18:30	18:35	P-0999	Drug Induced Liver Injury (2)	10185	Milben A.	Malbog	Incidence of Drug Induced Liver Injury in Government Hospital Patients on Anti-Koch's Treatment
February 23rd (Tue)	17:40	17:45	P-1000	Drug Induced Liver Injury (1)	10204	Sith	Siramolpiwat	Clinical and Histologic Features of Azathioprine-Induced Hepatotoxicity
February 23rd (Tue)	17:45	17:50	P-1001	Drug Induced Liver Injury (1)	10480	Chetan	Rathi	Drug-Induced Liver Injury at A Tertiary Care Hospital in India: Etiology, Presentation and Outcome
February 23rd (Tue)	17:50	17:55	P-1002	Drug Induced Liver Injury (1)	10489	Huiyu	Lin	A Rare Case of Levothyroxine-Induced Liver Injury
February 23rd (Tue)	17:55	18:00	P-1003	Drug Induced Liver Injury (1)	10552	Seok Hyun	Kim	Atypical Onset of Bicalutamide-Induced Liver Injury
February 23rd (Tue)	18:00	18:05	P-1004	Drug Induced Liver Injury (1)	10660	Tarkan	Karakan	Ecstasy Induced Steroid-Responsive Acute Hepatitis
February 23rd (Tue)	18:05	18:10	P-1005	NASH and Other Diseases (1)	10290	Metin	Basaranoglu	Non-Alcoholic Fatty Liver Disease and PCOS
February 23rd (Tue)	18:10	18:15	P-1006	NASH and Other Diseases (1)	10161	Ahmet	Uygun	Nonalcoholic Fatty Liver Disease is An Independent Risk Factor for Atherosclerosis in Young Adult
February 23rd (Tue)	18:15	18:20	P-1007	NASH and Other Diseases (1)	10821	Sum Team	Lo	Clinical Features and Survival of Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma
February 23rd (Tue)	18:20	18:25	P-1008	NASH and Other Diseases (1)	10920	Rahul	Kumar	Comparison between NASH and ASH Induced Hepatocellular Carcinoma (HCC)
February 23rd (Tue)	18:25	18:30	P-1009	NASH and Other Diseases (1)	10967	Alina	Kutsenko	Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma in Maritime South East Asians
February 23rd (Tue)	17:40	17:45	P-1010	Various Liver Diseases (1)	10455	Yuya	Seko	Progression and HCC in Japanese Patients with NAFLD
February 23rd (Tue)	17:45	17:50	P-1011	Various Liver Diseases (1)	10038	Yi-Chun	Chou	Risk and Mortality of Gastrointestinal Hemorrhage in Patients with Immune Thrombocytopenia
February 23rd (Tue)	17:50	17:55	P-1012	Various Liver Diseases (1)	10745	Mesut	Akarsu	Reliability and Validity of UCLA SCTC GIT 2.0 for Turkish Population
February 23rd (Tue)	17:55	18:00	P-1013	Various Liver Diseases (1)	11082	Giuseppe	Cerasari	Sarcoidosis with Liver Expression
February 23rd (Tue)	18:00	18:05	P-1014	Various Liver Diseases (1)	10070	Orhan	Sezgin	High Prevalence of Type 1 Gaucher Disease in Idiopathic Hepatosplenomegaly and/or Thrombocytopenia
February 23rd (Tue)	18:05	18:10	P-1015	Various Liver Diseases (1)	10413	Yuki	Hamada	Human Placental Extract Can Replace the Phlebotomy on Treating Hereditary Hemochromatosis
February 23rd (Tue)	18:10	18:15	P-1016	Various Liver Diseases (1)	10510	Husnu	Pullukcu	The Diagnosis of Leishmaniasis after Misdiagnosis Due to Hepato/Splenomegaly: A Review of 18 Cases
February 23rd (Tue)	18:15	18:20	P-1017	Pediatric Hepatology	10297	Shuichiro	Umetsu	Clinical Course and Outcome of PSC/AIH Overlap Syndrome in Children
February 23rd (Tue)	18:20	18:25	P-1018	Pediatric Hepatology	11026	Yi	Dong	Efficacy and Safety of INF Combined with LAM in Treatment of Cirrhotic Children with Hepatitis B
February 23rd (Tue)	18:25	18:30	P-1019	Pediatric Hepatology	10410	Wanvisa	Udomsinprasert	Lower Mitochondrial DNA Copy Number is Associated with Telomere Length in Biliary Atresia
February 23rd (Tue)	17:40	17:45	P-1020	Various Liver Diseases (2)	11353	Ramazan	Dertli	Transfusion Related Acute Lung Injury (TRALI) Due to Iatrogenic Intra-Abdominal Bleeding
February 23rd (Tue)	17:45	17:50	P-1021	Various Liver Diseases (2)	10366	Miho	Kaneto	A Case of Hepatitis Due to Hypereosinophilic Syndrome
February 23rd (Tue)	17:50	17:55	P-1022	Various Liver Diseases (2)	11300	Alexander	Nersesov	Some Clinical Associations of Thrombocytopenia in Liver Disease of Different Stages and Etiologies
February 23rd (Tue)	17:55	18:00	P-1023	Various Liver Diseases (2)	11247	Bo	Tu	Curative Effect on Foscavir Treatment for Patients Infected by HIV Merger EB Virus
February 23rd (Tue)	18:00	18:05	P-1024	Various Liver Diseases (2)	11167	Hasmik	Ghazinyan	Liver Injury Due to Epstein Barr Virus (EBV)
February 23rd (Tue)	18:05	18:10	P-1025	Various Liver Diseases (3)	11291	Xiaoyu	Wen	A Case of Severe Hemophagocytic Syndrome Secondary to Chronic Active EBV Infection.

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 23rd (Tue)	18:10	18:15	P-1026	Various Liver Diseases (3)	11242	Dewi Norwani	Basir	Herpes Simplex Virus Hepatitis: Identification of Institutional Cases.
February 23rd (Tue)	18:15	18:20	P-1027	Various Liver Diseases (3)	10160	Selcuk	Kaya	Liver Involvement in Leptospirosis Patients
February 23rd (Tue)	18:20	18:25	P-1028	Various Liver Diseases (3)	10782	Hakan	Leblebicioglu	Chronic Liver Disease and Crimean Congo Hemorrhagic Fever: Two Overlapping Disorder
February 23rd (Tue)	18:25	18:30	P-1029	Various Liver Diseases (3)	10516	Debnandan	Chowdhury	Dengue Hepatological Manifestation: from Acute Hepatitis to Fulminant Hepatic Failure
February 23rd (Tue)	18:30	18:35	P-1030	Various Liver Diseases (3)	10853	Husnu	Pullukcu	Hemophilia Patients' Level of Knowledge of about Viral Hepatitis
February 23rd (Tue)	17:40	17:45	P-1031	Pregnancy and Liver	10309	Huiyu	Lin	A Case Hepatic Rupture in Acute Fatty Liver of Pregnancy
February 23rd (Tue)	17:45	17:50	P-1032	Pregnancy and Liver	10367	Jurate	Kondrackiene	Diagnostic Value of Tests Commonly Used in the Diagnosis of Intrahepatic Cholestasis of Pregnancy
February 23rd (Tue)	17:50	17:55	P-1033	Pregnancy and Liver	10866	Liudmila K.	Palgova	Obstetric Complications in Obese Pregnant Women, Associated with Liver Steatosis.
February 23rd (Tue)	17:55	18:00	P-1034	Pregnancy and Liver	11330	Amna S.	Butt	Spectrum of Liver Disease during Pregnancy: A Cross Sectional Study from Pakistan
February 23rd (Tue)	18:00	18:05	P-1035	Pregnancy and Liver	11356	Yan-qiong	Zhang	Horizontal Transmission of HBV after Successful MTCT Prevention: A Case Report
February 23rd (Tue)	18:05	18:10	P-1036	Pregnancy and Liver	11373	Quanxin	Wu	Change Pattern of HBV B/C in Vertical Transmission
February 23rd (Tue)	18:10	18:15	P-1037	Health Care Workers, Patient's Care, and Social Action	11342	Selma	Tosun	Evaluating the HAV Seroprevalence of Health Care Workers
February 23rd (Tue)	18:15	18:20	P-1038	Health Care Workers, Patient's Care, and Social Action	11325	Selma	Tosun	Evaluation of Needle Stick and Sharp Injuries among Healthcare Personnel
February 23rd (Tue)	18:20	18:25	P-1039	Health Care Workers, Patient's Care, and Social Action	10514	Md. Fazal	Karim	Needle Stick Injury: An Alarming Problem for Healthcare in Bangladesh
February 23rd (Tue)	18:25	18:30	P-1040	Health Care Workers, Patient's Care, and Social Action	10296	Chern Hao	Chong	Taking Charge of My Life: Advance Care Planning in Patient with End Stage Liver Disease
February 23rd (Tue)	18:30	18:35	P-1041	Health Care Workers, Patient's Care, and Social Action	10227	Michiaki	Okada	Advice of Doctors and Surrounding People Influence Decisions on Hepatitis Screening and Treatment
February 23rd (Tue)	18:35	18:40	P-1042	Health Care Workers, Patient's Care, and Social Action	10928	Ling	Mo	FSS and SF-36 in Asian Patients with HCV G1 b Receiving DCV+ASV and IFN+RBV Intolerant/Ineligible
February 23rd (Tue)	18:40	18:45	P-1043	Health Care Workers, Patient's Care, and Social Action	10491	Emel	Ahishali	How Aware are Chronic Hepatitis B and C Patients of Their Diseases?
February 23rd (Tue)	18:45	18:50	P-1044	Health Care Workers, Patient's Care, and Social Action	10980	Janice	Pritchard-Jones	The Advanced Liver Disease Pilot Education Program for Nurses
February 23rd (Tue)	18:50	18:55	P-1045	Health Care Workers, Patient's Care, and Social Action	10485	Jonathan W.	Lee	Health Perceptions Amongst Patients with Fatty Liver - A Weighty Issue
February 21st (Sun)	17:20	17:25	LBP-001	HCV Basic	20127	Wei	Hou	Subcellular Localization of Cyclin G1 During Mitosis in JFH1-hmAG Infected Huh7.5 Cells
February 21st (Sun)	17:25	17:30	LBP-002	HCV Basic	20008	Sayuri	Nitta	In Vitro Characterization and Drug Sensitivity Analysis for HCV NS5A Resistance-Associated Variants
February 21st (Sun)	17:30	17:35	LBP-003	HCV Basic	20146	Fathy	Elghamry	T Cell Subpopulation Predict the Occurrence and Prognosis of Cryoglobulinemia in Chronic Hepatitis C
February 21st (Sun)	17:35	17:40	LBP-004	HCV Clinical (1)	20164	Mohammad	Khaneshi	Three Important Disorders Regarding Hepatitis C in the Middle East
February 21st (Sun)	17:40	17:45	LBP-005	HCV Clinical (1)	20128	Javed I.	Farooqi	IL28B Polymorphism as in Chronic Hepatitis C Genotype 3
February 21st (Sun)	17:45	17:50	LBP-006	HCV Clinical (1)	20007	Yanwei	Zhong	Relationship between IL28B Gene Polymorphism and Antiviral Efficacy in Children with CHC
February 21st (Sun)	17:50	17:55	LBP-007	HCV Clinical (1)	20015	Pavel	Ogurtsov	Blood Group and IL-28B Genotype in PEG-IFN- α and RIBAVIRIN Therapy for HCV-1 and Liver Fibrosis
February 21st (Sun)	17:55	18:00	LBP-008	HCV Clinical (1)	20114	Elia	Rakhmanaliev	Distribution of Resistance-Associated Variants (RAVs) in HCV Genotypes (GT) 1a and 1b Populations
February 21st (Sun)	18:00	18:05	LBP-009	HCV Clinical (1)	20070	Ming-Jong	Bair	Eosinophilic Enterocolitis in A Patient with Chronic Hepatitis C
February 21st (Sun)	18:05	18:10	LBP-010	HCV Clinical (2)	20089	Ching Hsiang	Chen	The Excellent Outcome of Interferon-Based Hepatitis C Treatment in Taiwanese Incarcerated Patients
February 21st (Sun)	18:10	18:15	LBP-011	HCV Clinical (2)	20108	Maiko	Akutagawa	Cost-Effectiveness of IFN + RBV α 2b for Hepatitis C: Results Based on the Interferon Database
February 21st (Sun)	18:15	18:20	LBP-012	HCV Clinical (2)	20156	Kaivan	Shah	Is Rapid Virological Response (RVR) Significant in the Present Era in the Treatment of Hepatitis C
February 21st (Sun)	18:20	18:25	LBP-013	HCV Clinical (2)	20016	Michael John A.	Oliman	The Use of Silymarin in Chronic Hepatitis C Infection: Updated Systematic Review and Meta-Analysis
February 21st (Sun)	18:25	18:30	LBP-014	HCV Clinical (2)	20125	Javed I.	Farooqi	Correlation of Virological & Clinical Profile of Patients with BC-Coinfection in Pakistan
February 21st (Sun)	18:30	18:35	LBP-015	HCV Clinical (2)	20133	Javed I.	Farooqi	Pretreatment Determinants of Early Virologic Response in Sofosbuvir Treated Patients.
February 21st (Sun)	18:35	18:40	LBP-016	HCV Clinical (2)	20162	Tatsuo	Kanda	Sofosbuvir-Including Regimens against Real-World Japanese Patients with HCV GT-1 and GT-2
February 21st (Sun)	17:20	17:25	LBP-017	HBV Basic	20077	Xiang	Zhu	Transmembrane Protein 2 Inhibits Hepatitis B Virus Infection in L02 Cells
February 21st (Sun)	17:25	17:30	LBP-018	HBV Basic	20068	Xiang	Zhu	Study of the Inhibitory Effect of TMEM2 in HBV Infection into Hepatocytes
February 21st (Sun)	17:30	17:35	LBP-019	HBV Basic	20028	Alongkorn	Pugasub	Urinary Peptidomics for Analysis of Proximal Renal Tubular Dysfunction in Chronic Hepatitis B
February 21st (Sun)	17:35	17:40	LBP-020	HBV Basic	20010	Abhasnee	Sobhonslidsuk	Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Hepatitis B
February 21st (Sun)	17:40	17:45	LBP-021	HBV Basic	20065	Dongbo	Wu	STAT1 Mediates Injury of HBV-Infected Cell Through Effect of TRAIL on IFN and Caspase Signal Pathway

Date	Start	End	Poster No.	Session Title	Submission No.	First Name	Last Name	Title of Abstract
February 21st (Sun)	17:45	17:50	LBP-022	HBV Basic	20151	Liping	Shen	Analysis for 12 Strains of Whole Sequence of HBV C/D Recombinant of People in Tibet, China
February 21st (Sun)	17:50	17:55	LBP-023	HBV Basic	20152	Kai	Wang	Increased A20 mRNA Level in PBMCs is Associated with Immune Phases of Chronic Hepatitis B
February 21st (Sun)	17:55	18:00	LBP-024	HBV Clinical (1)	20115	Xueping	Yu	The Clinical Significance of Serum HBsAg/HBV DNA Ratio in Patients with Chronic HBV Infection
February 21st (Sun)	18:00	18:05	LBP-025	HBV Clinical (1)	20012	Jing	Meng	Hospital Epidemiology of Hepatitis B Virus Infection
February 21st (Sun)	18:05	18:10	LBP-026	HBV Clinical (1)	20120	Yanwei	Zhong	HBsAg Decline is Associated with High Loss Rates of HBsAg in Children with HBeAg Positive CHB
February 21st (Sun)	18:10	18:15	LBP-027	HBV Clinical (1)	20006	Yanwei	Zhong	Is the Fetus with HBV Possible Infected Through the Route of Placenta?
February 21st (Sun)	18:15	18:20	LBP-028	HBV Clinical (1)	20046	Divyesh	Devaliya	Community Interventions and Sensitisation on Hepatitis B Infection with Pregnant Women & Babies
February 21st (Sun)	18:20	18:25	LBP-029	HBV Clinical (1)	20101	Wei	Hou	Pyrosequencing Analysis of HBV S Gene "a" Determinant Mutation in HBsAg⁺/Anti-HBs⁺ Patients
February 21st (Sun)	18:25	18:30	LBP-030	HBV Clinical (1)	20044	Airong	Hu	Analysis of HBV Gene Mutations Related to NAs in Chronic HBV Infection
February 21st (Sun)	17:20	17:25	LBP-031	HBV Clinical (2)	20050	Prachi	Nautiyal	Innovative Information-Education-Communication Strategies on Hepatitis B
February 21st (Sun)	17:25	17:30	LBP-032	HBV Clinical (2)	20019	Jie	Li	Relationship between Serum HBsAg Level and Intrahepatic cccDNA under Different Serum HBeAg Statuses
February 21st (Sun)	17:30	17:35	LBP-033	HBV Clinical (2)	20034	Ergenekon	Karagoz	Correlation Between Quantitative HBsAg Levels and Clinical Profile of Chronic HBV Patients.
February 21st (Sun)	17:35	17:40	LBP-034	HBV Clinical (2)	20090	Hyon-suk	Kim	Sensitivity of Elecsys HBsAg II Assay in Detection of HBsAg Mutant Forms in Korean HBV Patients
February 21st (Sun)	17:40	17:45	LBP-035	HBV Clinical (2)	20026	Nazlim	Aktug Demir	Assessment of Levels of Depression, Anxiety and Quality of Life in Chronic Hepatitis B Patients
February 21st (Sun)	17:45	17:50	LBP-036	HBV Clinical (2)	20032	Purnima	Bhat	HBV May Have An Enterohepatic Circulation: Implications for Viral Persistence and Tolerance.
February 21st (Sun)	17:50	17:55	LBP-037	HBV Clinical (2)	20027	Kanthanadon	Dittharot	Metabolomic Profiling of Human Urine from Hepatitis B Virus Infected Patients Using GC/MS
February 21st (Sun)	17:55	18:00	LBP-038	HBV Clinical (3)	20051	Xueping	Yu	IL-9 and IL-10 but not Th9 Cells are Associated with survival of Patients with ACLF
February 21st (Sun)	18:00	18:05	LBP-039	HBV Clinical (3)	20023	Ai rong	Hu	NUCs Improves the Long-Term Prognosis in Patients with CHB-Associated Liver Failure
February 21st (Sun)	18:05	18:10	LBP-040	HBV Clinical (3)	20054	Julio C.	Aguilar	HeberNasvac: Rationalities and Preclinical Development of A Novel Hepatitis B Therapeutic Vaccine.
February 21st (Sun)	18:10	18:15	LBP-041	HBV Clinical (3)	20086	Wenxiong	Xu	Immunologic Examinations in CHB Patients after NAs Treatments Cessation
February 21st (Sun)	18:15	18:20	LBP-042	HBV Clinical (3)	20118	Young	Chang	Efficacy of Antiviral Treatment for Immune Tolerant Phase of Chronic Hepatitis B Patients
February 21st (Sun)	18:20	18:25	LBP-043	HBV Clinical (3)	20163	Akinobu	Tawada	AFP Level is A Useful Predictor of HCC in Chronic Hepatitis B Patients Treated with NUCs
February 21st (Sun)	17:20	17:25	LBP-044	HCC: Basic	20060	Gai X.	He	A Novel Regulatory Mechanism of Hepatic Myeloid-Derived Suppressor Cell Accumulation
February 21st (Sun)	17:25	17:30	LBP-045	HCC: Basic	20084	Qiyi	Zhao	Up-Regulation of Tumoral IDO is Driven by Monocytes and T Lymphocytes Collaboration
February 21st (Sun)	17:30	17:35	LBP-046	HCC: Basic	20103	Joo Ho	Lee	Proteomic Analysis for Identification of Biomarkers in Non-B, Non-C Hepatocellular Carcinoma
February 21st (Sun)	17:35	17:40	LBP-047	HCC: Basic	20150	Hiroshi	Kono	M-CSF Receptor Antagonist Inhibits Progression of Hepatocellular Carcinoma in Vivo
February 21st (Sun)	17:40	17:45	LBP-048	HCC: Basic	20147	Yosuke	Hirotsu	Targeted and Exome Sequencing Analysis of Hepatocellular Carcinoma
February 21st (Sun)	17:45	17:50	LBP-049	HCC: Basic	20148	Yosuke	Hirotsu	Somatic Mutations in Non-Tumorous Fibrotic Tissue
February 21st (Sun)	17:50	17:55	LBP-050	HCC: Basic	20168	Tatsuo	Kanda	Effects of Androgen Receptor on Fatty Acid Metabolism in Human Hepatoma Cell Lines
February 21st (Sun)	17:55	18:00	LBP-051	HCC: Diangosis	20022	Rania Mohamed	Ellithy	SNPs Analysis of Oligo-Adenylate Synthetase & Interleukin 1B Genes in End-Stage Liver Disease
February 21st (Sun)	18:00	18:05	LBP-052	HCC: Diangosis	20045	Sung Hoon	Kim	The Meaning of AFP, AFP-L3 and PIVKA-II for Evaluating Recurrence in Patients with HCC
February 21st (Sun)	18:05	18:10	LBP-053	HCC: Diangosis	20093	Gabriele	Ricco	Etiology of Chronic Liver Disease and HCC Biomarkers
February 21st (Sun)	18:10	18:15	LBP-054	HCC: Diangosis	20134	Hong	Zhao	Des- γ -Carboxy Prothrombin is A Complementary Biomarker in Diagnosing Hepatocellular Carcinoma
February 21st (Sun)	18:15	18:20	LBP-055	HCC: Diangosis	20140	Javed I.	Farooqi	Characteristics of HCV-Related HCC in Pakistan
February 21st (Sun)	18:20	18:25	LBP-056	HCC: Diangosis	20021	Sherief M.	Abd-Elsalam	Aflatoxin Role in Liver Cancer in Nile Delta
February 21st (Sun)	17:20	17:25	LBP-057	HCC: Treatment	20073	Jing	Xie	Pre-Clinical Studies of Animal Irreversible Electroporation Treatment of Liver Cancer
February 21st (Sun)	17:25	17:30	LBP-058	HCC: Treatment	20087	Hitomi	Takechi	Late-Onset Diaphragmatic Hernia after Radiofrequency Ablation of Hepatocellular Carcinoma
February 21st (Sun)	17:30	17:35	LBP-059	HCC: Treatment	20056	Ratha-korn	Vilaichone	Clinical Characteristics and Treatment Outcomes of HCC Due to CHB and CHC Infections in Thailand
February 21st (Sun)	17:35	17:40	LBP-060	HCC: Treatment	20117	Joon Yeul	Nam	Oral Medications Improve Overall Survival by Enhancing Compliance to Surveillance for HCC
February 21st (Sun)	17:40	17:45	LBP-061	HCC: Treatment	20172	Sadahisa	Ogasawara	Liver Function Assessment According to the ALBI Grade in Sorafenib-Treated Advanced HCC Patients
February 21st (Sun)	17:45	17:50	LBP-062	HCC: Treatment	20112	Takeshi	Gocho	Efficacy of Sorafenib in Patients with Intermediate-Stage HCC Refractory to TACE

Date	Start	End	Poster No.	Session Tytle	Submission No.	First Name	Last Name	Title of Abstract
February 21st (Sun)	17:50	17:55	LBP-063	HCC: Treatment	20038	Ryusuke	Saito	A Case of Resection for Complete Spontaneous Regression of Hepatocellular Carcinoma.
February 21st (Sun)	17:55	18:00	LBP-064	HCC: Treatment	20109	Tharatip	Srisuk	Surgical Outcome of Hepatocellular Carcinoma with Intraatrial Thrombus in Child B Cirrhotic Patient.
February 21st (Sun)	18:00	18:05	LBP-065	ALF	20153	Yu-Chen	Fan	Elevated A20 Gene Expression in PBMCs is Associated with Acute-on-Chronic Hepatitis B Liver Failure
February 21st (Sun)	17:20	17:25	LBP-066	Hepatitis	20169	Tatsuo	Kanda	GRP78 is An Antiviral Factor and One of the Antiviral Targets against Hepatitis A Virus Replication
February 21st (Sun)	17:25	17:30	LBP-067	Hepatitis	20043	Daejin	Kim	HAV IgG Seroprevalence among HBV Liver Disease in Daegu city of South Korea
February 21st (Sun)	17:30	17:35	LBP-068	Hepatitis	20175	Dustov	Abdusamad	Hepatitis E virus in patients with HIV infection
February 21st (Sun)	17:35	17:40	LBP-069	Hepatitis	20095	Gabriele	Ricco	Total Anti-HBc/IgM Anti-HDV Ratio Helps to Identify Patients with Severe HDV-Induced Liver Disease
February 21st (Sun)	17:40	17:45	LBP-070	Hepatitis	20069	I. Che	Feng	Perihepatic Nodes by Point-of-Care Ultrasound in Acute Hepatitis and Acute-on-Chronic Liver Disease.
February 21st (Sun)	17:45	17:50	LBP-071	Hepatitis	20042	Ashok R.	Mohite	Changing Clinical Profile of Liver Enzyme Abnormalities among HIV-Infected Persons
February 21st (Sun)	17:40	17:45	LBP-072	Biliary Diseases	20014	Katrina Jewel S.	Cham	Initial Experience with A Biodegradable Stent on the Management of A Benign Bile Duct Stricture
February 21st (Sun)	17:45	17:50	LBP-073	Biliary Diseases	20024	Katrina Jewel S.	Cham	Wire-Guide Saving ERCP Rendezvous Technique
February 21st (Sun)	17:50	17:55	LBP-074	Biliary Diseases	20072	Lei	Li	Effects of UDCA on Bile Secretion in Patients with Cholestasis
February 21st (Sun)	17:55	18:00	LBP-075	Biliary Diseases	20041	Coskun	Ozturker	Acute Fatty Liver of Pregnancy Mimicking Acute Cholecystitis
February 21st (Sun)	18:00	18:05	LBP-076	Liver Transplantation	20030	Abd Elrazek	Ali Hussein	Novel Sonar Techniques for Patients Awaiting Liver Transplantation Clinical and Cost Impacts
February 21st (Sun)	18:05	18:10	LBP-077	Liver Transplantation	20100	Aiykul	Ashimkhanova	The Development of Organ Transplant Program in Kazakhstan
February 21st (Sun)	18:10	18:15	LBP-078	Liver Transplantation	20088	Junaid	Beig	Recurrent Hepatitis C after Liver Transplantation is Associated with Post-Transplant Diabetes
February 21st (Sun)	17:40	17:45	LBP-079	Basic Science	20076	Yuri	Cho	Activation of YAP-1 by c-Myc is A Therapeutic Target in Hepatocellular Carcinoma under Hypoxia
February 21st (Sun)	17:45	17:50	LBP-080	Basic Science	20081	Nadeem	Sheikh	Tacrolimus Induced Nephrotoxicity and Pulmonarytoxicity in Wistar Rats
February 21st (Sun)	17:50	17:55	LBP-081	Basic Science	20083	Nadeem	Sheikh	Histopathological Alterations in Nervous, Cardiac and Pulmonary Tissues Induced by Thioacetamide
February 21st (Sun)	17:55	18:00	LBP-082	Basic Science	20097	Rabia	Mehmood	Variations in Red Cell Indices and Protein Profiling Due to the Exposure of Metallic Dust
February 21st (Sun)	18:00	18:05	LBP-083	Basic Science	20031	Mohammad K.	Parvez	In Vitro Hepatoprotective and Anti-Hepatitis B Activitis of Cyperus Rotundus Tuber Fractions
February 23rd (Tue)	17:40	17:45	LBP-084	Complication of Cirrhosis (1)	20059	Katrina Jewel S.	Cham	Undiluted N-Butyl-2-Cyanoacrylate for Obliteration of Gastric Varices: A Single Center Experience
February 23rd (Tue)	17:45	17:50	LBP-085	Complication of Cirrhosis (1)	20064	Shigemune	Bekki	Serum Potassium Concentration is Associated with the Initial Effect of Tolvaptan to Liver Cirrhosis
February 23rd (Tue)	17:50	17:55	LBP-086	Complication of Cirrhosis (1)	20166	Shuntaro	Obi	Hyponatremia is Prognosis Factor of Refractory Ascites
February 23rd (Tue)	17:55	18:00	LBP-087	Complication of Cirrhosis (1)	20020	Sherief M.	Abd-Elsalam	Is Spontaneous Bacterial Peritonitis Still Responding to Third Generation Cephalosporins?
February 23rd (Tue)	18:00	18:05	LBP-088	Complication of Cirrhosis (1)	20039	Tin Tin	Hlaing	Persistent Spontaneous Bacterial Peritonitis in the Patient with End-Stage Liver Disease
February 23rd (Tue)	18:05	18:10	LBP-089	Complication of Cirrhosis (1)	20130	Benjamin Jr T.	Castro	Clinical Implications of Muscle Wasting in Cirrhosis
February 23rd (Tue)	18:10	18:15	LBP-090	Complication of Cirrhosis (1)	20048	Ming-Jong	Bair	Spontaneous Splenic Infarction in A Cirrhotic Patient
February 23rd (Tue)	18:15	18:20	LBP-091	Complication of Cirrhosis (1)	20047	Chun-Han	Cheng	Gastric Polypoid Lesions in Cirrhotic Patients
February 23rd (Tue)	18:20	18:25	LBP-092	Complication of Cirrhosis (2)	20011	Jong Sub	Choi	Novel Mutations in the CPT1A Gene Identified of Carnitine Palmitoyltransferase 1A Deficiency
February 23rd (Tue)	18:25	18:30	LBP-093	Complication of Cirrhosis (2)	20080	Yuki	Kugiyama	Serum M2BPGi and Sodium Level are Associated with Increased Risk of Mortality in Patients with LC
February 23rd (Tue)	18:30	18:35	LBP-094	Complication of Cirrhosis (2)	20141	Javed I.	Farooqi	Complications Profile of Liver Cirrhosis in Pakistan
February 23rd (Tue)	18:35	18:40	LBP-095	Complication of Cirrhosis (2)	20136	Hong	Zhao	Clinical Characteristics of Liver Cirrhosis Over 22 Years in China
February 23rd (Tue)	18:40	18:45	LBP-096	Complication of Cirrhosis (2)	20139	Javed I.	Farooqi	Rifaximin in the Treatment of Early Hepatic Encephalopathy
February 23rd (Tue)	18:45	18:50	LBP-097	Complication of Cirrhosis (2)	20092	Guanya	Guo	Severe Vitamin D Deficiency Identifies A Poor Pognosis in Patients with Primary Biliary Cirrhosis
February 23rd (Tue)	18:50	18:55	LBP-098	Complication of Cirrhosis (2)	20091	Xinmin	Zhou	Vitamin D Supplementation Therapy for Primary Biliary Cirrhosis: A Retrospective Clinical Study
February 23rd (Tue)	18:55	19:00	LBP-099	Complication of Cirrhosis (2)	20055	Chang Gue	Son	Experimental and Clinical Studies for Development of Anti-hepatofibrotic Herbal Drug, CGX
February 23rd (Tue)	17:40	17:45	LBP-100	Non-invasive Assessment of Liver Fibrosis and PH1	20126	Javed I.	Farooqi	Transient Elastography by FibroScan for the Assessment of Liver Fibrosis: First Study from Pakistan
February 23rd (Tue)	17:45	17:50	LBP-101	Non-invasive Assessment of Liver Fibrosis and PH1	20079	Yong-Qiong	Deng	Effect of ALT on Transient Elastography Diagnosing Liver Fibrosis in Chronic Hepatitis B Patients
February 23rd (Tue)	17:50	17:55	LBP-102	Non-invasive Assessment of Liver Fibrosis and PH1	20143	Amarsanaa	Jazag	Cause of Cirrhosis in Mongolia Evaluated by Non-Invasive Methods Including Fibroscan, FIB4 and APRI
February 23rd (Tue)	17:55	18:00	LBP-103	Non-invasive Assessment of Liver Fibrosis and PH1	20033	Ergenekon	Karagoz	ARFI is A Useful Tool in Patients with Chronic Hepatitis B Infection:A Case Report

Date	Start	End	Poster No.	Session Tyle	Submission No.	First Name	Last Name	Title of Abstract
February 23rd (Tue)	18:00	18:05	LBP-104	Non-invasive Assessment of Liver Fibrosis and PH1	20035	Ergenekon	Karagoz	Utility of ARFI in the Follow-Up of A Patient with Chronic Hepatitis B:A Case Report
February 23rd (Tue)	18:05	18:10	LBP-105	Non-invasive Assessment of Liver Fibrosis and PH1	20149	Coskun	Ozturker	Performance of Acoustic Radiation Force Impulse in Patients with Chronic Hepatitis B
February 23rd (Tue)	18:10	18:15	LBP-106	Non-invasive Assessment of Liver Fibrosis and PH1	20154	Luca	Rinaldi	Early Changes of Liver Stiffness in HCV Patients Undergoing Treatment with DDAs: A Multicenter Study
February 23rd (Tue)	18:15	18:20	LBP-107	Non-invasive Assessment of Liver Fibrosis and PH2	20025	Fathy	Elghamry	Egy-Score Can Predict Portal Hypertension in Chronic Hepatitis C with Good Accuracy
February 23rd (Tue)	18:20	18:25	LBP-108	Non-invasive Assessment of Liver Fibrosis and PH2	20170	Soichiro	Kiyono	Utility of Sonazoid-Enhanced Ultrasonography for Diagnosis of Portal Hypertensive Gastropathy
February 23rd (Tue)	18:25	18:30	LBP-109	Non-invasive Assessment of Liver Fibrosis and PH2	20029	Sherief M.	Abd-Elsalam	Non Invasive Diagnosis of Esophageal Varices: Can It Replace Screening Endoscopy?
February 23rd (Tue)	18:30	18:35	LBP-110	Non-invasive Assessment of Liver Fibrosis and PH2	20063	Biaoyang	Lin	CHI3L1 is A Liver-Enriched, Noninvasive Biomarker for Staging and Diagnosing Hepatic Fibrosis
February 23rd (Tue)	18:35	18:40	LBP-111	Non-invasive Assessment of Liver Fibrosis and PH2	20049	Ji-Yuan	Zhou	PDGF-BB as A Biomarker for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis B
February 23rd (Tue)	18:40	18:45	LBP-112	Non-invasive Assessment of Liver Fibrosis and PH2	20036	Coskun	Ozturker	Is Diffusion MRI A Useful Tool for Evaluating Liver Fibrosis?
February 23rd (Tue)	17:40	17:45	LBP-113	NAFLD/NASH	20066	Yen-Chih	Lin	Influence of Soil Heavy Metals in Fatty Liver Disease
February 23rd (Tue)	17:45	17:50	LBP-114	NAFLD/NASH	20138	Femmy Nurul	Akbar	Correlation between Lipid and BMI with Liver Fibrosis in NAFLD Patients
February 23rd (Tue)	17:50	17:55	LBP-115	NAFLD/NASH	20074	GU	Qiao-yan	The Relationship between Serum RPR and Hepatic Fibrosis in Male Nonalcoholic Fatty Liver Patients
February 23rd (Tue)	17:55	18:00	LBP-116	NAFLD/NASH	20078	Matthew M.	Yeh	Hepatic Steatosis is Associated with Hepatocellular Carcinoma in Patients without Viral Hepatitis
February 23rd (Tue)	18:00	18:05	LBP-117	NAFLD/NASH	20145	Shivaram P.	Singh	Socioeconomic Impact of Alcohol in Patients with Alcoholic Liver Disease [ALD] in Eastern India.
February 23rd (Tue)	18:05	18:10	LBP-118	NAFLD/NASH	20173	Mi Ah	Han	Associations between Vitamin D Level and Serum Aminotransferase Concentration in Korea
February 23rd (Tue)	18:10	18:15	LBP-119	GI and Others	20129	NamHee	Kim	Clinical Significance of Focal Hepatic Solid Lesions Incidentally Detected on Ultrasonography
February 23rd (Tue)	18:15	18:20	LBP-120	GI and Others	20135	Hong	Zhao	Unbalanced Distribution of Medical Resources for Liver Diseases in Mainland of China
February 23rd (Tue)	18:20	18:25	LBP-121	GI and Others	20018	Ermil R.	Magsino	D.I.Y. Dual Purpose Gastro-Enteric Tube(Simultaneous Gastric Decompression and Enteral Feeding)
February 23rd (Tue)	18:25	18:30	LBP-122	GI and Others	20013	Jing	Meng	Hemochromatosis with A Novel Mutation of SLC40A1 Gene in China:a Case Report
February 23rd (Tue)	17:40	17:45	LBP-123	Drug and Liver Toxicity	20102	Naveen	Kumar	Safety and Efficacy of Pyrazinamide in Compensated Cirrhosis: Time to Shun Hepatotoxicity Fear?
February 23rd (Tue)	17:45	17:50	LBP-124	Pediatric Hepatology (HBV)	20004	Yanwei	Zhong	The Correlation between HBV cccDNA and Clinical Features in Children with CHB
February 23rd (Tue)	17:50	17:55	LBP-125	Pediatric Hepatology (HBV)	20119	Yanwei	Zhong	Baseline Factors Predicting Antiviral Efficacy in Children with HBeAg Positive Chronic Hepatitis B
February 23rd (Tue)	17:55	18:00	LBP-126	Pediatric Hepatology (HBV)	20123	Yanwei	Zhong	The Effect of Myeloid Derived Suppressor Cells in Children with Chronic Hepatitis B Infection
February 23rd (Tue)	18:00	18:05	LBP-127	Complication of Cirrhosis (1)	20174	Gaurav	Pande	SCALFI±Terlipressin Mobilizes Refractory Ascites Safely in Decompensated Liver Cirrhosis